Abstract
The effects of drugs on the central and peripheral nervous systems can be easily recognized in normal animals. This does not necessarily mean that these effects can be used in therapy. Observing the global effects of drugs during LD50-determinations pharmacologists can detect psychotropic activity. Only, if these effects occur also in doses considerably below the LD50, are further evaluations justified. This basic experience resulted in the development of a variety of observational tests and activity measurements.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Haggerty GC (1991) Strategy for and experience with neurotoxicity testing of new pharmaceuticals. J Am Coll Toxicol 10: 677–688
Irwin S (1964) Drug screening and evaluation of new compounds in animals. In: Nodin JH, Siegler PE (eds.) Animal and clinical techniques in drug evaluation. Year Book Medical Publishers, Chicago, 36–54
Irwin S (1968) Comprehensive observational assessment: I a. A systematic, quantitative procedure for assessing the behavioural and physiologic state of the mouse. Psychopharmacologia (Berl.) 13: 222–257
Murray AM, Waddington JL (1990) The interaction of clozapine with dopamine D, versus dopamine DZ receptor-mediated function: behavioural indices. Eur J Pharmacol 186: 79–86
Silverman P (1978) Drug screening and brain pharmacology. In: Animal behaviour in the laboratory. Chapman and Hall, London, pp 58–78
Barnett SH (1963) “The Rat, A Study in Behavior.” Chicago: Aldine Publishing Co., pp 31–32
Geyer MA (1990) Approaches to the characterisation of drug effects on locomotor activity in rodents. Modern Methods in Pharmacology, Vol. 6, Testing and Evaluation of Drugs of Abuse. pp. 81–99, Wiley-Liss, Inc
Silverman P (1978) Motor activity. In: Animal behaviour in the laboratory. Chapman and Hall, London, pp 79–92
Turner RA (1965) Depressants of the central nervous system. In: Turner RA (ed) Screening Methods in Pharmacology, Vol. 1, Academic Press, New York and London, pp 69–86
Koek W, Woods JH, Ornstein P (1987) A simple and rapid method for assessing similarities among directly observable behavioural effects of drugs: PCP-like effects of 2-amino5-phosphonovalerate in rats. Psychopharmacology 91: 297–304
Meyer HJ (1962) Pharmakologie der wirksamen Prinzipien des Kawa-Rhizoms (Piper methysticum Frost) Arch Int Pharmacodyn 138: 505–536
Schaumann W, Stoepel K (1961) Zur quantitativen Beurteilung von zentraler Erregung und Dämpfung im Tierversuch. Naunyn-Schmiedeberg’s Arch exp Path Pharmakol 241: 383–392
Ther L (1953) Über eine einfache Methode zur Bestimmung von Weck-und Beruhigungsmitteln im Tierversuch. Dtsch Apoth Ztg 93: 292–294
Vogel G, Ther L (1963) Zur Wirkung der optischen Isomeren von Aethyltryptamin-acetat auf die Lagekatalepsie des Huhnes und auf die Motilität der Maus. Arzneim Forsch/ Drug Res 13: 779–783
Barros HMT, Tannhauser MAL, Tannhauser SL, Tannhauser M (1991) Enhanced detection of hyperactivity after drug withdrawal with a simple modification of the open-field apparatus. J Pharmacol Meth 26: 269–275
Becker H, Randall CL (1989) Effects of prenatal ethanol exposure in C57BL mice on locomotor activity and passive avoidance behavior. Psychopharmacol 97: 40–44
Carlezon WA, Cornfeldt ML, Szewczak MR, Fielding S, Dunn RW (1991) Reversal of both QNX-induced locomotion and habituation decrement is indicative of M, agonist properties. Drug Dev Res 23: 333–339
Choi OH, Shamin MT, Padgett WL, Daly JW (1988) Caffeine and theophylline analogues: correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. Life Sci 43: 387–398
Crabbe JC, Deutsch CM, Tam BR, Young ER (1988) Environmental variables differentially affect ethanol-stimulated activity in selectively bred mouse lines. Psychopharmacology 95: 103–108
Crabbe JC, Young ER, Deutsch CM, Tam BR, Kosobud A (1987) Mice genetically selected for differences in openfield activity after ethanol. Pharmacol Biochem Behav 27: 577–581
Crunelli V, Bernasconi S (1979) A new device to measure different size movements: Studies on d-amphetamine-induced locomotion and stereotypy. J Pharmacol Meth 2: 43–50
Dews PB (1953) The measurement of the influence of drugs on voluntary activity in mice. Br J Pharmacol 8: 46–48
Ericson E, Samuelsson J, Ahlenius S (1991) Photocell measurements of rat motor activity. J Pharmacol Meth 25: 111–122
Fontenay M, Le Cornec J, Zaczinska M, Debarele M, Simon P, Boissier J (1970) De trois tests de comportement du rat pour l’etude des medicaments psychotropes. J Pharmacol (Paris) 1: 243–254
Georgiev V, Getova D, Opitz M (1991) Mechanism of the an-giotensin II effects on exploratory behavior of rats in open field. III. Modulatory role of GABA. Meth Find Exp Clin Pharmacol 13: 5–9
Honma S, Honma KI, Hiroshige T (1991) Methamphetamine effects on rat circadian clock depend on actograph. Physiol Behav 49: 787–795
Ivens I (1990) Neurotoxicity testing during long-term studies. Neurotoxicol Teratol 12: 637–641
Kádár T, Telegdy G, Schally AV (1992) Behavioral effect of centrally administered LH-RH agonist in rats. Physiol Behan 51: 601–605
Kauppila T, Tanila H, Carlson S, Taira T (1991) Effects of atipamezole, a novel aZ-adrenoreceptor antagonist, in openfield, plus-maze, two compartment exploratory, and forced swimming tests in rats. Eur J Pharmacol 205: 177–182
Kulig BM (1989) A neurofunctional test battery for evaluating the effects of long-term exposure to chemicals. J Am Coll Toxicol 8: 71–83
Laviola G, Alleva E (1990) Ontogeny of muscimol effects on locomotor activity, habituation, and pain reactivity in mice. Psychopharmacol 102: 41–48
Nakatsu K, Owen JA (1980) A microprocessor-based animal monitoring system. J Pharmacol Meth 3: 71–82
Nieminen SA, Lecklin A, Heikkinen O, Ylitalo P (1990) Acute behavioral effects of the organophosphates Sarin and So-man in rats. Pharmacol Toxicol 67: 36–40
Okada K, Oishi R, Saeki K (1990) Inhibition by antimanic drugs of hyperactivity induced by methamphetaminechlordiazepoxide mixture in mice. Pharmacol Biochem Behav 35: 897–901
Rosenthal MJ, Morley JE (1989) Corticotropin releasing factor ( CRF) and age-related differences in behavior of mice. Neurobiol Aging 10: 167–171
Saelens JK, Kovacsics GB, Allen MP (1986) The influence of the adrenergic system on the 24-hour locomotor activity pattern in mice. Arch Int Pharmacodyn 173: 411–416
Silverman P (1978) Exploration. In: Animal behaviour in the laboratory. Chapman and Hall, London, pp 230–253
Strömberg C (1988) Interactions of antidepressants and ethanol on spontaneous locomotor activity and rotarod performance in NMRI and C57BL/6 mice. J Psychopharmacol 2: 61–66
Sugita R, Sawa Y, Nomura S, Zorn SH, Yamauchi T (1989) Effects of reserpine on dopamine metabolite in the nucleus accumbens and locomotor activity in freely moving rats. Neurochem Res 14: 267–270
Tanger HJ, Vanwersch RAP, Wolthuis OL (1978) Automated TV-based system for open field studies: Effects of meth-amphetamine. Pharmacol Biochem Behav 9: 557–557
VanHaaren F, Meyer ME (1991) Sex differences in locomotor activity after acute and chronic cocaine administration. Pharmacol Biochem Behav 39: 923–927
Wolffgramm J, Lechner J, Coper H (1988) Interaction or two barbiturates and an antihistamine on body temperature and motor performance in mice. Arzneim Forsch/Drug Res 38: 885–891
Boissier JR, Simon P (1964) Dissociation de deux composantes dans le comportement d’investigation de la souris. Arch Int Pharmacodyn 147: 372–388
Boissier JR, Simon P, Wolff J-ML (1964) L’utilisation d’une reaction particuliere de la souris ( Methode de la planche a trous) pour l’etude des medicaments psychotropes. Therapie 19: 571–586
Clark G, Koester AG, Pearson DW (1971) Exploratory behavior in chronic disulfoton poisoning in mice. Psychopharmacologie (Berl.) 20: 169–171
Adams LM, Geyer MA (1982) LSD-induced alterations of locomotor patterns and exploration in rats. Psychopharmacology 77: 179–185
Barbier P, Breteaudeau J, Autret E, Bertrand P, FoussardBlampin O, Breteau M (1991) Effects of prenatal exposure to diazepam on exploration behavior and learning retention in mice. Dev Pharmacol Ther 17: 35–43
Geyer MA (1982) Variational and probabilistic aspects of exploratory behavior in space: Four stimulant styles. Psycho-pharmacology Bulletin 18: 48–51
Geyer MA, Rosso PV, Masten VL (1986) Multivariate assessment of locomotor behavior: Pharmacological and behavioral analyses. Pharmacol. Biochem. Behay. 25: 277–288
Ljungberg T, Ungerstedt U (1977) Different behavioural patters induced by apomorphine: evidence that the method of administration determines the behavioural response to the drug. Eur J Pharmacol 46: 41–50
Weischer ML (1976) Eine einfache Versuchsanordnung zur quantitativen Beurteilung von Motilitaet and Neugierverhalten bei Maeusen. Psychopharmacology 50: 275–279
Wolffgramm J, Lechner J, Coper H (1988) Interaction of two barbiturates and an antihistamine on body temperature and motor performance of mice. Arzneim Forsch/Drug Res, 38: 885–891
de Simoni MG, de Luigi A, Imeri L, Algerin S (1990) Miniaturized optoelectronic system for telemetry of in vivo voltammetric signals. J Neurosci Meth 33: 233–240
Dimpfel W, Spüler M, Bonke (1990) Influence of repeated vitamin B administration on the frequency pattern analysed from rat brain electrical activity ( Tele-Stereo-EEG ). Klin Wschr 68: 136–141
Dimpfel W, Spüler M, Nichols DE (1989) Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat ( Tele-StereoEEG ). Psychopharmacol 98: 297–303
Dimpfel W, Spüler M, Nickel B (1986) Radioelectroencephalography ( Tele-Stereo-EEG) in the rat as a pharmacological model to differentiate the central action of flupirtine from that of opiates, diazepam and phenobarbital. Neuropsychobiol 16: 163–168
Dimpfel W, Wedekind W, Spüler M (1992) Field potential analysis in the freely moving rat during the action of cyclandelate or flunarizine. Pharmacol Res 25: 287–297
Kropf W, Kuschinsky K, Krieglstein J (1991) Conditioning of apomorphine effects: simultaneous analysis of the alterations in cortical electroencephalogram and behaviour. Naunyn-Schmiedeberg’s Arch Pharmacol 343: 559–567
Allmark MG, Bachinski WM (1949) A method of assay for curare using rats. J. Am. Pharm. Ass 38: 43–45
Randall LO, Heise GA, Schallek W, Bagdon, RE, Banzinger R, Boris A, Moe RA, Abrams WB (1961) Pharmacological and clinical studies on Valium(TM.). A new psychotherapeutic agent of the benzodiazepine class. Curr Ther Res 3: 405–425
Rivlin A, Tator C (1977) Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J Neurosurg 47: 577–581
Ther L, Vogel G, Werner Ph (1959) Zur pharmakologischen Differenzierung und Bewertung von Neuroleptica. Arzneim Forsch/Drug Res 9: 351–354
Boissier JR, Tardy J, Diverres JC (1960) Une novelle méthode simple pour explorer l’action “tranquillisante”: le test de la cheminée. Med. exp 3: 81–84
Simiand J, Keane PE. Biziere K, Soubrie P (1989) Comparative study in mice of Tetrazepam and other centrally active skeletal muscle relaxants. Arch Int Pharmacodyn 297:272–285
Turner RA (1965) Ataractic (tranquillizing, neuroleptic) agents. In: Screening Methods in Pharmacology. Chapter 7, pp 87–100, Academic Press, New York and London.
Barclay LL, Gibson GE, Blass JP (1981) The string test: an early behavioral change in thiamine deficiency. Pharmacol Biochem Behav 14: 153–157
Boissier JR, Simon P (1960) L’utilisation du test de la traction, ( Test de JULOU-COURVOISIER) pour l’etude des psycholeptiques. Therapie 15: 1170–1174
Deacon RMJ, Gardner CR (1984) The pull-up test in rats: a simple method for testing muscle relaxation. J Pharmacol Meth 11: 119–124
Fleury C (1957) Nouvelle technique pour mesurer l’effort musculaire de la souris, dite test de l’agrippement. Arch. Sci. 10: 107–112
Kondziella W (1964) Eine neue Methode zur Messung der muskulaeren Relaxation bei weissen Maeussen. Arch Int Pharmacodyn 152: 277–284
Kulig BM (1989) A neurofunctional test battery for evaluating the effects of long-term exposure to chemicals. J Am Coll Toxicol 8: 71–83
Meyer OA, Tilson HA, Bird WC, Riley MT (1979) A method for the routine assessment of fore-and hind limb grip strength of rats and mice. Neurobehav Toxicol 1: 233–236
Miguel J, Blasco M (1978) A simple technique for evaluation of vitality loss in aging mice, by testing their muscular coordination and vigor. Exp Geront 13: 389–396
Novack GD, Zwolshen JM (1983) Predictive value of muscle relaxant models in rats and cats. J Pharmacol Meth 10: 175–183
Simiand J, Keane, PA, Biziere K, Soubrie P (1989) Comparative study in mice of Tetrazepam and other centrally active skeletal muscle relaxants. Arch Int Pharmacodyn 297: 272–285
Tilson HA (1990) Behavioral indices of neurotoxicity. Toxicol Pathol 18: 96–104
Cartmell SM, Gelgor L, Mitchell D (1991) A revised rotarod procedure for measuring the effect of antinociceptive drugs on motor function in the rat. J Pharmacol Meth 26: 149–159
Dunham NW, Miya TS (1957) A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharmaceut Assoc 46: 208–210
Novack GD, Zwolshen JM (1983) Predictive value of muscle relaxant models in rats and cats. J Pharmacol Meth 10: 175–183
Saeed Dar M, Wooles WR (1986) Effect of chronically administered methylxanthines on ethanol-induced motor incoordination in mice. Life Sci 39: 1429–1437
Boissier JR, Simon P (1969) Evaluation of experimental techniques in the psycho-pharmacology of emotion. Ann NY Acad Sci 159: 898–914
Costa E, Corda MG, Epstein B, Forchetti C, Guidotti A (1983) GABA-benzodiazepine interactions. In: Costa E (ed) The Benzodiazepines. From Molecular Biology to Clinical Practice. Raven Press, New York, pp 117–136
Costall B, Naylor RJ, Tyers MB (1988) Recent advances in the neuropharmacology of 5HT3 agonists and antagonists. Rev Neuroscience 2: 41–65
Cotman CW, Iversen LL (1987) Excitatory amino acids in the brain-focus on NMDA receptors. Trends in Neurosci 10: 263–265
Fonnum F (1987) Biochemistry, anatomy, and pharmacology of GABA neurons. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress., Raven Press, New York, pp 173–182
Lippa AS, Priscilla A, Nash BA, Greenblatt EN (1979) Pre-clinical neuropharmacological testing procedures for anxiolytic drugs. In: Fielding St, Lal H (eds) Anxiolytics, Futura Publ. Comp. New York, pp 41–81
Lloyd KG, Morselli PL (1987) Psychopharmacology of Gabaergic drugs. In: Meltzer HY (ed) Psycho-pharmacology: The Third Generation of Progress., Raven Press, New York pp 183–195
Peroutka SJ (1988) 5-Hydroxytryptamine receptor subtypes: Molecular, biochemical and physiological characterization. Trends Neuroscience 11: 496–500
Watkins JC, Olverman HJ (1987) Agonists and antagonists for excitatory amino acid receptors. Trends in Neurosci 10: 265–272
Zukin SR, Young AB, Snyder SH (1974) Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. Proc Natl Acad Sci, USA, 71: 4801–4807
Enna SJ, Collins JF, Snyder SH (1977) Stereo specificity and structure-activity requirements of GABA receptor binding in rat brain. Brain Res. 124: 185–190
Enna SJ, Möller H (1987) y-aminobutyric acid (GABA) receptors and their association with benzodiazepine recognition sites. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress, Raven Press, New York, pp 265–272
Enna SJ, Snyder SH (1975) Properties of y-aminobutyric acid ( GABA) receptor binding in rat brain synaptic membrane fractions. Brain Res. 100: 81–97
Enna SJ, Snyder SH (1977) Influence of ions, enzymes, and detergents on y-aminobutyric acid-receptor binding in synaptic membranes of rat brain. Mol Pharmacol 13: 442–453
Knott C, Bowery NG (1991) Pharmacological characterization of GABAA and GABAB receptors in mammalian CNS by receptor binding assays. In: Greenstein B (ed) Neuroendocrine Research Methods. Vol 2, Harwood Academic Publ., Chur, pp 699–722
Lüddens H, Korpi ER (1995) Biological function of GABAA/benzodiazepine receptor heterogeneity. J Psychiat Res 29: 77–94
Matsumoto RR (1989) GABA receptors: are cellular differences reflected in function? Brain Res Rev 14: 203–225
Möhler H (1992) Gabaergic synaptic transmission. Arzneim Forsch/Drug Res 42: 211–214
Zukin SR, Young AB, Snyder SH (1974) Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. Proc Nat Acad Sci, USA 71: 4802–4807
Beaumont K, Chilton WS, Yamamura HI, Enna, SJ (1978) Muscimol binding in rat brain: Association with synaptic GABA receptors. Brain Res. 148: 153–162
Chambon JP, Feltz P, Heaulme M, Restle S, Schlichter R, Biziere K, Wermuth CG (1985) An arylaminopyridazine derivative of y-aminobutyric acid (GABA) is a selective and competitive antagonist of the GABAA receptor site. Proc. Natl. Acad. Sci. USA 82: 1832–1836
Cheng YC, Prusoff WH (1973) Relationship between the in hibition constant (K ; ) and the concentration of inhibitor which causes 50 per cent inhibition (1 50 ) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099–3108
Enna SJ, Möller H (1987) y-aminobutyric acid (GABA) receptors and their association with benzodiazepine recognition sites. In: Meltzer HY (ed) Psychopharmacology: The Third Generation Schwartz RD, Mindlin MC (1988) Inhibition of the GABA receptor-gated chloride ion channel in brain by noncompetitive inhibitors of the nicotinic receptor-gated cation channel. J Pharmacol Exp Ther 244: 963–970
Enna SJ, Snyder SH (1976) Influence of ions, enzymes, and detergents on y-aminobutyric acid-receptor binding in synaptic membranes of rat brain. Mol Pharmacol 13: 442–453
Gusti P, Ducic I, Puia G, Arban R, Walser A, Guidotti A, Costa E (1993) Imidazenil: A new partial positive allosteric modulator of y-aminobutyric acid (GABA) action at GABAA receptors. J Pharmacol Exp Ther 266: 1018–1028
Heaulme M, Chambon JP, Leyris R, Molimard JC, Wermuth CG, Biziere K (1986) Biochemical characterization of the interaction of three pyridazinyl-GABA derivatives with the GABAA receptor site. Brain Res 384: 224–231
Heaulme M, Chambon JP, Leyris R, Wermuth CG, Biziere K (1987) Characterisation of the binding of [3H]SR 95531, a GABAA antagonist, to rat brain membranes. J. Neurochem. 48: 1677–1686
Kleingoor C, Ewert M, von Blankenfeld G, Seeburg PH, Kettenmann H (1991) Inverse but not full benzodiazepine agonists modulate recombinant a613,y2GABAA receptors in transfected human embryonic kidney cells. Neurosci Lett 130: 169–172
Krogsgaard-Larsen P, Frolund B, Jorgensen FS, Schousboe A (1994) GABAA receptor agonists, partial agonists, and antagonists. Design and therapeutic prospects. J Med Chem 37: 2489–2505
Lewin AH, de Costa BR, Rice KC, Solnick P (1989) meta-and para-Isothiocyanato-t-butylbicycloorthobenzoate: irreversible ligand of the γ-aminobutyric acid-regulated chloride ionophore. Mol Pharmacol 35: 189–194
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J. Biol Chem. 193: 265–275
Martini C, Rigacci T, Lucacchini A (1983) [3H]muscimol binding site on purified benzodiazepine receptor. J Neurochem 41: 1183–1185
Mohler H, Malherbe P, Draguhn A, Richards JG (1990) GABAA-receptors: structural requirements and sites of gene expression in mammalian brain. Neurochem Res 15: 199–207
Snodgrass SR (1978) Use of 3H-muscimol for GABA receptor studies. Nature 273: 392–394
Turner DM, Sapp DW, Olsen RW (1991) The benzodiazepin/alcohol antagonist Ro 15–4513: binding to a GABAA receptor subtype that is insensitive to diazepam. J Pharmacol Exp Ther 257: 1236–1242
Vicini S (1991) Pharmacologic significance of the structural heterogeneity of the GABAA receptor-chloride ion channel complex. Neuropsychopharmacol 4: 9–15
Williams M, Risley EA (1978) Characterization of the binding of [3H]muscimol, a potent γ-aminobutyric acid antagonist, to rat synaptosomal membranes using a filtration assay. J Neurochem 32: 713–718
Bittiger H, Bernasconi R, Froestl W, Hall R, Jaekel J, Klebs K, Krueger L, Mickel SJ, Mondadori C, Olpe HR, Pfannkuch F, Pozza M, Probst A, van Riezen H, Schmutz M, Schuetz H, Steinmann MW, Vassout A, Waldmeyer P, Bieck P, Farger G, Gleiter C, Schmidt EK, Marescuax C (1992) GABAB antagonists: potential new drugs. Pharmacol Commun 2: 70–74
Bonanno G, Raiteri M (1992) Functional evidence for multiple y-aminobutyric acide receptor subtypes in the rat cerebral cortex. J Pharmacol Exp Ther 262: 114–118
Bonanno G, Raiteri M (1993 a) Multiple GABAB receptors. Trends Pharmacol Sci 14: 259–261
Bonanno G, Raiteri M (1993 b) y-Aminobutyric acid (GABA) autoreceptors in rat cerebral cortex and spinal cord represent pharmacologically distinct subtypes of the GABAB receptor. J Pharmacol Exp Ther 265: 765–770
Bowery G, Hill DR, Hudson AL (1983) Characterization of GABAB receptor binding sites on rat whole brain synaptic membranes. Br J Pharmacol 78: 191–206
Bowery NG (1993) GABAB receptor pharmacology. Annu Rev Pharmacol Toxicol 33: 109–147
Bowery NG, Hill DR, Hudson AL (1985) (3H)(—)baclofen: An improved ligand for GABAB sites. Neuropharmacol 24: 207–210
Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099–3108
Drew CA, Johnston GAR, Weatherby RP (1984) Bicucculineinsensitive GABA receptors: Studies on the binding of (—)baclafen to rat cerebellar membranes. Neurosci Lett 52: 317–321
Enna SJ, Möller H (1987) γ-aminobutyric acid (GABA) receptors and their association with benzodiazepine recognition sites. In: Psychopharmacology: The Third Generation of Progress. ed. by HY Meltzer, Raven Press, New York, pp 265–272
Hill DR, Bowery NG (1981) 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABAB sites in rat brain. Nature 290: 149–152
Kato K, Goto M, Fukuda H (1983) Regulation by divalent cations of 3H-baclofen binding to GABAB sites in rat cerebellar membranes. Life Sci 32: 879–887
Kerr DIB, Ong J, Johnston GAR, Abbenante J, Prager RH (1988) 2-Hydroxy-saclofen: am improved antagonist at central and peripheral GABAB receptors. Neurosci Lett 92: 92–96
Kerr DIB, Ong J, Johnston GAR, Abbenante J, Prager RH (1989) Antagonism of GABAB receptors by saclofen and related sulphonic analogues of baclofen and GABA. Neurosci Lett 107: 239–244
Kerr DIB, Ong J, Prager RH. Gynther BD, Curtis DR (1987) Phaclofen: a peripheral and central baclofen antagonist. Brain Res 405: 150–154
Lanza M, Fassio A, Gemignani A, Bonanno G, Raiteri M (1993) CGP 52432: a novel potent and selective GABAB autoreceptor antagonist in rat cerebral cortex. Eur J Pharmacol 237: 191–195
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J. Biol Chem. 193: 265–275
Olpe HR, Karlsson G, Pozza MF, Brugger F, Steinman M, van Riezen H, Fagg G, Hall RG, Froestl W, Bittiger H (1990) CGP 35348: a centrally active blocker of GABAB receptors. Eur J Pharmacol 187: 27–38
Paredes RG, Agmo A (1992) GABA and behavior: The role of receptor subtypes. Neurosci Behav Rev 16: 145–170
Robinson TM, Cross AJ, Green AR, Toczek JM, Boar BR (1989) Effects of the putative antagonists phaclofen and 6aminovaleric acid on GABAB receptor biochemistry. Br J Pharmacol 98: 833–840
Scherer RA, Ferkany JW, Enna SJ (1988) Evidence for pharmacologically distinct subsets of GABAB receptors. Brain Res Bull 21: 439–443
Shank RP, Baldy WJ, Mattucci LC, Vilani FJ Jr (1990) Ion and temperature effects on the biding of y-aminobutyrate to its receptors and the high-affinity transport system. J Neurochem 54: 2007–2015
Shoulson I, Odoroff Ch, Oakes D, Behr J, Goldblatt D, Caine E, Kennedy J, Miller Ch, Bamford K, Rubin A, Plumb S, Kurlan R (1989) A controlled clinical trial of baclofen as protective therapy in early Huntington’s disease. Ann Neurol 25: 252–259
Wilkin GP, Hudson AL, Hill DR, Bowery NG (1981) Autoradiographic localisation of GABAB receptors in rat cerebellum. Nature 294: 584–587
Chang RSL, Snyder SH (1978) Benzodiazepine receptors: labelling in intact animals with [3H]-flunitrazepam. Eur J Pharmacol 48: 213–218
Damm HW, Müller WE, Schläfer U, Wollert U (1978) [3H]Flunitrazepam: its advantages as a ligand for the identification of benzodiazepine receptors in rat brain membranes. Res Commun Chem Pathol Pharmacol 22: 597–600
Davies MF, Onaivi ES, Chen SW, Maguire PA, Tsai NF, Loew GH (1994) Evidence for central benzodiazepine receptor heterogeneity from behavior tests. Pharmacol Biochem Behav 49: 47–56
Hafely WE, Martin JR, Richard JG, Schoch P (1993) The multiplicity of actions of benzodiazepine receptor ligands. Can J Psychiatry 38, Suppl 4: S102 — S108
Iversen LL (1983) Biochemical characterisation of benzodiazepine receptors. In: Trimble MR (ed.) Benzodiazepines Divided. John Wiley & Sons Ltd. pp 79–85
Jacqmin P, Wibo M, Lesne M (1986) Classification of benzodiazepine receptor agonists, inverse agonists and antagonists using bicuculline in an in vitro test. J Pharmacol (Paris) 17: 139–145
Klepner CA, Lippa AS, Benson DI, Sano MC, Beer B (1979) Resolution in two biochemically and pharmacologically distinct benzodiazepine receptors. Pharmacol Biochem Behav 11: 457–462
Mennini T, Garattini A (1982) Benzodiazepine receptors: Correlation with pharmacological responses in living animals, Life Sci 31: 2025–2035
Möhler H, Okada T (1977) Benzodiazepine receptor: Demonstration in the central nervous system. Science 198: 849–851
Möhler H, Okada T (1977) Properties of ‘H-diazepam binding to benzodiazepine receptors in rat cerebral cortex. Life Sci 20: 2101–2110
Möhler H, Richards JG (1983) Benzodiazepine receptors in the central nervous system. In: Costa E (ed) The Benzodiazepines: From Molecular Biology to Clinical Practice. Raven Press, New York, pp. 93–116
Olsen RW (1981) GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 37: 1–13
Schacht U, Baecker G (1982) Effects of clobazam in benzodiazepine-receptor binding assays Drug Dev. Res. Suppl. 1, 83–93
Speth RC, Wastek GJ, Johnson PC, Yamamura HI (1978) Benzodiazepine binding in human brain: characterization using [3H]flunitrazepam. Life Sci 22: 859–866
Speth RC, Wastek GJ, Yamamura HI (1979) Benzodiazepine receptors: Temperature dependence of 3H-diazepam binding. Life Sci 24: 351–358
Squires RF, Braestrup C (1977) Benzodiazepine receptors in rat brain. Nature 266: 732–734
Supavilai P, Karobath M (1980) Heterogeneity of benzodiazepine receptors in rat cerebellum and hippocampus. Eur J Pharmacol 64: 91–93
Sweetnam PM, Tallman JF (1985) Regional difference in brain benzodiazepine receptor carbohydrates. Mol Pharmacol 29: 299–306
Takeuchi T, Tanaka S, Rechnitz GA (1992) Biotinylated 1012-S conjugate as a probe ligand for benzodiazepine receptors: characterization of receptor binding sites and receptor assay for benzodiazepine drugs. Anal Biochem 203: 158–162
Tallman JF (1980) Interaction between GABA and benzodiazepines. Brain Res Bull 5: 829–832
Cowen PJ (1991) Serotonin receptor subtypes: Implications for psychopharmacology. Br J Psychiatry 159 (Suppl 12): 7–14
Dourish CT, Hutson PH, Curzon G (1986) Putative anxiolytics 8-OH-DPAT, buspirone and TVX Q 7821 are agonists at 5HT,A autoreceptors in the raphe nucleus. TIPS 7: 212–214
Fozard JR (1984) MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 326: 36–44
Frazer A, Maayani S, Wolfe BB (1990) Subtypes of receptors for serotonin. Annu Rev Pharmacol Toxicol 30: 307–348
Fuller RW (1990) Serotonin receptors and neuroendocrine responses. Neuropsychopharmacol 3: 495–502
Glennon RA (1991) Serotonin receptors and site-selective agents. J Physiol Pharmacol 42: 49–60
Göthert M (1990) Presynaptic serotonin receptors in the central nervous system. Ann NY Acad Sci 604: 102–112
Gozlan H, El Mestikawy S, Pichat L, Glowinsky J, Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand:’H-PAT. Nature 305: 140–142
Grossman CJ, Kilpatrick GJ, Bunce KT (1993) Development of a radioligand binding assay for 5-HT4receptors in guinea-pig and rat brain. Br J Pharmacol 109: 618–624
Hall MD, El Mestikawy S, Emerit MB, Pichat L, Hamon M, Gozlan H (1985) [41]-8-Hydroxy-2-(di-n-propylamino)tetralin binding to pre-and postsynaptic 5-hydroxytryptamine sites in various regions of rat brain. J Neurochem 44: 1685–1696
Heuring RE, Peroutka SJ (1987) Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J Neurosci 7: 894–903
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994) VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine ( Serotonin ). Pharmacol Rev 46: 157–203
Humphrey PPA, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14: 233–236
Iversen SD (1984) 5-HT and anxiety. Neuropharmacol 23: 1553–1560
Jenck F, Moreau JL, Mutel V, Martin JR (1994) Brain 5-HT,c receptors and antidepressants. Progr Neuropsychopharmacol Biol Psychiat 18: 563–574
Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE (1993) Evidence for a role of 5-HT,c receptors in the antiserotoninergic properties of some antidepressant drugs. Eur J Pharmacol 231: 223–229
Kung HF, Kung MP, Clarke W, Maayani S, Zhuang ZP (1994) A potential 5-HT,A receptor antagonist: p-MPPI. Life RI 55: 1459–1462
Kung MP, Frederick D, Mu M, Zhuang ZP, Kung HF (1995) 4-(2’-Methoxyphenyl)-1-[2’-(n-2“-pyridinyl)-p-iodobenzamido]-ethyl-piperazine ([125I]p-MPPI) as a new selective radioligand on serotonin-1A sites in rat brain: In vitro binding and autoradiographic studies. J Pharmacol Exp Ther 272:429–437
Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, Foye PE, Racke M, Slone AL, Siegel BW, Danielson PE, Sutcliffe JG, Erlander MG (1994) A novel adenyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 11: 449–458
Martin GR, Humphrey PPA (1994) Classification review. Receptors for 5-hydroxytryptamine: Current perspectives on classification and nomenclature. Neuropharmacol 33: 261–273
Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5HT1 recognition site. Eur J Pharmacol 90: 151–153
New JS (1990) The discovery and development of buspirone: a new approach to the treatment of anxiety. Med Res Rev 10: 283–326
Newman ME, Lerer B, Shapira B (1992) 5-HT-1A receptor-mediated effects of antidepressants. Progr Neuropsychopharmacol Biol Psychiat 17: 1–19
Pazos A, Hoyer D, Palacios JM (1984) The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol 106: 539–546
Pedigo NW, Yammamura HI, Nelson DL (1981) Discrimination of multiple [3H15-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36: 220–226
Peroutka SJ (1985) Selective interaction of novel anxiolytics with 5-hydroxytryptamine,A receptors. Biol Psychiatry 20: 971–979
Peroutka SJ (1986) Pharmacological differentiation and characterization of 5-HT1A 5-HT,B and 5-HT,c binding sites in rat frontal cortex. J Neûrochem 47: 29–540
Peroutka SJ (1988) 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization Trends Neurosci 11:496–500
Raymond JR, El Mestikawy S, Fargin A (1992) The 5-HTIA receptor: from molecular characteristics to clinical conelates. In: Brann MR (ed) Molecular Biology of G-Proteincoupled receptors. Birkhäuser Boston Basel Berlin pp 113–141
Saxena PR (1994) Modern 5-HT receptor classification and 5-HT based drugs. Exp Opin Invest Drugs 3: 513–523
Saxena PR, Lawang A (1985) A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5carboxamidotryptamine, a selective agonist of 5HT, receptors. Arch Int Pharmacodyn 277: 235–252
Schlegel JR, Peroutka SJ (1986) Nucleotide interactions with 5-HTIA binding sites directly labeled by [41]-8-hydroxy-2(di-n-propylamino)tetralin ([’H] -8-OH-DPAT). Biochem Pharmacol 35: 1943–1949
Sleight Ai, Boess FG, Bourson A, Sibley DR, Monsma FJ (1995) 5-HT6 and 5-HT, serotonin receptors: Molecular biology and pharmacology. Neurotransmiss 11,(3):1–5
Traber J, Glaser T (1987) 5-HT,A receptor-related anxiolytics. TIPS 8: 432–437
Verge D, Daval G, Marcinkiewicz M, Patey A, El Mestikawy H, Gozlan Hamon M (1986) Quantitative autoradiography of multiple 5-HT, receptor subtypes in the brain of control of 5,7-dihydroxytryptamine-treated rats. J Neurosci 6: 3474–3482
Yocca FD, Hyslop DK, Smith DW, Maayani S (1987) BMY 7378, a buspirone analog with high affinity, selectivity and low intrinsic activity at the 5-HT,A receptor in rat and guinea pig hippocampal membranes. Eur J Pharmacol 137: 293–294
Boulenguez P, Chauveau J, Segu L, Morel A, Lanoir J, Delaage M (1992) Biochemical and pharmacological characterization of serotonin-O-carboxymethylglycyl[125I]iodotyrosinamide, a new radioligand probe for 5-HT,B and 5HT,D binding sites. J Neurochem 58: 951–959
Hartig PR, Branchek TA, Weinshank RL (1992) A subfamily of 5-HT,D receptor genes. Trends Pharmacol Sci 13: 152–159
Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT, and 5-HT2recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8OH-DPAT, (—)I[125I]iodocyanopindolol, [’H]mesulergine and [3H]ketanserin. Eur J Pharmacol 118: 13–23
Hoyer D, Schoeffter P, Waeber C, Palacios JM (1990) Sero- tonin 5-HT,D receptors. Ann NY Acad Sci 600: 168–181
Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML (1991) Preclinical studies on the anti-migraine drug, Sumatriptan. Eur Neurol 31: 282–290
Middlemiss DN (1984) Stereoselective blockade at [3H]5-HT binding sites and at the 5-HT autoreceptor by propranonol. Eur J Pharmacol 101: 289–293
Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5HT1 recognition site. Eur J Pharmacol 90: 151–153
Palacios JM, Waeber C, Bruinvels AT, Hoyer D (1992) Direct visualisation of serotonin,D receptors in the human brain using a new iodinated ligand. Mol Brain Res 346: 175–179
Pedigo NW, Yammamura HI, Nelson DL (1981) Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36: 220–226
Peroutka S, Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 16: 687–699
Peroutka SJ (1986) Pharmacological differentiation and characterization of 5-HT,A, 5-HT,B and 5-HT,c binding sites in rat frontal cortex. J Neurochem 47: 529–540
Peroutka SJ (1988) 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. TINS 11:496–500
Schlicker E, Werner U, Hamon M, Gozlan H, Nickel B, Szelenyi I, Göthert M (1992) Anpirtoline, a novel highly potent 5-HT,B receptor agonist with antinociceptive/antidepressant-like actions in rodents. Br J Pharmacol 105: 732–738
Segu L, Chauveau J, Boulenguez P, Morel A, Lanoir J, Delaage M (1991) Synthesis and pharmacological study of radioiodinated serotonin derivative specific for 5-HTIB and 5-HT,D binding sites in the central nervous system. CR Acad Sci (Paris) 312: 655–661
Barnes NM, Costall B, Naylor RJ (1988) [3H]Zacopride: Ligand for the identification of 5-HT3 recognition sites. J Pharm Pharmacol 40: 548–551
Butler A, Hill JM, Ireland SJ, Jordan CD, Tyres MB (1988) Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 94: 397–412
Costall B, Naylor RJ, Tyers MB (1988) Recent advances in the neuropharmacology of 5-HT3 agonists and antagonists. Rev Neuroscience 2: 41–65
Costall B, Naylor RT, Tyers MB (1990) The psychopharmacology of 5-HT,receptors. Pharmac Ther 47: 181–202
Hoyer D (1990) Serotonin 5HT3, 5HT, and 5-HT-M receptors. Neuropsychopharmacol 3: 371–383
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994) VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine ( Serotonin ). Pharmacol Rev 46: 157–203
Hoyer D, Neijt HC (1988) Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding. Mol Pharmacol 33: 303–309
Kilpatrick GJ, Bunce KT, Tyer MB (1990) 5-HT, Receptors. Med Res Rev 10: 441–475
Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5HT3 receptors in rat brain using radioligand binding. Nature 330: 746–748
Kilpatrick GJ, Jones BJ, Tyers MB (1989) Binding of the 5HT3 ligand, [3H]-GR 65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 159: 157–164
Martin GR, Humphrey PPA (1994) Classification review. Receptors for 5-hydroxytryptamine: Current perspectives on classification and nomenclature. Neuropharmacol 33: 261–273
Peroutka SJ (1988) 5-Hydroxytryptamine receptor subtypes: Molecular, biochemical and physiological characterization. Trends Neuroscience 11: 496–500
Peroutka SJ (1991) Serotonin receptor subtypes and neuropsychiatric diseases: Focus on 5HT,D and 5HT3 receptor agents. Pharmacol Rev 43: 579–586
Pinkus LM, Sarbin NS, Barefoot DS, Gordon JC (1989) Association of [3H]zacopride with 5-HT3 binding sites. Eur J Pharmacol 168: 355–362
Saxena PR (1994) Modern 5-HT receptor classification and 5-HT based drugs. Exp Opin Invest Drugs 3: 513–523
Watling KJ (1989) 5HT3 Receptor agonists and antagonists. Neurotransmission 3:1–4
Watling KJ, Aspley S, Swain CJ, Saunders J (1988) [3H]Quaternised ICS 205–930 labels 5-HT3 receptor binding sites in rat brain. Eur. J. Pharmacol. 149: 397–398
Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, Schunack W, Schwartz JC (1987) Highly potent and selective ligands for histamine H3-receptors. Nature 327: 117–123
Arrang JM, Garbarg M, Schwartz JC (1985) Autoregulation of histamine release in brain by presynaptic H3-receptors. Neurosci 15: 533–562
Arrang JM, Roy J, Morgat JL, Schunack W, Schwartz JC (1990) Histamine H3-receptor binding sites in rat brain membranes: modulation by guanine nucleotides and divalent cations. Eur J Pharmacol 188: 219–227
Haaksma EEJ, Leurs R, Timmerman H (1990) Histamine receptors: subclasses and specific ligands. Pharmac Ther 47: 73–104
Hew KWS, Hodgkinson CR, Hill SJ (1990) Characterization of histamine H3-receptors in guinea-pig ileum with H3-selective ligands. Br J Pharmacol 101: 621–624
Hill SJ (1990) Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev 42: 45–83
Hill SJ (1992) Histamine receptor agonists and antagonists. Neurotransmiss 8 (1): 1–5
Jansen FP, Rademaker B, Bast A, Timmerman H (1992) The first radiolabeled histamine H3 receptor antagonist, [’23I]iodophenpropit: saturable and reversible binding to rat cortex membranes. Eur J Pharmacol 217: 203–205
Korte A, Myers J, Shih NY, Egan RW, Clark MA (1990) Characterization and tissue distribution of H3 histamine receptors in guinea pigs by Na-methylhistamine. Biochem Biophys Res Commun 168: 979–986
Leurs R, van der Goot H, Timmerman H (1991) Histaminergic agonists and antagonists. Recent developments. Adv Drug Res 20: 217–304
Lowry OH, Rosebrough NJ, Fan AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275
Schlicker E, Betz R, Göthert M (1988) Histamine H3-receptormediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 337: 588–590
Timmerman H (1990) Histamine H3 ligands: just pharmacological tools or potential therapeutic agents? J Med Chem 33: 4–11
Van der Goot H, Schepers MJP, Sterk GJ, Timmerman H (1992) Isothiourea analogues of histamine as potent agonists or antagonists of the histamine H3-receptor. Eur J Med Chem 27: 511–517
Van der Werf JF, Timmerman H (1989) The histamine H3 receptor: a general presynaptic regulatory system? Trends Pharmacol Sci 10: 159–162
West RE Jr, Zweig A, Shih NY, Siegel MI, Egan RW, Clark MA (1990) Identification of two H3-histamine receptor subtypes. Mol Pharmacol 38: 610–613
Bastian JW, Krause WE, Ridlon SA, Ercoli N (1959) CNS drug specificity as determined by the mouse intravenous pentylenetetrazol technique. J Pharmacol Exp Ther 127: 75–80
Domino EF (1964) Centrally acting skeletal muscle relaxants. In: Laurence DR, Bacharach AL (eds.) Evaluation of Drug Activities: Pharmacometrics. Academic Press, London and New York. pp 313–324
Lippa AS, Priscilla A, Nash, BA, Greenblatt EN (1979) Pre-clinical neuro-psychopharmacological testing procedures for anxiolytic drugs. In: Fielding St, Lal H (eds) Anxiolytics, Futura Publishing Comp. Inc., New York, pp. 41–81
Starzl TE, Niemer WT, Dell M, Forgrave PR (1953) Cortical and subcortical electrical activity in experimental seizures induced by Metrazol. J Neuropath Exp Neurol 12: 262–276
Bigler ED (1977) Comparison of effects of bicuculline, strychnine, and picrotoxin with those of pentylenetetrazol on photically evoked afterdischarges. Epilepsia 18: 465–470
Costa E, Guidotti A, Mao CC (1975) New concepts in the mechanism of action of benzodiazepines. Life Sci. 17: 167–186
Lambert DM, Poupaert JH, Maloteaux JM, Dumont P (1994) Anticonvulsant activities of N-benzyloxycarbonylglycine after parenteral administration. Neuro Report 5: 777–780.
McAllister KH (1992) N-Methyl-D-aspartate receptor antagonists and channel blockers have different effects upon a spinal seizure model in mice. Eur J Pharmacol 211: 105–108
Buckett WR (1981) Intravenous bicuculline test in mice: Characterisation with Gabaergic drugs. J Pharmacol Meth 5: 35–41
Costa E, Guidotti A, Mao CC, Suria A (1975) New concepts in the mechanism of action of benzodiazepines. Life Sci 17: 167–186
Enna SJ, Möhler H (1987) y-Aminobutyric acid (GABA) receptors and their association with benzodiazepine recognition sites. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress. Raven Press New York, pp. 265–272
Usunoff G, Atsev E, Tchavdarov D (1969) On the mechanisms of picrotoxin epileptic seizure (macro-and micro-electrode investigations). Electroencephalogr Clin Neurophysiol 27: 444
Costa E, Guidotti A, Mao CC (1975) Evidence for involvement of GABA in the action of benzodiazepines: Studies on rat cerebellum. In: Costa E, Greengard P (eds) Mechanisms of Action of Benzodiazepines. Advances in Biochemical Psychopharmacology, Vol 14. Raven Press, New York, pp 113–151
Litchfiled J, Wilcoxon F (1949) A simplified method of evaluating dose effect experiments. J Pharmacol Exp Ther 96: 99–113
Dunn R, Fielding S (1987) Yohimbine-induced seizures in mice: A model predictive of potential anxiolytic and GABA-mimetic agents. Drug Dev Res 10: 177–188
Dunn RW, Corbett R, Martin LL, Payack JF, Laws-Ricker L, Wilmot CA, Rush DK, Cornfeldt ML, Fielding S (1990) Preclinical anxiolytic profiles of 7189 and 8319, novel noncompetitive NMDA antagonists. Current and Future Trends in Anticonvulsant, Anxiety, and Stroke Therapy, Wiley-Liss, Inc., pp 495–512
Dunn RW, Corbett R (1992) Yohimbine-induced convulsions involve Nmda and Gabaergic transmission. Neuropharmacology 31: 389–395
Brady JV, Nauta WJH (1953) Subcortical mechanisms in emotional behavior: Affective changes following septal forebrain lesions in the albino rat. J Comp Physiol Psycho! 46: 339–346
Chen G, Bohner B, Bratten AC (1963) The influence of certain central depressants on fighting behavior of mice. Arch Int Pharmacodyn 142: 30–34
Heise GA, Boff E (1961) Taming action of chlordiazepoxide. Fed Proc 20: 393–397
Irwin S, Kinohi R, Van Sloten M, Workman MP (1971) Drug effects on distress-evoked behavior in mice: Methodology and drug class comparisons. Psychopharmacologia (Berl.) 20:172–185
Randall LO, Heise GA, Schalleck W, Bagdon R.E, Banziger R, Boris A, Moe A, Abrams WB (1961) Pharmacological and clinical studies on Valium(T.M.). A new psychotherapeutic agent of the benzodiazepine class. Current Ther Res 9: 405–425
Rudzik AD, Hester JB, Tang AH, Straw RN, Friis W (1973) Triazolobenzazepines, a new class of central nervous system-depressant compounds. In: Garattini S, Mussini E, Randall LO (eds.) The Benzodiazepines, Raven Press New York, pp 285–297
Tedeschi DH, Fowler PJ, Miller RB, Macko E (1969) Pharmacological analysis of footshock-induced fighting behaviour. In: Garattini S, Sigg EB (eds.) Aggressive behaviour. Excerpta Medica Foundation Amsterdam, pp 245–252
Tedeschi RE, Tedeschi DH, Mucha A, Cook L, Mattis PA, Fellows EJ (1959) Effects of various centrally acting drugs on fighting behavior of mice. J Pharmacol Exp Ther 125: 28–34
Ulrich R, Symannek B (1969) Pain as a stimulus for aggression In: Garattini S, Sigg EB (eds.) Aggressive behaviour. Excerpta Medica Foundation Amsterdam, pp 59–69
Caharperntier J (1969) Analysis and measurement of aggressive behaviour in mice. In: Garattini S, Sigg EB (eds) Aggressive Behaviour. Excerpta Medica Foundation, Amsterdam, pp 86–100
Davbanzo JP (1969) Observations related to drug-induced alterations in aggressive behaviour. In: Garattini S, Sigg EB (eds) Aggressive Behaviour. Excerpta Medica Foundation, Amsterdam, pp 263–272
Hoffmeister F, Wuttke W (1969) On the actions of psychotropic drugs on the attack-and aggressive-defensive behaviour of mice and cats. In: Garattini S, Sigg EB (eds) Aggressive Behaviour. Excerpta Medica Foundation, Amsterdam, pp 273–280
Krsiak M, Janku I (1969) The development of aggressive behaviour in mice by isolation. In: Garattini S, Sigg EB (eds.) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam pp 101–105
Lagerspetz KMJ (1969) Aggression and aggressiveness in laboratory mice. In: Garattini S, Sigg EB (eds) Aggressive Behaviour. Excerpta Medica Foundation, Amsterdam, pp 77–85
Le Douarec JC, Broussy L (1969) Dissociation of the aggressive behaviour in mice produced by certain drugs. In: Garattini S, Sigg EB (eds) Aggressive Behaviour. Excerpta Medica Foundation, Amsterdam, pp 281–295
McMillen BA, Wooten MH, King SW, Scott SM, Williams HI. (1992) Interaction between subchronic administration of alprazolam and aryl-piperazine anxiolytic drugs in aggressive mice. Biogenic Amines 9: 131–140
Mos J, Oliver B, van Oorschot R, van Aken H, Zethof T (1989) Experimental and ethological aspect of maternal aggression in rats: five years of observations. In: Blanchard RJ, Brain PF, Blanchard DC, Parmigiani s (eds) Ethoexperimental Approaches to the Study of Behavior. Kluver Acad Publ, Dordrecht, Boston, London, pp 385–398
Oliver B Mos J ( 1992 Rodent models of aggressive behavior and serotonergic drugs. Progr Neuro-Psychopharm Biol Psychiat 16: 847–870
Oliver B, Mos J (1986) A female aggression paradigm for use in psychopharmacology: maternal agonistic behavior in rats. In: Brain PF, Ramirez JM (eds) Corss-Disciplinary Studies on Aggression. University of Seville Press, Seville, pp 73–111
Oliver B, Mos J. van Oorschot R (1985) Maternal aggression in rats: effects of chlordiazepoxide and fluprazine. Psycho-pharmacology 86: 68–76
Scriabine A, Blake M (1962) Evaluation of centrally acting drugs in mice with fighting behavior induced by isolation. Psychopharmacologia 3: 224–226
Valzelli L (1967) Drugs and aggressiveness. In: Garratini S, Shore PA (eds.) Advances in Pharmacology, Vol. 5, pp 79108, Academic Press, New York
Valzelli L (1969) Aggressive behaviour induced by isolation. In: Garattini S, Sigg EB (eds) Aggressive Behaviour. Excerpta Medica Foundation, Amsterdam, pp 70–76
Yen CY, Stanger RL, Millman N (1959) Ataractic suppression of isolation-induced aggressive behavior. Arch Im Pharmacodyn 123: 179–185
Costall B, Hendrie CA, Kelly ME, Naylor RJ (1987) Actions of sulpiride and tiapride in a simple model of anxiety in mice. Neuropharmacol 26: 195–200
Crawley J, Goodwin KK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13: 167–170
Crawley JN (1981) Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15: 695–699
Kilfoil T, Michel A, Montgomery D, Whithing RL (1989) Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice. Neuropharmacol 28: 901–905
Borsini F, Lecci A, Volterra G, Meli A (1989) A model to measure anticipatory anxiety in mice? Psychopharmacology 98: 207–211
Lecci A, Borsini F, Mancinelli A, D’Aranno V, Stasi MA, Volterra G, Meli A (1990) Effects of serotoninergic drugs on stress-induced hyperthermia in mice. J Neur Transmiss 82: 219–230
Lecci A, Borsini F, Volterra G, Meli A (1990) Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology 101: 255–261
Tulp M, Olivier B, Schipper J, van der Pel G, Mos J, van der Heyden J (1991) Serotonin reuptake blockers: Is there preclinical evidence for their efficacy in obsessive-compulsive disorder? Human Psychopharmacol 6: S63 - S71
Zelthof TJJ, van der Heyden JAM, Olivier B (1991) A new animal model for anticipatory anxiety? In: Olivier B, Mos J, Slangen JL (eds) Animal Models in Psychopharmacology. Birkhäuser Verlag, Basel, pp 65–68
Angelis L, File SE (1979) Acute and chronic effects of three benzodiazepines in the social interaction test in mice. Psychopharmacology (Berlin) 64: 127–129
Barnes NM, Costall B, Domeney AM, Gerrard PA, Kelly ME, Krähling H, Naylor RJ, Tomkins DM, Williams TJ (1991) The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav 40: 89–96
Corbett R, Dunn RW (1991) Effects of HA-966 on conflict, social interaction, and plus maze behaviors. Drug Dev Res 24: 201–205
Corbett R, Fielding S, Cornfeldt M, Dunn RW (1991) GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology 104: 312–316
Corbett R, Hartman H, Kerman LL, Woods AT, Strupczewski JT, Helsley GC, Conway PC, Dunn RW (1993) Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 45: 9–17
Dunn RW, Corbett R, Martin LL, Payack JF, Laws-Ricker L, Wilmot CA, Rush DK, Cornfeldt ML, Fielding S (1990) Preclinical anxiolytic profiles of 7189 and 8319, novel noncompetitive NMDA antagonists. Current and Future Trends in Anticonvulsant, Anxiety, and Stroke Therapy, Wiley-Liss, Inc., pp 495–512
File SE (1980) The use of social interactions as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Meth 1: 219–238
File SE, Hyde RJ (1979) A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilizers and stimulants. Pharmacol Biochem Behav 11: 65–69
Gardner C, Guy A (1984) A social interaction model of anxiety sensitive to acutely administered benzodiazepines. Drug Dev Res 4: 207–216
Szewczak MR, Cornfeldt, ML, Dunn RW, Wilker JC, Geyer HM, Glamkowski EJ, Chiang Y, Fielding S (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent. 1. In vivo profile. Drug Dev Res 11: 157–168
Treit D (1985) Animal models for the study of anti-anxiety agents: A review. Neurosci Biobehav Reviews 9: 203–222
Brett RR, Pratt JA (1990) Chronic handling modifies the anxiolytic effect of diazepam in the elevated plus-maze. Eur J Pharmacol 178: 135–138
Corbett R, Fielding St, Cornfeldt M, Dunn RW (1991) Gabamimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology 104: 312–316
Danks AM, Oestreicher AB, Spruijt Gispen WH, Isaakson RL (1991) Behavioral and anatomical consequences of unilateral fornix lesions and the administration of nimodipine. Brain Res 557: 308–312
Di Cicco D, Antal S, Ammassari-Teule M (1991) Prenatal exposure to gamma/neutron irradiation: sensorimotor alterations and paradoxical effects on learning. Teratology 43: 61–70
Dunn RW, Carlezon WA, Corbett R (1991) Preclinical anxiolytic versus antipsychotic profiles of the 5-HT, antagonists ondansetron, zacopride, 3a-tropanyl-1 H-indole-3carboxylic acid ester, and laH, 3a, 5aH-Tropan-3-y1–3,5dichlorobenzoate. Drug Dev Res 23: 289–300
File SE, Mabbutt PS, Hitchcott, PH (1990) Characterisation of the phenomenon of “one-trial tolerance” to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology 102: 98–101
Harro J, Pöld M, Vasar E (1990) Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. Naunynschmiedeberg’s Arch Pharmacol 341: 62–67
Kauppila T, Tanila H, Carlson S, Taira T (1991) Effects of atipamezole, a novel a2-adrenoreceptor antagonist, in openfield, plus-maze, two compartment exploratory, and forced swimming tests in rats. Eur J Pharmacol 205: 177–182
Montgomery KC (1958) The relation between fear induced by novel stimulation and exploratory behaviour. J Comp Physiol Psychol 48: 254–260
Munn NL (1950) The role of sensory processes in maze behavior. In: Handbook of Psychological Research in the Rat. Houghton Mifflin Comp., Boston, pp 181–225
Pellow S (1986) Anxiolytic and anxiogenic drug effects in a novel test of anxiety: Are exploratory models of anxiety in rodents valid? Meth and Find Exptl Clin Pharmacol 8: 557–565
Pellow S, Chopin Ph, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth 14: 149–167
Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 25: 525–529
Silverman P (1978) Approach to a conditioned stimulus: mazes. In: Animal behaviour in the laboratory. Chapman and Hall, London, pp 110–119
Toubas PL, Abla KA, Cao W, Logan LG, Seale TW (1990) Latency to enter a mirrored chamber: a novel behavioral assay for anxiolytic agents. Pharmacol Biochem Behav 35: 121–126
Connor DJ, Langlais PJ, Thal LJ (1991) Behavioral impairments after lesions in the nucleus basalis by ibotenic acid and quisqualic acid. Brain Res 555: 84–90
McNaughton N, Morris RGM (1987) Chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. Behav Brain Res 24: 39–46
Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Meth I1: 47–60
Morris RGM (1981) Spatial localization does not require the presence of local cues. Learn Motiv 12: 239–260
Morris RGM, Anderson E, Lynch GS, Baudry M (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature: 319: 774–776
Rowan MJ, Culle WK, Moulton B (1990) Buspirone impairment of performance of passive avoidance and spatial learning tasks in the rat. Psychopharmacology 100: 393–398
Emmanouil D, Quock RM (1990) Effects of benzodiazepine antagonist, inverse agonist and antagonist drugs in mouse staircase test. Psychopharmacology 102: 95–97
Houri D (1985) Staircase test of central nervous system drugs. Pharmacometrics 30: 467–479
Keane PE, Simiand J, Morre M, Biziere K (1988) Tetrazepam: A benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents. J Pharmacol Exper Ther 245: 692–698
Porsolt RD, Lenègre A, Avril I, Doumont G (1988) Antagonism by exifone, a new cognitive enhancing agent, of the amnesias induced by four benzodiazepines in mice. Psychopharmacology 95: 291–297
Simiand J, Keane PE, Morre M (1984) The staircase test in mice: A simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology 84: 48–53
Stem L, Thierry B, Chermat R, Millet B, Simon P, Porsolt RD (1987) Comparing benzodiazepines using the staircase test in mice. Psychopharmacology 92: 106–109
Thiébot MH, Soubrié P, Simon P, Boissier JR (1973) Dissociation de deux composantes du comportement chez le Rat sous l’effet de psychotropes. Application à l’etude des anxiolytiques. Psychopharmacologia 31: 77–90
Pollard GT, Howard JL (1991) Cork gnawing in the rat as a screening method for buspirone-like anxiolytics. Drug Dev Res 22: 179–187
Pollard GT, Nanry KP, Howard JL (1992) Effects of tandospirone in three behavioral tests for anxiolytics. Eur J Pharmacol221: 297–305
Gardner CR (1985) Distress vocalisation in rat pups: A simple screening method for anxiolytic drugs. J Pharmacol Meth 14: 181–187
Schipper J, Tulp MThM, Berkelmans B, Mos J, Van der Heijden JAM, Olivier B (1991) Preclinical pharmacology of Flesinoxan: A potential anxiolytic and antidepressant drug. Human Psychopharmacol 6: 53–61
Tulp M, Olivier B, Schipper J, van der Poel G, Mos J, van der Heyden J (1991) Serotonin reuptake blockers: Is there preclinical evidence for their efficacy in obsessive-compulsive disorder? Hum Psychopharmacol 6: S63 - S71
Barnes NM, Cheng CHK, Costall B, Ge J, Kelly ME, Naylor RJ (1992) Profiles of R(+)/S(—)-Zacopride and anxiolytic agents in a mouse model. Eur J Pharmacol 218: 91–100
Barnes NM, Costalj B, Domeney AM, Gerrard PA, Kelly ME, Krähling H, Naylor RJ, Tomkins DM, Williams TJ (1991) The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav 40: 89–96
Blumstein LK, Crawley JN (1983) Further characterisation of a simple, automated exploratory model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 18: 37–40
Crawley JN (1981) Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15: 695–699
Crawley JN, Goodwin FK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13: 167–170
Kauppila T, Tanila H, Carlson S, Taira T (1991) Effects of atipamezole, a novel a2-adrenoreceptor antagonist, in openfield, plus-maze, two compartment exploratory, and forced swimming tests in rats. Eur J Pharmacol 205: 177–182
Schipper J, Tulp MThM, Berkelmans B, Mos J, Van der Heijden JAM, Olivier B (1991) Preclinical pharmacology of Flesinoxan: A potential anxiolytic and antidepressant drug. Human Psychopharmacol 6: 53–61
Treit D (1985) Animal models for the study of anti-anxiety agents: A review. Neurosci Biobehav Reviews 9: 203–222
Falk JL (1971) The nature and determinants of adjunctive behavior. Physiol Behav 6: 577–588
Pellon R, Blackman DE (1992) Effects of drugs on the temporal distribution of schedule-induced polydipsia in rats. Pharmacol Biochem Behav 43: 689–695
Pitman RK (1989) Animal models of compulsive behavior. Biol Psychiatry 26: 189–198
Woods A, Smith C, Szewczak M, Dunn RW, Cornfeldt M, Corbett R (1993) Selective re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology 112: 195–198
Aron C, Simon P, Larousse C, Boissier JR (1971) Evaluation of a rapid technique for detecting minor tranquillizers. Neuropharmacol 10: 459–469
Boissier JR, Simon P, Aron C (1968) A new method for rapid screening of minor tranquilizers in mice. Eur J Pharmacol 4: 145–151
Lenègre A, Chermat R, Avril I, Stéru L, Porsolt RD (1988) Specificity of Piracetam’s anti-amnesic activity in three models of amnesia in the mouse. Pharmacol Biochem Behav 29: 625–629
Simon P (1970) Les Anxiolytiques. Possibilités d’étude chez l’animal. Actualités pharmacol. 23: 47–78
Stephens DN, Schneider HH, Kehr W, Andrews JS, Rettig K-J, Turski L, Schmiechen R, Turner JD, Jensen LH, Petersen EN, Honore T, Bondo Jansen J (1990) Abecarnil, a metabolically stable, anxioselective ß-carboline acting at benzodiazepine receptors. J Pharmacol Exper Ther 253: 334–343
Conti LH, Maciver CR, Ferkany JW, Abreu ME (1990) Footshock-induced freezing behavior in rats as a model for assessing anxiolytics. Psychopharmacology 102: 492–497
Acri JB, Grunberg NE, Morse DA (1991) Effects of nicotine on the acoustic startle reflex amplitude in rats. Psycho-pharmacology 104: 244–248
Astrachan DI, Davis M (1981) Spinal modulation of the acoustic startle response: the role of norepinephrine, serotonin and dopamine. Brain Res 206: 223–228
Cadet JL, Kuyatt B, Fahn S, De Souza EB (1987) Differential changes in 125I-LSD-labeled 5-HT-2 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN): evidence from autoradiographic studies. Brain Res 437: 383–386
Davis M (1980) Neurochemical modulation of sensory-motor reactivity: Acoustic and tactile startle reflexes. Neurosci Biobehav Rev 4: 241–263
Davis M (1982) Agonist-induced changes in behavior as a measure of functional changes in receptor sensitivity following chronic antidepressant treatment. Science 18: 137–147
Davis M (1986) Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav Neurosci 100: 814–824
Davis M (1992) The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 13: 35–41
Davis M, Astrachan DI, Kass E (1980) Excitatory and inhibitory effects of serotonin on sensomotoric reactivity measured with acoustic startle. Science 209: 521–523
Hijzen TH, Woudenberg F, Slangen JL (1990) The long-term effects of diazepam and pentylenetetrazol on the potentiated startle response. Pharmacol Biochem Behav 36: 35–38
Keith VA, Mansbach RS, Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30: 557–566
Mansbach RS, Markou A, Patrick GA (1994) Lack of altered startle response in rats following termination of self-administered or noncontingently infused cocaine. Pharmacol Biochem Behav 48: 453–458
Rigdon GC, Viik K (1991) Prepulse inhibition as a screening test for potential antipsychotics. Drug Dev Res 23: 91–99
Taylor MK, Ison JR, Schwarzkopf SB (1995) Effects of single and repeated exposure to apomorphine on the acoustic startle reflex and its inhibition by a visual prepulse. Psychopharmacology 120: 117–127
Varty GB, Higgins GA (1994) Differences between three rat strains in sensitivity to prepulse inhibition of an acoustic startle response: influence of apomorphine and phencyclidine pretreatment. J Psychopharmacol 8: 148–156
Vivian JA, Farrell WJ, Sapperstein SB, Miczek KA (1994) Diazepam withdrawal: effects of diazepam and gespirone on acoustic startle-induced 22 kHz ultrasonic vocalizations. Psychopharmacology 114: 101–108
Weiss GT, Davis M (1976) Automated system for acquisition and reduction of startle response data. Pharmacol Biochem Behav 4: 713–720
Young BJ, Helmstetter FJ, Rabchenuk SA, Leaton RN (1991) Effects of systemic and intra-amygdaloid diazepam on long-term habituation of acoustic startle in rats. Pharmacol Biochem Behav 39: 903–909
Zajaczkowski W, Gbrka Z (1993) The effects of single and repeated administration of MAO inhibitors on acoustic startle response in rats. Pol J Pharmacol 45: 157–166
Miklya I, Knoll J (1988) A new sensitive method which unlike the VOGEL test detects the anxiolytic effect of tofisopam. Pol J Pharmacol Pharm 40: 561–572
Przegalinski E, Chojnacka-Wojcik E, Filip M (1992) Stimulation of 5-HTIA receptors is responsible for the anticonflict effect of ipsapirone in rats. J Pharm Pharmacol 44: 780–782
Uyeno ET, Davies MF, Pryor GT, Loew GH (1990) Selective effect on punished versus unpunished responding in a conflict test as the criterion for anxiogenic activity. Life Sci 47: 1375–1382
Vogel JR, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia (Berl.) 21: 1–7
Balfour DJK (1990) A comparison of the effects of nicotine and (+)-amphetamine on rat behavior in an unsignalled Sidman avoidance schedule. J Pharm Pharmacol 42: 257–260
Duffield PH, Jamieson DD, Duffield AM (1989) Effect of aqueous and lipid-soluble extracts of Kava on the conditioned avoidance in rats. Arch Int Pharmacodyn 301: 81–90
Galizio M, Journey JW, Royal SA, Welker JA (1990) Variable-interval schedules of time-out from avoidance: Effects of anxiolytic and antipsychotic drugs in rats. Pharmacol Biochem Behav 37: 235–238
Heise GA, Boff E (1962) Continuous avoidance as a base-line for measuring behavioral effects of drugs. Psychopharmacologia 3: 264–282
Shekar A, Hingtgen JN, DiMicco JA (1987) Selective enhancement of shock avoidance responding elicited by GABA blockade in the posterior hypothalamus of rats. Brain Res 420: 118–128
Sidman M (1953) Avoidance conditioning with brief shock and no enteroceptive warning signal. Science 118: 157–158
Sidman M (1953) Two temporal parameters of the maintenance of avoidance behavior by the white rat. J Comp Physiol Psychol 46: 253–261
Barrett JE, Gleeson S, Nader MA, Hoffmann SM (1989) Anti-conflict effects of the 5-HTIA compound flesinoxan. J Psychopharmacol 3: 64–69
Bignami G (1988) Pharmacology and anxiety: Inadequacies of current experimental approaches and working models. Pharmacol Biochem Behav 29: 771–774
Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH39166: A dopamine Dl selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exper. Ther 247: 1093–1102
Cook L, Davidson AB (1973) Effects of behaviorally active drugs in a conflict-punishment procedure in rats. In: Garattini S, Mussini E, Randall LO (eds.) The Benzodiazepines, Raven Press, New York, pp 327–345
Cook L, Sepinwall J (1975) Behavioral analysis of the effects and mechanisms of action of benzodiazepines. In: Costa E, Greengard P (eds.) Mechanisms of Action of Benzodiazepines. Raven Press, New York, pp 1–28
Davidson AB, Cook L (1969) Effects of combined treatment with trifluoperazine-HCI and amobarbital on punished behavior in rats. Psychopharmacologia (Berl.) 15: 159–168
Ervin GN, Cooper BR (1988) Use of conditioned taste aversion as a conflict model: Effects of anxiolytic drugs. J Pharmacol Exp Ther 245: 137–146
Geller I, Kulak JT, Seifter J (1962) The effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacologia 3: 374–385
Geller I, Seifter J (1960) The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia 1: 482–492
Hanson HM, Stone CA (1964) Animal techniques for evaluating antianxiety drugs. In: Nodine JN, Siegler PE (eds.) Animal and Clinical Pharmacologic Techniques in Drug Evaluation. Year Book Medical Publ., Chicago, pp 317–324
Howard JL, Pollard GT (1990) Effects of buspirone in the Geller-Seifter conflict test with incremental shock. Drug Dev Res 19: 37–49
Iorio LC, Barnett A, Billard W, Gold EH (1986) Benzodiazepines: Structure-activity relationships between D, receptor blockade and selected pharmacological effects. In: Breese GR, Creese I (eds.) Neurobiology of central D,- dopamine receptors. pp 1–14, Plenum Press, New York
Iversen S (1983) Animal models of anxiety. In: Trimble RM (ed.) Benzodiazepines Divided. John Wiley & Sons Ltd., pp 87–99
Keane PE, Siminand J, Morre M, Biziere K (1988) Tetrazepam: A benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents. J Pharmacol Exper Ther 245: 692–698
Mc Milian DE (1973) Drugs and punished responding. I: Rate-dependent effects under multiple schedules. J Exp Anal Behav 19: 133–145
Morse WH (1964) Effect of amobarbital and chlorpromazine on punished behavior in the pigeon. Psychopharmacologica 6: 286–294
Prado de Carvalho L, Venault P, Potier MC, Dodd RH, Brown CL, Chapoutier G, Rossier RH (1986) 3-(Methoxycarbony1)-amino-13-carboline, a selective antagonist of the sedative effects of benzodiazepines. Eur J Pharmacol 129: 232–233
Schipper J, Tulp MThM, Berkelmans B, Mos J, Van der Heijden JAM, Olivier B (1991) Preclinical pharmacology of Flesinoxan: A potential anxiolytic and antidepressant drug. Human Psychopharmacol 6: 53–61
Silverman P (1978) Operant conditioning. In: Animal behaviour in the laboratory. Chapman and Hall, London, pp 141–178
Thiébot MH, Dangoumau L, Richard G, Puech AJ (1991) Safety signal withdrawal: a behavioral paradigm sensitive to both “anxiolytic” and “anxiogenic” drugs under identical experimental conditions. Psychopharmacology 103: 415–424
Wuttke W, Kelleher RT (1970) Effects of some benzodiazepines on punished and unpunished behavior in the pigeon. J Pharmacol Exper Ther 172: 397–405
Craft RM, Howard JL, Pollard GT (1988) Conditioned defensive burying as a model for identifying anxiolytics. Pharmacol Biochem Behav 30: 775–780
deBoer SF, Slangen JL, van der Gugten J (1990) Plasma catecholamine and corticosterone levels during active and passive shock-prod avoidance behavior in rats: effects of chlordiazepoxide. Physiol Behav 47: 1089–1098
Diamant M, Croiset G, de Zwart N, de Wied D (1991) Shock-prod burying test in rats: autonomic and behavioral responses. Physiol Behav 50: 23–31
Pinel JPJ, Treit D (1978) Burying as a defensive response in rats. J Compar Physiol Psycho] 92: 708–712
Pinel JPJ, Treit D (1983) The conditioned defensive burying paradigm and behavioral neuroscience. In: Robinson T (ed.) Pinel JPJ, Treit D. pp 212–234. Oxford Press
Treit D, Pinel JPJ, Fibiger HC (1981) Conditioned defensive burying: A new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 15: 619–626
Broqua P, Baudrie V, Laude D, Chaouloff F (1992) Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats. Biol Psychiatry 31: 391–400
deBoer SF, deBeun R, Slangen JL, van der Gugten J (1990) Dynamics of plasma catecholamine and corticosterone concentrations during reinforced and extinguished operant behavior in rats. Physiol Behav 47: 691–698
deBoer SF, Slangen JL, van der Gugten J (1990) Plasma catecholamine and corticosterone levels during active and passive shock-prod avoidance behavior in rats: effects of chlordiazepoxide. Physiol Behav 47: 1089–1098
Krieman MJ, Hershock DM, Greenberg IJ, Vogel WH (1992) Effects of adinazolam on plasma catecholamine, heart rate and blood pressure responses in stressed and non-stressed rats. Neurophannacol 31: 33–38
Livesey GT, Miller JM, Vogel WH (1985) Plasma norepinephrine, epinephrine and corticosterone stress responses to restraint in individual male and female rats. Neurosci Lett 62: 51–56
Natelson BH, Creighton D, McCarty R, Tapp WN, Pittman D, Ottenweller JE (1987) Adrenal hormonal indices of stress in laboratory rats. Physiol Behav 39: 117–125
Rittenhouse PA, Bakkum EA, O’Connor PA, Carnes M, Bethea CL, van de Kar LD (1992) Comparison of neuroendocrine and behavioral effects of ipsapirone, a 5-HT1A agonist, in three stress paradigms: immobilization, forced swim and conditioned fear. Brain Res 580: 205–214
Taylor J, Harris N, Krieman M, Vogel WH (1989) Effects of buspirone on plasma catecholamines, heart rate and blood pressure in stressed and non-stressed rats. Pharmacol Biochem Behav 34: 349–353
Vogel WH, Miller J, DeTurck KH, Routzahn BK (1984) Effects of psychoactive drugs on plasma catecholamines during stress in rats. Neuropharmacology 23: 1105–1109
Cotman CW, Iversen LL (1987) Excitatory amino acids in the brain-focus on NMDA receptors. Trends in Neurosci 10: 263–265
Fisher RS (1989) Animal models of the epilepsies. Brain Res Rev 14: 245–278
Gale K (1992) GABA and epilepsy: Basic concepts from pre-clinical research. Epilepsia 33 (Suppl. 5): S3 - S12
Hout J, Raduoco-Thomas S, RaduocoThomas C (1973) Qualitative and quantitative evaluation of experimentally induced seizures. In: Anticonvulsant Drugs, Vol I, Pergamon Press, Oxford, New York, pp 123–185
Koella WP (1985) Animal experimental methods in the study of antiepileptic drugs. In: Frey HH, Janz D (eds) Antiepileptic Drugs. Handbook of Experimental Pharmacology Vol 74, pp 283–339, Springer Verlag, Berlin, Heidelberg
Löscher W, Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2: 145–181
MacDonald RL, McLean MJ (1986) Anticonvulsant drugs: Mechanisms of action. Adv Neurol 44: 713–736
Meldrum BS (1986) Pharmacological approaches to the treatment of epilepsy. In: Meldrum BS, Porter RJ (eds) New Anticonvulsant Drugs. John Libbey, London Paris, pp 17–30
Meldrum BS (1989) Gabaergic mechanisms in the pathogenesis and treatment of epilepsy. Br J Pharmacol 27: 3S - 11S
Porter RJ, Rogawski MA (1992) New antiepileptic drugs: From serendipity to rational discovery. Epilepsia 33. (Suppl. 1): S1 — S6
Rogawski MA, Porter RJ (1990) Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42: 223–286
Rump S, Kowalczyk M (1987) Effects of antiepileptic drugs in electrophysiological tests. Pol J Pharmacol Pharm 39: 557–566
Swinyard EA (1973) Assay of antiepileptic drug activity in experimental animals: standard tests. In: Anticonvulsant Drugs, Vol 1, Pergamon Press, Oxford, New York, pp 47–65
Toman JEP, Everett GM (1964) Anticonvulsants. In: Laurence DR, Bacharach AL (eds.) Evaluation of Drug Activities: Pharmacometrics. pp 287–300. Academic Press, London and New Woodbury DM (1972) Applications to drug evaluations. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental Models of Epilepsy — A Manual for the Laboratory Worker. Raven Press, New York, pp 557–583
Watkins JC, Olverman RI (1987) Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci 10: 265–272
Fonnum F (1987) Biochemistry, anatomy, and pharmacology of GABA neurons. In: Meltzer HY (ed.) Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp 173–182.
Lloyd KG, Morselli PL (1987) Psychopharmacology of Gabaergic drugs. In: Meltzer HY (ed.) Psychopharmacology: The Third Generation of Progress. Raven Press, New York pp 183–195.
Falch E, Larsson OM, Schousboe A. Krogsgard-Larsen P (1990) Gaba-A agonists and Gaba uptake inhibitors. Drug Dev Res 21: 169–188
Huger FP, Smith CP, Chiang Y, Glamkowski EJ, Ellis DB (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent. 2. in vitro profile. Drug Dev Res 11: 169–175
Lajtha A, Sershen H (1975) Inhibition of amino acid uptake by the absence of Na’ in slices of brain. J Neurochem 24: 667–672
Lüddens H, Korpi ER (1995) Biological function of GABAA/benzodiazepine receptor heterogeneity. J Psychiat Res 29: 77–94
Möhler H (1992) Gabaergic synaptic transmission. Arzneim Forsch/Drug Res 42: 211–214
Nilsson M, Hansson E, Rönnbäck L (1990) Transport of valproate and its effects on GABA uptake in astroglial primary culture. Neurochem Res 15: 763–767
Nilsson M, Hansson E, Rönnbäck L (1992) Interactions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary cultures. Neurochem Res 17: 327–332
Roskoski R (1978) Net uptake of L-glutamate and GABA by high affinity synaptosomal transport systems. J Neurochem 31: 493–498
Suzdak PD, Jansen JA (1995) A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36: 612–626
Taylor CP (1990) GABA receptors and GABAergic synapses as targets for drug development. Drug Dev Res 21: 151–160
Taylor CP, Vartanian MG, Schwarz RD, Rock DM, Callahan MJ, Davis MD (1990) Pharmacology of CI-966:a potent GABA uptake inhibitor, in vitro and in experimental animals. Drug Dev Res 21: 195–215
Walton NY, Gunnawan S, Treiman DM (1994) Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine. Epilepsy Res 19: 237–244
Cotman CW, Iversen LL (1987) Excitatory amino acids in the brain-focus on NMDA receptors. Trends Neurosci 10: 263–265
Davies J, Evans RH, Herrling PL, Jones AW, Olverman HJ, Pook P, Watkins JC (1986) CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity for [3H]D-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res 382: 169–173
Dunn RW, Corbett R, Martin LL, Payack JF, Laws-Ricker L, Wilmot CA, Rush DK, Cornfeldt ML, Fielding S (1990) Preclinical anxiolytic profiles of 7189 and 8319, novel noncompetitive NMDA antagonists. Current and Future Trends in Anticonvulsant, Anxiety, and Stroke Therapy, pp 495512. Wiley-Liss, Inc
Ferkany J, Coyle JT (1986) Heterogeneity of sodium-dependent excitatory amino acid uptake mechanisms in rat brain. J Neurosci Res 16: 491–503
Foster AC, Fagg GE (1984) Acidic amino acid binding sites in mammalian neuronal membranes: Their characteristics and relationship to synaptic receptors. Brain Res Rev 7: 103–164
Foster AC, Fagg GE (1987) Comparison of L-[3H]glutamate, D-[3H]aspartate, DL-[3H]AP5 and [3H]NMDA as ligands for NMDA receptors in crude postsynaptic densities from rat brain. Eur J Pharmacol 133: 291–300
Harris EW, Ganong AH, Monaghan DT, Watkins JC, Cotman CW (1986) Action of 3-((±)-2-carboxypiperazin-4-yl)propyl-l-phosphonic acid (CPP): a new and highly potent antagonist of N-methyl-D-aspartate receptors in the hippocampus. Brain Res 382: 174–177
Honoré T, Davies SN, Drejer J, Fletchner EJ, Jacobsen P, Lodge D, Nielsen FE (1988) Quinoxalidinediones: Potent competitive non-NMDA glutamate receptor antagonists. Science 241: 701–703
Honoré T, Lauridsen J, Krogsgaard-Larsen P (1982) The binding of [3H]AMPA, a structural analogue of glutamic acid to rat brain membranes. J Neurochem 38: 173–178
Jones SM, Snell LD, Johnson KM (1989) Characterization of the binding of radioligands to the N-methyl-D-aspartate, phenylcyclidine and glycine receptors in buffy coat membranes. J Pharmacol Meth 21: 161–168
Kemp JA, Foster AC, Wong EHF (1987) Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci 10: 294–298
Lehmann J, Hutchison AJ, McPherson SE, Mondadori C, Schmutz M, Sinton CM, Tsai C, Murphy DE, Steel DJ, Williams M, Cheney DL, Wood PL (1988) CGS 19755, a selective and competitive N-methyl-D-aspartate type excitatory amino acid receptor antagonist. J Pharmacol Exp Ther 246: 65–75
Lehmann J, Schneider J, McPherson S, Murphy DE, Bernard P, Tsai C, Bennett DA, Pastor G, Steel DJ, Boehm C, Cheney DL, Liebman JM, Williams M, Wood PL (1987) CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist: characterization in vitro and in vivo. J Pharmacol Exp Ther 240: 737–746
London ED, Coyle JT (1979) Specific binding of [3H]kainic acid to receptor sites in rat brain. Mol Pharmacol 15: 492–505
Mayer ML, Westbrook GL (1987) The physiology of excitatory amino acids in the vertebrate central nervous system. Progr Neurobiol 28: 197–276
Monaghan DT, Cotman CW (1982) The distribution of [3H]kainic acid binding sites in rat CNS as determined by autoradiography. Brain Res 252: 91–100
Murphy D, Schneider J, Boehm C, Lehmann J, Williams M (1987) Binding of [3H]3-(2-carboxypiperazin-4-yl)propyl1-phosphonic acid to rat brain membranes: A selective, high-affinity ligand for N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 240: 778–784
Murphy DE, Hutchinson AJ, Hurt SD, Williams M, Sills MA (1988) Characterization of the binding of [3H]-CGS 19755, a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain. Br J Phannacol 95: 932–938
Murphy DE, Snowhill EW, Williams M (1987) Characterization of quisqualate recognition sites in rat brain tissue using DL-[3H]a-amino-3-hydroxy-5-methylisoxazole-4-propion is acid ( AMPA) and a filtration assay. Neurochem Res 12: 775–782
Olney JW (1990) Excitotoxic amino acids and neuropsychiatric disorders. Annu Rev Pharmacol Toxicol 30: 47–71
Olsen RW, Szamraj O, Houser CR (1987) [3H]AMPA binding to glutamate receptor subpopulations in rat brain. Brain Res 402: 243–254
Olverman JH, Monaghan DT, Cotman CW, Watkins JC (1986) [3H]CPP, a new competitive ligand for NMDA receptors. Eur J Pharmacol 131: 161–162
Piotrovsky LB, Garyaev AP, Poznyakova LN (1991) Dipeptide analogues of N-acetylaspartylglutamate inhibit convulsive effects of excitatory amino acids in mice. Neurosci Lett 125: 227–230
Rogawski MA, Porter RJ (1990) Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with considerations of promising developmental stage compounds. Pharmacol Rev 42: 223–286
Watkins JC, Olverman HJ (1987) Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci 10: 265–272
Worms P, Willigens MT, Lloyd KG (1981) The behavioral effects of systemically administered kainic acid: a pharmacological analysis. Life Sci 29: 2215–2225
Zeman S, Lodge D (1992) Pharmacological characterization of non-NMDA subtypes of glutamate receptor in the neonatal rat hemidissected spinal cord in vitro. Br J Pharmacol 106: 367–372
Abe T, Sugihara H, Nawa H, Shigemoto R, Mizuno N, Nakanishi S (1992) Molecular characterization of a novel metabotropic glutamate receptor mglurs coupled to inositol phosphate/Ca’ signal transduction. J Biol Chem 267: 13361–13368
Bashir ZI, Bortolotto ZA, Davies CH, Berretta M, Irving AJ, Seal AJ, Henley AM, Jane DE, Watkins JC, Collingridge GL (1993) Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors. Nature 363: 347–350
Cotman CW, Iversen LL (1987) Excitatory amino acids in the brain-focus on NMDA receptors. Trends Neurosci 10: 263–265
Dannhardt G, von Gruchalla M, Elben U (1994) Tools for NMDA-receptor elucidation: Synthesis of spacer-coupled MK-801 derivatives. Pharm Pharmacol Lett 4: 12–15
Dunn RW, Corbett R, Martin LL, Payack JF, Laws-Ricker L, Wilmot CA, Rush DK, Cornfeldt ML, Fielding S (1990) Preclinical anxiolytic profiles of 7189 and 8319, novel noncompetitive NMDA antagonists. Current and Future Trends in Anticonvulsant, Anxiety, and Stroke Therapy, pp 495512. Wiley-Liss, Inc
Ebert B, Madsen U, Lund TM, Lenz SM, Krogsgaard-Larsen P (1994) Molecular pharmacology of the AMPA agonist, (S)2-amino-3-(3-hydroxy-5-phenyl-4-isoxazolyl)propionic acid [(S)-APPA] and the AMPA antagonist, ( R)-APPA. Neurochem Int 24: 507–515
Goldman ME, ME, Jacobson AE, Rice KC, Paul SM (1985) Differentiation of [’H]phencyclidine and (+)-[3H]SKF10,047 binding sites in rat cerebral cortex. FEBS Lett 190: 333–336
Hansen JJ, Krogsgaard-Larsen P (1990) Structural, conformational, and stereochemical requirements of central excitatory amino acid receptors. Med Res Rev 10: 55–94
Iversen LL (1994) MK-801 (Dizocilpine maleate) — NMDA receptor antagonist. Neurotransmiss 10, 1: 1–4
Javitt DC, Zukin SR (1989) Biexponential kinetics of [’H]MK801 binding: Evidence for access to closed and open Nmethyl-D-aspartate receptor channels. Mol Pharmacol 35: 387–393
Johnson KM, Jones SM (1990) Neuropharmacology of phencyclidine: Basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30: 707–750
Keinänen K, Wisden W, Sommer B, Werner P, Herb A, Ver-Doom TA, Sakmann B, Seeburg PH (1990) A family of AMPA-selective glutamate receptors. Science 249: 556–560
Kemp JA, Foster AC Wong EHF (1987) Non-competitive antagonists of excitatory amino acid receptors. Trends Neurosci 10: 294–298
Loo P, Braunwalder A, Lehmann J, Williams M (1986) Radio-ligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists. Eur J Pharmacol 123: 467–468
Loo PS, Braunwalder AF, Lehmann J, Williams M, Sills MA (1987) Interaction of L-glutamate and magnesium with phencyclidine recognition sites in rats brain: evidence for multiple affinity states of the phencyclidine/N-methyl-Daspartate receptor complex. Mol Pharmacol 32: 820–830
Maragos WF, Chu DCM, Greenamyre T, Penney JB, Young AB (1986) High correlation between the localization of [3H]TCP binding and NMDA receptors. Eur J Pharmacol 123: 173–174
Masu M, Tanabe Y, Tsuchida K, Shigemoto R, Nakanishi S (1991,) Sequence and expression of a metabotropic glutamate receptor. Nature 349: 760–765
Meguro H, Mori H, Araki K, Kushiya E, Katsuwada T, Yamazaki M, Kumanishi T, Arakawa M, Sakimura K, Mishina M (1992) Functional characterization of a heteromeric Nmda receptor channel expressed from cloned cdnas. Nature 357: 70–74
Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B, Seeburg PH (1992) Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 256: 1217–1221
Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S (1991) Molecular cloning and characterization of the rat NMDA receptor. Nature 354: 31–37
Nakajima Y, Iwakabe H, Akazawa C, Nawa H, Shigemoto R, Mizuno N, Nakanishi N (1993) Molecular characterization of a novel retina] metabotropic glutamate receptor mglur with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J Biol Chem 268: 11868–11873
Nowak G, Remond A, McNamara M, Paul IA (1995) Swim stress increases the potency of glycine at the N-methyl-Daspartate receptor complex. J Neurochem 64: 925–927
Reynolds IJ, Miller RJ (1988) Multiple sites for the regulation of the N-methyl-D-aspartate receptor. Mol Pharmacol 33: 581–584
Rogawski MA, Porter RJ (1990) Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with considerations of promising developmental stage compounds. Pharmacol Reviews 42: 223–286
Sacaan AI, Johnson KM (1989) Spermine enhances binding to the glycine site associated with the N-methyl-D-aspartate receptor complex. Mol Pharmacol 36: 836–839
Schoepp D, Bockaert J, Sladeczek F (1990) Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors. Trends Pharmacol Sci 11: 508–515
Sills MA, Fagg G, Pozza M, Angst C, Brundish DE, Hurt SD, Wilusz EJ, Williams M (1991) [3H]CGP 39653: a new Nmethyl-D-aspartate antagonist radioligand with low nano-molar affinity in rat brain. Eur J Pharmacol 192: 19–24
Simon RP, Swan JH, Griffiths T, Meldrum BS (1984) Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226: 850–852
Snell LD, Morter RS, Johnson KD (1988) Structural requirements for activation of the glycine receptor that modulates the N-methyl-D-aspartate operated ion channel. Eur J Pharmacol 156: 105–110
Snell LD, Morter RS, Johnson KM (1987) Glycine potentiates N-methyl-D-aspartate-induced [3H]TCP binding to rat cortical membranes. Neurosci Lett 83: 313–320
Tanabe Y, Nomura A, Masu M, Shigemoto R, Mizuno N, Nakanishi S (1993) Signal tranduction, pharmacological properties, and expression patterns of two metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci 13: 1372–1378
Thedinga KH, Benedict MS, Fagg GE (1989) The N-methylD-aspartate (NMDA) receptor complex: a stoichiometric analysis of radioligand binding domains. Neurosci Lett 104: 217–222
Thomson AM (1989) Glycine modulation of the NMDA receptor/channel complex. Trends in Neurosci 12: 349–353
Vignon J, Chicheportiche R, Chicheportiche M, Kamenka JM, Geneste P, Lazdunski M (1983) [3H]TPC: a new tool with high affinity to the PCP receptor in rat brain. Brain Res 280: 194–197
Watkins JC, Krogsgaard-Larsen P, Honoré T (1990) Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol Sci 11: 25–33
Watkins JC, Olverman HJ (1987) Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci 10: 265–272
Williams K, Romano C, Molinoff PB (1989) Effects of polyamines on the binding of [3H]MK-801 to the N-methylD-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site. Mol Pharmacol 36: 575–581
Wong EHF, Kemp JA (1991) Sites for antagonism on the Nmethyl-D-aspartate receptor channel complex. Ann Rev Pharmac Toxic 31: 401–425
Wong EHF, Knight AR, Woodruff GN (1988) [3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J Neurochem 50: 274–281
Yoneda Y, Ogita K (1991) Neurochemical aspects of the Nmethyl-D-aspartate receptor complex. Neurosci Res 10: 1–33
Casida JE, Palmer CJ, Cole LM (1985) Bicycloorthocarboxylate convulsants. Potent GABAA receptor antagonists. Mol Pharmacol 28: 246–253
Gee KW, Lawrence LJ, Yamamura HI (1986) Modulation of the chloride ionophore by benzodiazepine receptor ligands: influence of gamma-aminobutyric acid and ligand efficacy. Mol Pharmacol 30: 218–225
Macksay G, Ticku MK (1985) Dissociation of [35S]-tbutylbicyclophosphorothionate binding differentiates convulsant and depressant drugs that modulate GABAergic transmission. J Neurochem 44: 480–486
Macksay G, Ticku MK (1985) GABA, depressants and chloride ions affect the rate of dissociation of [35S1-t-butylbicyclophosphorothionate binding. Life Sci 37: 2173–2180
Olsen RW, Yang J, King RG, Dilber A, Stauber GB, Ransom RW (1986) Barbiturate and benzodiazepine modulation of GABA receptor binding and function. Life Sci 39: 1969–1976
Squires RF, Casida JE, Richardson M, Saederup E (1983) [35S]t-Butylbicyclophosphorothionate binds with high affinity to brain specific sites coupled to y-aminobutyric acid-A and ion recognition sites. Mol Pharmacol 23: 326–336
Supavilai P, Karabath M (1984) [35S]-t-Butylbicyclophosphorothionate binding sites are constituents of the y-aminobutyric acid benzodiazepine receptor complex. J Neurosci 4: 1193–1200
Trifiletti RR, Snowman AM, Snyder SH (1985) Barbiturate recognition site on the GABA/Benzodiazepine receptor complex is distinct from the picrotoxin/TBPS recognition site. Eur J Pharmacol 106: 441–447
Baron BM, Harrison BL, Miller FP, McDonald IA, Salituro FG, Schmidt CJ, Sorensen SM, White HS, Palfreyman MG (1990) Activity of 5,7-dichtorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site. Mol Pharmacol 38: 554–561
Bonhaus DW, Burge BC, McNamara JO (1978) Biochemical evidence that glycine allosterically regulates an NMDA receptor-coupled ion channel. Eur J Pharmacol 142: 489–490
Bonhaus DW, Yeh G-C, Skaryak L, McNamara JO (1989) Glycine regulation of the N-methyl-D-aspartate receptor-gated ion channel in hippocampal membranes. Mol Pharmacol 36: 273–279
Cotman CW, Monaghan DT, Ottersen OP, Storm-Mathisen J (1987) Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci 10: 273–280
Danysz W, Wroblewski JT, Brooker G, Costa E (1989) Modulation of glutamate receptors by phencyclidine and glycine in the rat cerebellum: cGMP increase in vivo. Brain Res 479: 270–276
Foster AC, Kemp JA, Leeson PD, Grimwood S, Donald AE, Marshall GR, Priestley T, Smith JD, Carling RW (1992) Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-D-aspartate receptor from rat brain. Mol Pharmacol 41: 914–922
Hargreaves RJ, Rigby M, Smith D, Hill RG (1993) Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br J Pharmacol 110: 36–42
Jansen KLR, Dragunow M, Faull RLM (1989) [3H]Glycine binding sites, NMDA and PCP receptors have similar distributions in the human hippocampus: an autoradiographic study. Brain Res 482: 174–1178
Kessler M, Terramani T, Lynch B, Baudry M (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52: 1319–1328
Monahan JB, Corpus VM, Hood WF, Thomas JW, Compton RP (1989) Characterization of a [3H]glycine recognition site as a modulatory site of the N-Methyl-D-aspartate receptor complex. J Neurochem 53: 370–375
Oliver MW, Kessler M, Larson J, Schottler F, Lynch G (1990) Glycine site associated with the NMDA receptor modulates long-term potentiation. Synapse 5: 265–270
Ransom RW, Deschenes NL (1988) NMDA-induced hippocampal [3H]norepinephrine release is modulated by glycine. Eur J Pharmacol 156: 149–155
Rao TS, Cler JA, Emmet MR, Mick SJ, Iyengar S, Wood PL (1990) Glycine, glycinamide, and D-serine act as positive modulators of signal transduction at the N-methyl-Daspartate (NMDA) receptor in vivo: differential effects on mouse cerebellar cyclic guanosine monophosphate levels. Neuropharmacol 29: 1075–1080
Reynolds IJ, Murphy SN, Miller RJ (1987) ‘H-labeled MK-801 binding to the excitatory amino acid receptor complex from rat brain is enhanced by glycine. Proc Natl Acad Sci USA 84: 7744–7748
Sacaan AI, Johnson KM (1989) Spermine enhances binding to the glycine site associated with N-methyl-D-aspartate receptor complex. Mol Pharmacol 36: 836–839
Snell LD, Morter RS, Johnson KM (1987) Glycine potentiates N-methyl-D-aspartate induced [3H]TCP binding to rat cortical membranes. Neurosci Lett 83: 313–317
Snell LD, Morter RS, Johnson KM (1988) Structural requirements for activation of the glycine receptor that modulates the N-methyl-D-aspartate operated ion channel. Eur J Pharmacol 156: 105–110
Thomson AM (1989) Glycine modulation of the NMDA recep- tor/channel complex. Trends Neuroscience 12: 349–353
White HS, Harmsworth WL, Sofia RD, Wof HH (1995) Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 20: 41–48
Braestrup C, Nielsen M, Krogsgaard-Larsen P (1986) Glycine antagonists structurally related to 4.5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol inhibit binding of [3H]strychnine to rat brain membranes. J Neurochem 47: 691–696
Bristow DR, Bowery NG, Woodruff GN (1986) Light microscopic autoradiographic localisation of [3H]glycine and [3H]strychnine binding sites in rat brain. Eur J Pharmacol 126: 303–307
Bruns RF, Welbaum BEA (1985) A sodium chloride shift method to distinguish glycine agonists from antagonists in [3H]strychnine binding. Fed Proc 44: 1828
Graham D, Pfeiffer F, Simler R, Betz H (1985) Purification and characterization of the glycine receptor of pig spinal cord. Biochemistry 24: 990–994
Johnson G, Drummond JT, Boxer PA, Bruns RF (1992) Proline analogues as agonists at the strychnine-sensitive glycine receptor. J Med Chem 35: 233–241
Johnson G, Nickell DG, Ortwine D, Drummond JT, Bruns RF, Welbaum BE (1989) Evaluation and synthesis of aminohydroxyisoxazoles and pyrazoles as potential glycine agonists. J Med Chem 32: 2116–2128
Kishimoto H, Simon JR, Aprison MH (1981) Determination of the equilibrium constants and number of glycine binding sites in several areas of the rat central nervous system, using a sodium-independent system. J Neurochem 37: 1015–1024
Lambert DM, Poupaert JH, Maloteaux JM, Dumont P (1994) Anticonvulsant activities of N-benzyloxycarbonylglycine after parenteral administration. Neuroreport 5: 777–780
Marvizön JCG, Vazquez J, Calvo MG, Mayor F Jr, Gbmez AR, Valdivieso F, Benavides J (1986) The glycine receptor: Pharmacological studies and mathematical modeling of the allosteric interaction between the glycine-and strychnine-binding sites. Mol Pharmacol 30: 590–597
Young AB, Snyder SH (1974) Strychnine binding in rat spinal cord membranes associated with the synaptic glycine receptor: cooperativity of glycine interactions. Mol Pharmacol 10: 790–809
Alger BE (1984) Hippocampus. Electrophysiological studies of epileptiform activity in vitro. In: Dingledine R (ed) Brain Slices. Plenum Press, New York, London, pp 155–199
Alger BE, Dhanjal SS, Dingledine R, Garthwaite J, Henderson G, King GL, Lipton P, North A, Schwartzkroin PA, Sears TA, Segal M, Whittingham TS, Williams J (1984) Brain Slice methods. In: Dingledine R (ed) Brain Slices. Plenum Press, New York, London, pp 381–437
Alger BE, Nicoll RA (1982) Pharmacological evidence of two kinds of GABA receptor on rat hippocampal pyramidal cells studied in vitro. J Physiol 328: 125–141
Bingmann D, Speckmann EJ (1986) Actions of pentylenetetrazol (PTZ) on CA3 neurons in hippocampal slices of guinea pigs. Exp Brain Res 64: 94–104
Coan EJ, Saywood W, Collingridge GL (1987) MK-801 blocks NMDA receptor-mediated synaptic transmission and long term potentiation in rat hippocampal slices. Neurosci Lett 80: 111–114
Crain SM (1972) Tissue culture models of epileptiform activity. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental Models of Epilepsy — A Manual for the Laboratory Worker. Raven Press, New York, pp 291–316
Dingledine R, Dodd J, Kelly JS (1980) The in vitro brain slice as a useful neurophysiological preparation for intracellular recording. J Neurosci Meth 2: 323–362
Fisher RS (1987) The hippocampal slice. Am J EEG Technol 27: 1–14
Fisher RS, Alger BE (1984) Electrophysiological mechanisms of kainic acid-induced epileptiform activity in the rat hippocampal slice. J Neurosci 4: 1312–1323
Fredholm BB, Dunwiddie TV, Bergman B, Lindström K (1984) Levels of adenosine and adenine nucleotides in slices of rat hippocampus. Brain Res 295: 127–136
Harrison NL, Simmonds MA(1985) Quantitative studies on some antagonists of N-methyl-D-aspartate in slices of rat cerebral cortex. Br J Pharmacol 84: 381–391
Langmoe IA, Andersen P (1981) The hippocampal slice in vitro. A description of the technique and some examples of the opportunities it offers. In: Kerkut GA, Wheal HV (eds) Electrophysiology of Isolated Mammalian CNS Preparations. Academic Press, London, New York, pp 51–105
Misgeld U (1992) Hippocampal slices. In: Kettenmann H, Grantyn R (eds) Practical ‘Electrophysiological Methods. John Wiley & Sons, New York, pp 41–44
Mosfeldt Laursen A (1984) The contribution of in vitro studies to the understanding of epilepsy. Acta Neurol Scand 69: 367–375
Müller CM (1992) Extra-and intracellular voltage recording in the slice. In: Kettenmann H, Grantyn R (eds) Practical Electrophysiological Methods. John Wiley & Sons, New York, pp 249–295
Oh DJ, Dichter MA (1994) Effect of a γ-aminobutyric acid uptake inhibitor, NNC-711, on spontaneous postsynaptic currents in cultured rat hippocampal neurons: implications for antiepileptic drug development. Epilepsia 35: 426–430
Okada Y, Ozawa S (1980) Inhibitory action of adenosine on synaptic transmission in the hippocampus of the guinea pig in vitro. Eur J Pharmacol 68: 483–492
Oliver AP, Hoffer BJ, Wyatt RJ (1977) The hippocampal slice: a model system for studying the pharmacology of seizures and for screening of anticonvulsant drugs. Epilepsia 18: 543–548
Pandanaboina MM, Sastry BR (1984) Rat neocortical slice preparation for electrophysiological and pharmacological studies. J Pharmacol Meth 11: 177–186
Saltarelli MD, Lowenstein PR, Coyle JT (1987) Rapid in vitro modulation of [3H]hemicholinium-3 binding sites in rat striatal slices. Eur J Pharmacol 135: 35–40
Schwartzkroin PA (1975) Characteristics of CAI neurons recorded intracellularly in the hippocampal in vitro slice preparation. Brain Res 85: 423–436
Siggins GR, Schubert P (1981) Adenosine depression of hippocampal neurons in vitro: an intracellular study of dose-dependent actions on synaptic and membrane potentials. Neurosci Lett 23: 55–60
Skrede KK, Westgard RH (1971) The transverse hippocampal slice: A well-defined cortical structure maintained in vitro. Brain Res 35: 589–659
Teyler TT (1980) Brain slice preparation: Hippocampus. Brain Res Bull 5: 391–403
Löscher W, Stephens DN (1988) Chronic treatment with diazepam or the inverse benzodiazepine receptor agonist FG 7142 causes different changes in the effects of GABA receptor stimulation. Epilepsy Res. 2: 253–259
Rastogi SA, Ticku MK (1985) Involvement of a Gabaergic mechanism in the anticonvulsant effect of phenobarbital against maximal electroshock-induced seizures in rats. Pharmacol. Biochem. Behay. 222: 141–146
Sohn YJ, Levitt B, Raines A (1970) Anticonvulsive properties of diphenylthiohydantoin. Arch. int. Pharmacodyn. 188: 284–289
Swinyard EA (1972) Electrically induced convulsions. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental Models of Epilepsy — A Manual for the Laboratory Worker. Raven Press, New York, pp 433–458
Swinyard EA, Brown WC, Goodman LS (1952) Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106: 319–330
Toman JEP (1964) Animal techniques for evaluating anticonvulsants. In: Nodin JH and Siegler PE (eds) Animal and Clinical Techniques in Drug Evaluation. Year Book Med. Publ. vol 1: 348–352
Toman JEP; Everett GM (1964) Anticonvulsants. In: Laurence DR, Bacharach AL (eds) Evaluation of Drug Activities: Pharmacometrics. Academic Press, London and New York, pp 287–300
Turner RA (1965) Anticonvulsants, Academic Press, New York & London, pp 164–172
Woodbury LA, Davenport VO (1952) Design and use of a new electroshock seizure apparatus and analysis of factors altering seizure threshold and pattern. Arch. int. Pharmacodyn. 92: 97–107
Hahn F, Oberdorf A (1960) Vergleichende Untersuchungen über die Krampfwirkung von Begrimid, Pentetrazol and Pikrotoxin. Arch Int Pharmacodyn 135: 9–30
Leander JD, Lawson RR, Ornstein PL, Zimmerman DM (1988) N-methyl-D-aspartic acid induced lethality in mice: selective antagonism by phencyclidine-like drugs. Brain Res 448: 115–120
Pollack GM, Shen DD (1985) A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anti-convulsant effect of valproic acid in the rat. J Pharmacol Meth 13: 135–146
Shouse MN, Siegel JM, Wu MF, Szymusiak R, Morrison AR (1989) Mechanism of seizure suppression during rapid-eyemovement ( REM) sleep in cats. Brain Res 505: 271–282
Snead III OC (1988) y-Hydroxybutyrate model of generalized absence seizures: Further characterization and comparison with other absence models. Epilepsia 29: 361–368
Stone WE (1972) Systemic chemical convulsants and metabolic derangements. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental Models of Epilepsy — A Manual for the Laboratory Worker. Raven Press, New York, pp 407–432
Testa R, Graziani L, Graziani G (1983) Do different anticonvulsant tests provide the same information concerning the profiles of antiepileptic activity? Pharmacol Res Commun 15: 765–774
Toussi HR, Schatz RAS, Waszczak BL (1987) Suppression of methionine sulfoximine seizures by intranigral y-vinyl GABA injection. Eur J Pharmacol 137: 261–264
Tursky WA, Cavalheiro EA, Coimbra C, da Penha Berzaghi M Ikonomidou-Turski C, Turski L (1987) Only certain antiepileptic drugs prevent seizures induced by pilocarpine. Brain Res Rev 12: 281–305
Buckett WR (1981) Intravenous bicuculline test in mice: Characterisation with Gabaergig drugs. J Pharmacol Meth 5: 35–41
Clineschmidt BV, Martin GE, Bunting PR (1982) Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 123–134
Czuczwar SJ, Frey HH, Löscher W (1985) Antagonism of Nmethyl-D,L-aspartic acid-induced convulsions by antiepileptic drugs and other agents. Eur J Pharmacol 108: 273–280
Lloyd KG, Morselli PL (1987) Psychopharmacology of Gabaergic drugs. In: Meltzer HY (ed.) Psychopharmacology: The Third Generation of Progress. Raven Press, New York pp 183–195
Mecarelli O, de Feo MR, Rina MF, Ricci GF (1988) Effects of Progabide on bicuculline-induced epileptic seizures in developing rats. Clin Neuropharmacol 11: 443–453
Rogawski MA, Porter RJ (1990) Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42: 223–286
Rutecki PA, Lebeda FJ, Johnston D (1987) 4-Aminopyridine produces epileptiform activity in hippocampus and enhances synaptic excitation and inhibition. J Neurophysiol 57: 1911–1924
Schaefer Jr. EW, Brunton RB, Cunningham DJ (1973) A summary of the acute toxicity of 4-aminopyridine to birds and mammals. Toxicol Appl Pharmacol 26: 532–538
Yamaguchi SI, Rogawski MA (1992) Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res 11. 9–16.
Albe-Fessard D, Stutinsky F, Libouban S (1971) Atlas Stéréo- taxique du Diencéphale du Rat Blanc. C.N.R.S., Paris
Atsev E, Yosiphov T (1969) Changes in evoked perifocal electrical activity with an acute epileptogenic focus in cat’s cortex. Electrencephalogr Clin Neurophysiol 27: 444
Black RG, Abraham J, Ward AA Jr (1967) The preparation of tungstic acid gel and its use in the production of experimental epilepsy. Epilepsia 8: 58–63
Blum B, Liban E (1960) Experimental basotemporal epilepsy in the cat. Discrete epileptogenic lesions produced in the hippocampus or amygdaloid by tungstic acid. Neurology 10: 546–554
Campell AM, Holmes 0 (1984) Bicuculline epileptogenesis in the rat. Brain Res 323: 239–246
Cavalheiro EA, Riche DA, Le Gal la Salle G (1982) Long-term effects of intrahippocampal kainic acid injections in rats: a method for inducing spontaneous recurrent seizures. Electroencephalogr Clin Neurophysiol 53: 581–589
Daniels JC, Spehlman R (1973) The convulsant effect of topically applied atropine. Electroencephalogr Clin Neurophysiol 34: 83–87
Dow RS, Fernândez-Guardiola A, Manni E (1962) The production of cobalt experimental epilepsy in the rat. Electroencephalogr Clin Neurophysiol 14: 399–407
Ferguson JH, Jasper HH (1971) Laminar DC studies of acetylcholine-activated epileptiform discharge in cerebral cortex. Electroencephalogr Clin Neurophysiol 30: 377–390
Feria-Velasco A, Olivares N, Rivas F, Velasco M,. Velasco F (1980) Alumina cream-induced focal motor epilepsy in cats. Arch Neurol 37: 287–290
Fischer J, Holubar J, Malik V (1967) A new method of producing chronic epileptogenic cortical foci in the rat. Physiol Bohemosclov 16: 272–277
Hanna GR, Stalmaster RM (1973) Cortical epileptic lesions produced by freezing. Neurology 23: 918–925
Hawkins CA, Mellanby JH (1987) Limbic epilepsy induced by tetanus toxin: a longitudinal electroencephalographic study. Epilepsia 28: 431–444
Karpiak SE, Graf L, Rapport MM (1976) Antiserum to brain gangliosides produces recurrent epileptiform activity. Science 194: 735–737
Karpiak SE, Mahadik SP, Graf L, Rapport MM (1981) An immunological model of epilepsy: seizures induced by antibodies to GM, ganglioside. Epilepsia 22: 189–196
Kopeloff L, Chusid JG, Kopeloff N (1955) Epilepsy in Mac-caca mulatta after cortical or intracerebral alumina. Arch Neurol Psychiatry 74: 523–526
Kopeloff LM, Barrera SE, Kopeloff N (1942) Recurrent convulsive seizures in animals produced by immunologic and chemical means. Am J Psychiatry 98: 881–902
Lange SC, Neafsey EJ, Wyler AR (1980) Neuronal activity in chronic ferric chloride epileptic foci in cats and monkey. Epilepsia 21: 251–254
Loiseau H, Avaret N, Arrigoni E, Cohadon F (1987) The early phase of cryogenic lesions: an experimental model of seizures updated. Epilepsia 28: 251–258
Marsan CA (1972) Focal electrical stimulation. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental Models of Epilepsy — A Manual for the Laboratory Worker. Raven Press, New York, pp 147–172
Matsumoto H, Marsan CA (1964) Cortical cellular phenomena in experimental epilepsy: interictal manifestations. Exper Neurol 9: 286–304
Mellanby J, Hawkins C, Mellanby H, Rawlins JNP, Impey ME (1984) Tetanus toxin as a tool for studying epilepsy. J Physiol, Paris 79: 207–215
Pei Y, Zhao D, Huang J, Cao L (1983) Zinc-induced seizures: a new experimental model of epilepsy. Epilepsia 24: 169–176
Racine RJ (1972) Modification of seizure activity by electrical stimulation: I. After-discharge threshold. Electroencephalogr Clin Neurophysiol 32: 269–279
Reid SA, Sypert GW, Boggs WM, Wilmore LJ (1979) Histopathology of the ferric-induced chronic epileptic focus in cat: a Golgi study. Exper Neurol 66: 205–219
Remler MP, Marcussen WH (1986) Systemic focal epileptogenesis. Epilepsia 27: 35–42
Remler MP, Sigvardt K, Marcussen WH (1986) Pharmacological response of systemically derived focal epileptic lesions. Epilepsia 27: 671–6777
Stalmaster RM, Hanna GR (1972) Epileptic phenomena of cortical freezing in the cat: Persistent multifocal effects of discrete superficial lesions. Epilepsia 13: 313–324
Turski WA, Czuczwar SJ, Kleinrok Z, Turski L (1983) Cholinomimetics produce seizures and brain damage in rats. Experientia 39: 1408–1411
Walton NY, Gunnawan S, Treiman DM (1994) Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine. Epilepsy Res 19: 237–244
Walton NY, Treiman DM (1989) Phenobarbital treatment of status epilepticus in a rodent model. Epilepsy Res 4: 216–222
Ward AA Jr (1972) Topical convulsant metals. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental Models of Epilepsy — A Manual for the Laboratory Worker. Raven Press, New York, pp 13–35
Girgis M (1981) Kindling as a model for limbic epilepsy. Neurosci 6: 1695–1706
Goddard GV (1967) Development of epileptic seizures through brain stimulation at low intensity. Nature 214: 1020–1021
Goddard GV, Dragunow M, Maru E, Macleod EK (1986) Kindling and the forces that oppose it. In: Doane BK, Livingston KE (eds) The Limbic System: Functional Organization and Clinical Disorders. Raven Press, New York, pp 95–108
Goddard GV, McIntyre DC, Leech CK (1969) A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 25: 295–330
Heit MC, Schwark WS (1987) An efficient method for time course studies of antiepileptic drugs using the kindled rat seizure model. J Pharmacol Meth. 18: 319–325
Hoenack D, Loescher W (1989) Amygdala-kindling as a model for chronic efficacy studies on antiepileptic drugs: Experiments with carbamazepine. Neuropharmacology 28: 599–610
Koella WP (1985) Animal experimental methods in the study of antiepileptic drugs. In: Frey HH, Danz D (eds) Antiepileptic Drugs, Chapter 12, 283–339. Springer Verlag Heidelberg, New York, Tokyo
Le Gal la Salle G (1981) Amygdaloid kindling in the rat: regional differences and general properties. In: Wada JA (ed) Kindling 2, Raven Press, New York, pp 31–47
Löscher W, Nolting B, Hönack D (1988) Evaluation of CPP, a selective NMDA antagonist, in various rodent models of epilepsy. Comparison with other NMDA antagonists, and with diazepam and phenobarbital. Eur J Pharmacol 152: 9–17
Lothman EW, Salerno RA, Perlin JB, Kaiser DL (1988) Screening and characterization of anti-epileptic drugs with rapidly recurring hippocampal seizures in rats. Epilepsy Res. 2: 367–379
Mason CR, Cooper RM (1972) A permanent change in convulsive threshold in normal and brain-damaged rats with repeated small doses of pentylenetetrazol. Epilepsia 13: 663–674
McNamara JO (1984) Kindling: an animal model of complex partial epilepsy. Ann Neurol 16 (Suppl): S72 - S76
McNamara JO (1986) Kindling model of epilepsy. In: Advances in Neurology. Basic Mechanisms of the Epilepsies. Molecular and Cellular Approaches. Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ (eds) Vol 44, Chapter 14, 303–318. Raven Press; New York
Pellegrino LJ, Pellegrino AS, Cushman Ai (1979) A Stereo- tactic Atlas of the Brain. 2nd ed. New York: Plenum Press
Pinel JPJ, Rovner LI (1978) Experimental epileptogenesis: kindling-induced epilepsy in rats. Exper Neurol 58: 190–202
Racine R (1978) Kindling: the first decade. Neurosurg 3: 234–252
Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin Neurophysiol 32: 281–294
Schmidt J (1990) Comparative studies on the anticonvulsant effectiveness of nootropic drugs in kindled rats. Biomed Biochim Acta 49: 413–419
Wada JA (1977) Pharmacological prophylaxis in the kindling model of epilepsy. Arch Neurol 34: 387–395
Wada JA, Mizoguichi T, Osawa T (1978) Secondarily generalized convulsive seizures induced by daily amygdaloid stimulation in rhesus monkeys. Neurol 28: 1026–1036
Wada JKA, Osawa T (1976) Spontaneous recurrent seizure state induced by daily amygdaloid stimulation in Senegalese baboons ( Papio papio ). Neurol 22: 273–286
Wahnschaffe U, Loescher W (1990) Effect of selective bilateral destruction of the substantia nigra on antiepileptic drug actions in kindled rats. Eur J Pharmacol 186: 157–167
Bartoszyk GD, Hamer M (1987) The genetic animal model of reflex epilepsy in the Mongolian gerbil: differential efficacy of new anticonvulsive drugs and prototype antiepileptics. Pharmacol Res Commun 19: 429–440
Chapman AG, Croucher MJ, Meldrum BS (1984) Evaluation of anticonvulsant drugs in DBA/2 mice with sound-induced seizures. Arzneim Forsch/Drug Res 34: 1261–1264
Collins RL (1972) Audiogenic seizures. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental Models of Epilepsy–A Manual for the Laboratory Worker. Raven Press, New York, pp 347–372
Consroe P, Picchioni A, Chin L (1979) Audiogenic seizure susceptible rats. Fed Proc 38: 2411–2416
Crawford RD (1969) A new mutant causing epileptic seizures in domestic fowl. Poultry Sci 48: 1799
Crawford RD (1970) Epileptic seizures in domestic fowl. J Hered 61: 185–188
Cunningham JG (1971) Canine seizure disorders. J Am Vet Med Ass 158: 589–598
Edmonds HL, Hegreberg GA, van Gelder NM, Sylvester DM, Clemmons RM, Chatburn CG (1979) Fed Proc 38: 2424–2428
Faingold CL, Naritoku DK (1992) The genetically epilepsy-prone rat: Neuronal networks and actions of amino acid neurotransmitters. In: Faingold CL, Fromm GH (eds) Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders. CRC Press, Boca Raton, Fl, pp 277–308
Faingold CL, Randall ME, Boersma Anderson CA (1994) Blockade of GABA uptake with tiagabine inhibits audio-genic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat. Exp Neurol 126: 225–232
Green MC, Sidman RL (1962) Tottering–A neuromuscular mutation in the mouse. J Hered 53: 233–237
Imaizumi K, Ito S, Kutukake G, Takizawa T, Fujiwara K, Tutikawa K (1959) Epilepsy like anomaly of mice. Exp Anim (Tokyo) 8: 6–10
Jobe PC, Mishira PK, Dailey JW (1992) Genetically epilepsy-prone rats: Actions of antiepileptic drugs and monoaminergic neurotransmitters. In: Faingold CL, Fromm GH (eds) Drugs for Control of Epilepsy: Actions on Neuronal Networks Involved in Seizure Disorders. CRC Press, Boca Raton, Fl, pp 253–275
Johnson DD, Davis HL, Crawford RD (1979) Pharmacological and biochemical studies in epileptic fowl. Fed Proc 38: 2417–2423
Killam KF, Killam EK, Naquet R (1967) An animal model of light sensitivity epilepsy. Electroencephalogr Clin Neurophysiol 22: 497–513
Killam KF, Naquet R, Bert J (1966) Paroxysmal responses to intermittent light stimulation in a population of baboons ( Papio papio ). Epilepsia 7: 215–219
Löscher W (1984) Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review. Meth Find Exptl Clin Pharmacol 6: 531–547
Löscher W, Frey HH (1984) Evaluation of anticonvulsant drugs with reflex epilepsy. Arzneim.-Forsch./Drug Res. 34: 1484–1488
Löscher W, Meldrum BS (1984) Evaluation of anticonvulsant drugs in genetic animal models of epilepsy. Fed Proc 43: 276–284
Loskota WJ, Lomax P, Rich ST (1974) The gerbil as a model for the study of epilepsies. Epilepsia 15: 109–119
Majkowski J, Kaplan H (1983) Value of Mongolian gerbils in antiepileptic drug evaluation. Epilepsia 24: 609–615
Naquet R, Meldrum BS (1972) Photogenic seizures in baboon. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD (eds) Experimental Models of Epilepsy–A Manual for the Laboratory Worker. Raven Press, New York, pp 373–406
Noebels JL (1979) Analysis of inherited epilepsy using single locus mutations in mice. Fed Proc 38: 2405–2410
Oguro K, Ito M, Tsuda H, Mutoh K, Shiraishi H, Shirasaka Y, Mikawa H (1991) Association of NMDA receptor sites and seizures El mice. Epilepsy Res 9: 225–230
Reigel CE, Dailey JW, Jobe PC (1986) The genetically epilepsy-prone rat: an overview of seizure-prone characteristics and responsiveness to anticonvulsant drugs. Life Sci 39: 763–774
Sasa M, Ohno Y, Ujihara H, Fujita Y, Yoshimura M, Takaori S, Serikawa T, Yamada J (1988) Effects of antiepileptic drugs on absence-like and tonic seizures in the spontaneously epileptic rat, a double mutant rat. Epilepsia 29: 505–513
Serikawa T, Kogishi K, Yamada J, Ohno Y, Ujihara H, Fujita Y, Sasa M, Takaori S (1990) Long-term effects of continual intake of phenobarbital on the spontaneously epileptic rat. Epilepsia 31: 9–14
Serikawa T, Yamada J (1986) Epileptic seizures in rats homozygous for two mutations, zitter and tremor. J Hered 77: 441–444
Seyfried TN (1979) Audiogenic seizures in mice. Fed Proc 38: 2399–2404
Smith SE, Dürmüller N. Meldrum BS (1991) The non-Nmethyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol 201: 179–183
Stark LG, Killam KF, Killam EK (1970) The anticonvulsant effects of phenobarbital, diphenylhydantoin and two benzodiazepines in the baboon, Papio papio. J Pharmacol Exp Ther 173: 125–132
Tacke U, Björk E, Tuomisto J (1984) The effect of changes in sound pressure level and frequency on the seizure response of audiogenic seizure susceptible rats. J Pharmacol Meth 11: 279–290
Thiessen DD, Lindzey G, Friend HC (1968) Spontaneous seizures in the Mongolian gerbil (Meriones unguiculatus) Psycho Sci 11: 227–228
Ujihara H, Renming X, Sasa M, Ishihara K, Fujita Y, Yoshimura M, Kishimoto T, Serikawa T, Yamada J. Takaori S (1991) Inhibition by thyrotropin-releasing hormone of epileptic seizures in spontaneously epileptic rats. Eur J Pharmacol 196: 15–19
Vergnes M, Marescaux C, Micheletti G, Reis J, Depaulis A, Rumbach L, Warter SM (1982) Spontaneous paroxysmal electroclincal patterns in the rat: A model of generalized non-convulsive epilepsy. Neurosci Lett 33: 97–101
Xie R, Fujita Y, Sasa M, Ishihara K, Ujihara H, Takaori S, Serikawa T, Jamada J (1990) Antiepileptic effect of CNK602A, a TRH analogue, in the spontaneously epileptic rat (SER), a double mutant. Jap J Pharmacol 52 (Suppl 1): 290 P
Balazs T, Grice HC (1963) The relationship between liver necrosis and pentobarbital sleeping time in rats. Toxicol Appl Pharmacol 5: 387–391
Harris LS, Uhle FC (1961) Enhancement of amphetamine stimulation and prolongation of barbiturate depression by a substituted pyrid[3,4-b]indole derivative. J Pharmacol Exp Ther 132: 251–257
Lim, RKS (1964) Animal techniques for evaluating hypnotics. In: Nodine JH Siegler PE (eds.) Animal and Clinical Pharmacologic Techniques in Drug Evaluation. Year Book Medical Publ., Inc., Chicago, pp 291–297
Mason DFJ (1964) Hypnotics and general anaesthetics. In: Laurence DR, Bacharach AL (eds) Evaluation of Drug Activities: Pharmacometrics. Academic Press, London and New York, pp 261–286
Gardner CR, James V (1987) Activity of some benzodiazepine receptor ligands with reduced sedative and muscle relaxant properties on stress-induced electrocorticogram arousal in sleeping rats. J Pharmacol Meth 18: 47–54
James GWL, Piper DC (1978) A method for evaluating potential hypnotic compounds in rats. J Pharmacol Meth 1: 145–154
Baust W, Heinemann H (1967) The role of the baroreceptors and of blood pressure in the regulation of sleep and wakefulness. Exp Brain Res 3: 12–24
Hashimoto T, Hamada C, Wada T, Fukuda N (1992) Comparative study on the behavioral and EEG changes induced by diazepam. buspirone and a novel anxioselective anxiolytic, DN-2327, in the cat. Neuropsychobiol 26: 89–99
Heinemann H, Hartmann A, Stock G, Sturm V (1970) Die Wirkungen von Medazepam auf Schwellen subcorticaler, limbischer Reizantworten gemessen an unnarkotisierten, frei beweglichen Katzen. Arzneim Forsch/Drug Res 20: 413–415
Heinemann H, Hartmann A, Sturm V (1968) Der Einfluß von Medazepam auf die Schlaf-Wach-Regulation von wachen, unnarkotisierten Katzen. Arzneim Forsch/Drug Res 18: 1557–1559
Heinemann H, Stock G (1973) Chlordiazepoxide and its effect on sleep-wakefulness behavior in unrestrained cats. Arzneim Forsch/Drug Res 23: 823–825
Hirotsu I, Kihara T, Nakamura S, Hattori Y, Hatta M, Kitakaze Y, Takahama K, Hashimoto Y, Miyata T, Ishihara T, Satoh F (1988) General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. Arzneim Forsch/Drug Res 38: 1398–1410
Holm E, Staedt U, Heep J, Kortsik C, Behne F, Kaske A, Men-nicke I (1991) Untersuchungen zum Wirkungsprofil von D,L-Kavain. Zerebrale Angriffsorte and Schlaf-WachRhythmus im Tierexperiment. Arzneim Forsch/Drug Res 41: 673–683
Kuhn FJ, Schingnitz G, Lehr E, Montagna E, Hinzen HD, Giachetti A (1988) Pharmacology of WEB 1881-FU, a central cholinergic agent, which enhances cognition and cerebral metabolism. Arch Int Pharmacodyn 292: 13–34
Ruckert RT, Johnson DN, Robins AH (1983) Effects of antihistaminic agents on sleep pattern in cats: a new method for detecting sedative potential. Pharmacologist 25: 180
Shouse MN, Siegel JM, Wu MF, Szymusiak R, Morrison AR (1989) Mechanisms of seizure suppression during rapideye-movement ( REM) sleep in cats. Brain Res 505: 271–282
Sommerfelt L, Ursin R (1991) Behavioral, sleep-waking and EEG power spectral effects following the two specific 5-HT uptake inhibitors zimeldine and alaproclate in cats. Behav Brain Res 45: 105–115
Tobler I, Scherschlicht R (1990) Sleep and EEG slow-wave activity in the domestic cat: effect of sleep deprivation. Behav Brain Res 37: 109–118
Wallach MB, Rogers C, Dawber M (1976) Cat sleep: A unique first night effect. Brain Res Bull 1: 425–427
Wetzel W (1985) Effects of nootropic drugs on the sleep-waking pattern of the rat. Biomed Biochim Acta 44: 1211–1217
Yamagushi N, Ling GM, Marczynski TJ (1964) Recruiting responses observed during wakefulness and sleep in unanesthetized chronic cats. Electroenceph Clin Neurophysiol 17: 246–254
Courvoisier S (1956) Pharmacodynamic basis for the use of chlorpromazine in psychiatry. J Clin Exp Psychopathol 17: 25–37
Anderson PH, Gingrich JA, Bates MD, Dearry AD, Falardeau P, Senogles SE, Caron MG (1990) Dopamine receptor subtypes: beyond the D,/D2 lassification. Trends Pharmacol Sci 11: 213–236
Anderson PH, Gronvald FC, Jansen JA (1985) A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum. Life Sci 37: 1971–1983
Anderson PH, Nielsen EB, Gronvald FC, Breastrup C (1986) Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo. Eur J Pharmacol 120: 143–144
Baldessarini RJ, Kula NS, McGrath CR, Bakthavachalam V, Kebabian JW, Neumeyer JL (1993) Isomeric selectivity at dopamine D3 receptors. Eur J Pharmacol 239: 269–270
Billard W, Ruperto V, Crosby G, Iorio LC, Barnett A (1984) Characterisation of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci 35: 1885–1893
Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247: 1093–1102
Civelli O, Bunzow JR, Grandy DK, Zhou QY, Van Tol HHM (1991) Molecular biology of the dopamine receptors. Eur H Pharmacol, Mol Pharmacol Sect 207: 277–286
Clement-Cormier YC, Kebabian JW, Petzold GR, Greengard P (1974) Dopamine-sensitive adenylate cyclase in mammalian brain. A possible site of action of anti-psychotic drugs. Proc Natl Acad Sci USA 71: 1113–1117
Creese I (1987) Biochemical properties of CNS dopamine receptors. In: Meltzer HY (ed) Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp 257–264
Dawson TM, Gehlert DR, Yamamura HI, Barnett A, Wamsley JK (1985) D-1 dopamine receptors in the rat brain: Autoradiographic localisation using [3H]SCH 23390. Eur J Pharmacol 108: 323–325
Dearry A, Gingrich JA, Falardeau P, Fremeau RT, Bates MD, Caron MG (1990) Molecular cloning and expression of the gene for a human D, dopamine receptor. Nature 347: 72–76
DeNinno MP, Schoenleber R, MacKenzie R, Britton DR, Asin KE, Briggs C, Trugman JM, Ackerman M, Artman L, Bednarz L, Bhatt R, Curzon P, Gomez E, Kang CH, Stittsworth J, Kebabian JW (1991) A68930: a potent agonist selective for the dopamine D, receptor: Eur J Pharmacol 199: 209–219
Gerhardt S, Gerber R, Liebman JM (1985) SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models. Life Sci 37: 2355–2363
Ginrich JA, Caron MC (1993) Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16: 299–321
Grandy DK, Zhang Y, Bouvier C, Zhou QY, Johnson RA, Allen L, Buck K, Bunzow JR, Salon J, Civelli 0 (1991) Multiple human dopamine receptor genes: a functional D5 receptor and two pseudogenes. Proc Natl Acad Sci USA 88: 9175–9179
Hess E, Battaglia G, Norman AB, Iorio LC, Creese I (1986) Guanine nucleotide regulation of agonist Robinson T (ed.) Interactions at [3H]SCH 23390-labelled D1 dopamine receptors in rat striatum. Eur J Pharmacol 121: 31–38
Hyttel J (1983) SCH 23390–the first selective dopamine D-1 antagonist. Eur J Pharmacol 91: 153–154
Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopamine systems. J Pharm Exper Ther 226: 462–468
Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M (1992) A-77363: a potent and selective D, receptor antagonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229: 203–209
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96
Kilpatrick GJ, Jenner P, Mardsen CD (1986) [3H]SCH 23390 identifies D-1 binding sites in rat striatum and other brain areas. J Pharm Pharmacol 38: 907–912
Lévesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC (1992) Identification, characterization, and localization of the dopamine D, receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2aminotetralin. Proc Natl Acad Sci USA 89: 8155–8159
Neumeyer JL, Kula NS, Baldessarini RJ, Baindur (1992) Stereoisomeric probes for the D, dopamine receptor: Synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-l -phenyl-2,3,4,5-tetrahydro-1 H-3benzazepine and its 6-bromo analogue. J Med Chem 35: 1466–1471
Niznik HB, Sunahara RK, van Tol HHM, Seeman P, Weiner DM, Stormann TM, Brann MR, O’Dowd BF (1992) The dopamine D, receptors. In: Brann MR (ed) Molecular Biology of G-Protein Coupled Receptors. Birkhäuser, Boston Basel Berlin, pp 142–159
O’Boyle KM, Waddington JL (1992) Agonist and antagonist interaction with D, dopamine receptors: agonist induced masking of D, receptors depends on intrinsic activity. Neurophartnacol 31: 177–183
Seeman P (1977) Anti-schizophrenic drugs. Membrane receptor sites of action. Biochem Pharmacol 26: 1741–1748
Seeman P, Chau-Wong C, Tedesco J, Wong K (1975) Binding receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72: 4376–4380
Snyder SH, Creese I, Burt DR (1975) The brain’s dopamine receptor: labeling with [3H]dopamine. Psychopharmacol Commun 1: 663–673
Stoff JC, Kebabian JW (1982) Independent in vitro regulation by the D-2 dopamine receptor of dopamine-stimulated efflux of cyclic AMP and K’-stimulated release of acetylcholine from rat neostriatum. Brain Res 250: 263–270
Sunahara RK, Niznik HB, Weiner DM, Stormann TM, Brann MR, Kennedy JL, Gelernter JE, Rozmahel R, Yang Y, Israel Y, Seeman P, O’Dowd BF (1990) Human dopamine D, receptor encoded by an intronless gene on chromosome 5. Nature 347: 80–83
Todd RD, O’Malley KL (1993) Family ties: The dopamine D2-like receptor genes. Neurotransmiss 9 (3): 1–4
Trampus M, Ongini E, Borea PA (1991) The neutral endopeptidase-24.11 inhibitor SCH 34826 does not change opioid binding but reduces D, dopamine receptors in rat brain. Eur J Pharmacol 194: 17–23
Tricklebank MD, Bristow LJ, Hutson PH (1992) Alternative approaches to the discovery of novel antipsychotic agents. Progr Drug Res 38: 299–336
Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli 0 (1991) Cloning of the gene of a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614
Weinshank RL, Adham N, Macchi M, Olsen MA, Branchek TA, Hartig PR (1991) Molecular cloning and characterization of a high affinity dopamine receptor (D,1) and its pseudogene. J Biol Chem 266: 22427–22435
Zhou QY, Grandy DK, Thambi L, Kusher JA, Van Tol HHM, Cone R, Pribnow D, Salon J, Bunzow JR, Civelli O (1990) Cloning and expression of human and rat dopamine D, receptors. Nature 347: 76–80
Bunzow JR, Van Tol HHM, Grandy DK, Albert P, Salon J, Christie MD, Machida CA, Neve KA, Civelli 0 (1988) Cloning and expression of rat D2 dopamine receptor cDNA. Nature 336: 783–787
Civelli O, Bunzow J, Albert P, van Tol HHM, Grandy D (1992) The dopamine D2 receptor. In: Brann MR (ed) Molecular Biology of G-Protein Coupled Receptors. Birkhäuser, Boston Basel Berlin, pp 160–169
Fields, JZ, Reisine TD, Yamamura HI (1977) Biochemical demonstration of dopaminergic receptors in rat and human brain using [3H1-spiroperidol. Brain Res 136: 578–584
Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fischer JB, Burke-Howie KJ, Bunzow JR, Server AC, Civelli 0 (1989) Cloning of the cdna and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 86: 9762–9766
Hall H, Köhler C, Gawell L (1985) Some in vitro receptor binding properties of [3H]eticlopride, a novel substituted benzamide, selective for dopamine-D2 receptors in the rat brain. Eur J Pharmacol 111: 191–199
Hayes G, Biden TJ, Selbie LA, Shine J (1992) Structural subtypes of the dopamine D2 receptor are functionally distinct: Expression of the D2A and D2B subtypes in a heterologous cell line. Mol Endocrinol 6: 920–926
Laduron PM, Janssen PFM, Leysen JE (1978) Spiperone: A ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs. Biochem Pharmacol 27: 317–328
Leysen JE, Gommeren W, Laduron PM (1978) Spiroperone: A ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol 27: 307–316
Locke KW, Dunn RW, Hubbard JW, Vanselous ChL, Cornfeldt M, Fielding St, Strupczewski JT (1990) HP 818: A centrally acting analgesic with neuroleptic properties. Drug Dev Res 19: 239–256
Martres MP, Bouthenet ML, Sales N, Sokoloff P, Schwartz JC (1985) Widespread distribution of brain dopamine receptors evidenced with [’25I]iodosulpiride, a highly selective ligand. Science 228: 752–755
McConnell HM, Owicki JC, Parce JW, Miller DL, Baxter GT, Wada HG, Pitchford S (1992) The Cytosensor Microphysiometer: biological applications of silicon technology. Science 257: 1906–1912
McConnell HM, Rice P, Wada GH, Owicki JC, Parce JW (1991) The microphysiometer biosensor. Curr Opin Struct Biol 1: 647–652
Neve KA, Kozlowski MR, Rosser MP (1992) Dopamine D2 receptor stimulation of Na’/H’ exchange assessed by quantification of extracellular acidification. J Biol Chem 267: 25748–25753
Niznik HB, Grigoriadis DE, Pri-Bar I, Buchman O, Seeman P (1985) Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151–2. Naunyn-Schmiedeberg’s Arch Pharmacol 329: 333–343
Owicki JC, Parce JW. (1992) Biosensors based on the energy metabolism of living cells: The physical chemistry and cell biology of extracellular acidification. Biosensors Bioelectronics 7: 255–272
Seeman Ph (1981) Brain dopamine receptors. Pharmacol Rev 32: 229–313
Sibley DR, Monsma FJ Jr (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13: 61–69
Terai M, Hidaka K, Nakamura Y (1989) Comparison of [3H]YM-09151–2 with [3H]spiperone and [3H]raclopride for dopamine D-2 receptor binding to rat striatum. Eur J Pharmacol 173: 177–182
Baldessarini RJ, Kula NS, McGrath CR, Bakthavachalam V, Kebabian JW, Neumeyer JL (1993) Isomeric selectivity at dopamine D3 receptors. Eur J Pharmacol 239: 269–270
Brücke T, Wenger S, Podreka I, Asenbaum S (1991) Dopamine receptor classification, neuroanatomical distribution and in vivo imaging. Wien Klin Wochenschr 103: 639–646
Ginrich JA, Caron MC (1993) Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16: 299–321
Kung MP, Fung HF, Chumpradit S, Foulon C (1993) In vitro binding of a novel dopamine D3 receptor ligand: [125I]trans7-OH-PIPAT-A. Eur J Pharmacol 235: 165–166
Lévesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2aminotetralin. Proc Natl Acad Sci USA 89: 8155–8159
MacKenzie RG, VanLeeuwen D, Pugsley TA, Shih YH, Demattos S, Tang L, Todd RD, O’Malley KL (1994) Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol, Mol Pharmacol Sect 266: 79–85
Sibley DR (1991) Cloning of a `D3’ receptor subtype expands dopamine receptor family. Trend Pharmacol Sci 12: 7–9
Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347: 146–151
Todd RD, O’Malley KL (1993) Family ties: The dopamine D2-like receptor genes. Neurotransmiss 9 (3): 1–4
Ginrich JA, Caron MC (1993) Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16: 299–321
Sunahara RK, Guan HC, O’Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HHM, Niznik HB (1991) Cloning of the gene for a human D5 receptor with higher affinity for dopamine than D,. Nature 350: 614–619
Todd RD, O’Malley KL (1993) Family ties: The dopamine D2-like receptor genes. Neurotransmiss 9 (3): 1–4
Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli 0 (1991) Cloning of the gene for a human dopamine D, receptor with high affinity for the antipsychotic clozapine. Nature 350: 610–614
Van Tol HHM, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1992) Multiple dopamine D4 receptor variants in the human population. Nature 358: 149–152
Broaddus WC, Bennett JP Jr (1990) Postnatal development of striatal dopamine function. I. An examination of D, and D2 receptors, adenylate cyclase regulation and presynaptic dopamine markers. Develop Brain Res 52: 265–271
Clement-Cormier YC, Kebabian JW, Petzold GL, Greengard P (1974) Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc Natl Acad Sci USA 71: 1113–1 117
Clement-Cormier YC, Parrish RG, Petzold GL, Kebabian JW, Greengard P (1975) Characterisation of a dopamine-sensitive adenylate cyclase in the rat caudate nucleus. J Neurochem 25: 143–149
Creese I (1987) Biochemical properties of CNS dopamine receptors. In: Meltzer HY (ed.) Psychopharmacology; The Third Generation of Progress. Raven Press New York, pp 257–264
Gale K, Giudotti A, Costa E (1977) Dopamine-sensitive adeny- late cyclase: Location in substantia nigra. Science 195: 503–505
Horn S, Cuello AC, Miller RJ (1974) Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effect of drugs on the uptake mechanism and stimulation of adenylate cyclase activity. J Neurochem 22: 265–270
Iversen LL (1975) Dopamine receptors in the brain. Science 188: 1084–1089
Kebabian JW, Petzold GL, Greengard P (1972) Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the “dopamine receptor” Proc Nat Acad Sci USA 69: 2145–2149
Kebabian JW; Caine DB (1979) Multiple receptors for dopamine. Nature 277: 93–96
Magnusson O, Mohringe B, Fowler CJ (1987) Comparison of the effects of dopamine D1 and D2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilisation. J Neural Transm 69: 163–177
Setler PE, Rarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50: 419–430
Creese I (1978) Receptor binding as a primary drug screening device. In: ( HI Yamamura et al, eds.) Neurotransmitter receptor binding pp 141–170, Raven Press, New York
Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483
Greenberg DA, U’Prichard DC, Snyder SH (1976) Alphanoradrenergic receptor binding in mammalian brain: Differential labelling of agonist and antagonist states. Life Sci 19: 69–76
Huger FP, Smith CP, Chiang Y, Glamkowski EJ, Ellis DB (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent. Drug Dev Res 11: 169–175
Janowsky A, Sulser F (1987) Alpha and beta adrenoreceptors in brain. In: Meltzer HY (ed.) Psychopharmacology: The Third Generation of Progress. pp. 249–256, Raven Press, New York
Mottram DR, Kapur H (1975) The a-adrenoceptor blocking effects of a new benzodioxane. J Pharm Pharmacol 27: 295–296
Peroutka SJ, U’Prichard DC, Greenberg DA, Snyder SH (1977) Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. Neuropharmacol 16: 549–566
U’Prichard DC, Snyder SH (1979) Distinct a-noradrenergic receptors differentiated by binding and physiological relationships. Life Sci 24: 79–88
U’Prichard DC, Greenberg DA, Shehan PP, Snyder SH (1978) Tricyclic antidepressants: Therapeutic properties and affinity for a-noradrenergic receptor binding sites in the brain. Science 199: 197–198
Yamada S et al (1980) Characterisation of alpha-1 adrenergic receptors in the heart using [3H]-WB 4101: Effect of 6hydroxydopamine treatment. J Pharmacol Exper Ther 215: 176–185
Altar CA, Wasley AM, Neale RF, Stone GA (1986) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16: 517–525
Bennett JP Jr, Snyder SH (1976) Serotonin and lysergic acid diethylamide binding in rat brain membranes: Relationship to postsynaptic serotonin receptors. Mol Pharmacol 12: 373–389
Costalj B, Fortune DH, Naylor RJ, Marsden CD, Pycock C (1975) Serotonergic involvement with neuroleptic catalepsy. Neuropharmacol 14: 859–868
Fajolles C, Boireau A, Pochant M, Laduron PM (1992) [3H]RP 62203, a ligand of choice to label in vivo brain 5-HT, receptors. Eur J Pharmacol 216: 53–57
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994) VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine ( Serotonin ). Pharmacol Rev 46: 157–203
Humphrey PPA, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14: 233–236
Leysen JE, de Chaffoy de Courcelles D, de Clerck F, Niemegeers CJE, van Nueten JM (1984) Serotonin-S2 receptor binding sites and functional correlates. Neuropharmacol 23: 1493–1501
Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM (1978) Serotonergic component of neuroleptic receptors. Nature 272: 168–171
Leysen JE, Niemegeers CJE, van Nueten JM, Laduron PM (1981) [’H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin, receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21: 301–314
Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3H]Ketanserin (R41 468) a selective 3H-ligand for serotonin, receptor binding sites. Mol Pharmacol 21: 301–314
List SJ, Seeman P (1981) Resolution of dopamine and serotonin receptor components of [3H]spiperone binding of rat brain regions. Proc Natl Acad Sci USA 78: 2620–2624
Martin GR, Humphrey PPA (1994) Classification review. Receptors for 5-hydroxytryptamine: Current perspectives on classification and nomenclature. Neuropharmacol 33: 261–273
Meltzer HV, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D„ D2 and serotonin2 pK, values. J Pharmacol Exp Ther251: 238–246
Morgan DG, Marcusson JO, Finch CE (1984) Contamination of serotonin-2 binding sites with an alpha-] adrenergic component in assays with (3H)spiperone. Life Sci 34: 2507–2514
Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Aihara H (1988) Serotonin-2 receptor mediated regulation of release of acetylcholine by minaprine in cholinergic nerve terminal of hippocampus of rat. Neuropharmacol 27: 603–609
Palacios JM, Niehoff DL, Kuhar MJ (1981) [3H]Spiperone binding sites in brain: autoradiographic localization of multiple receptors. Brain Res 213: 277–289
Pazos A, Cortés R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 2346: 231–249
Pedigo NW, Yamamura HI, Nelson DL (1981) Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36: 220–226
Peroutka SJ, Lebovitz RM, Snyder SH (1979) Serotonin receptors binding sites affected differentially by guanine nucleotides. Mol Pharmacol 16: 700–708
Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: Differential binding of [3H]5-hydroxytryptamine, [3H]-lysergic acid diethylamide and [’H)spiroperido1. Mol Pharmacol 16: 687–699
Rastogi RB, Singhal RL, Lapierre YD (1981) Effects of short-and long-term neuroleptic treatment on brain serotonin synthesis and turnover: Focus on the serotonin hypothesis of schizophrenia. Life Sci. 29: 735–741
Samanin R, Quattrone A, Peri G, Ladinsky H, Consolo S (1978). Evidence of an interaction between serotonergic and cholinergic neurons in the corpus striatum and hippocampus of the rat brain. Brain Res 151: 73–82
Saxena PR (1994) Modern 5-HT receptor classification and 5-HT based drugs. Exp Opin Invest Drugs 3: 513–523
Scatton B (1982) Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: Evidence against dopamine receptor multiplicity. J Pharmacol Exp Ther 220: 197–202
Abou-Gharbia M, Ablordeppey SY, Glennon RA (1993) Sigma receptors and their ligands: the sigma enigma. Ann Rep Med Chem 28: 1–10
Angulo JA, Cadet JL, McEwen BS (1990) a Receptor blockade by BMY 14802 affects enkephalinergic and tachykinin cells differentially in the striatum of the rat. Eur J Pharmacol 175: 225–228
de Costa BR, Bowen WD, Hellewell SB, Walker JM, Thurkauf A, Jacobson AE, Rice KC (1989) Synthesis and evaluation of optically pure [3H1-(+)-pentazocine, a highly potent and selective radioligand for a receptors. FEBS Lett 251: 53–58
DeHaven-Hudkins DL, Fleissner LC, Ford-Rice FY (1992) Characterization of the binding of [3H1(+)-pentazocine to a recognition sites in guinea pig brain. Eur J Pharmacol 227: 371–378
Deutsch SI, Weizman A, Goldman ME, Morihisa JM (1988) The sigma receptor: A novel site implicated in psychosis and antipsychotic drug efficacy. Clin Neuropharmacol 11: 105–119
Ferris RM, Tang FLM, Chang KJ, Russell A (1986) Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain. Life Sci 38: 2329–2339
Goldman ME, Jacobson AE, Rice KC, Paul SM (1985) Differentiation of [3H]phencyclidine and (+)-[3H]SKF-10,047 binding sites in rat cerebral cortex. FEBS Lett 190: 333–336
Hoffman DW (1990) Neuroleptic drugs and the sigma receptor. Am J Psychiatry 147: 1093–1094
Itzhak Y, Hiller JM, Simon EJ (1985) Characterisation of specific binding sites for [3H](ci7-N-allylnormetazocine in rat brain membranes. Mol Pharmacol 27: 46–52
Kaiser C, Pontecorvo MJ, Mewshaw RE (1991) Sigma receptor ligands: Function and activity. Neurotransm 7: 1–5
Khazan N, Young GA, El-Fakany EE, Hong O, Calligaro D (1984) Sigma receptors mediate the psychotomimetic effects of N-allylnor-metazocine (SKF-0,047), but not its opioid agonistic-antagonistic properties. Neuropharmacol. 23: 983–987
Largent BL, Gundlach AL, Snyder SH (1986) Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J Pharmacol Exp Ther 238: 739–748
Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, Su TP, Tam SW, Taylor DP (1992) A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 13: 85–86
Quirion R, Chicheportiche R, Contreras PC, Johnson KM, Lodge D, Tam SW, Woods JH, Zukin SR (1987) Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci 10: 444–446
Sircar R, Nichtenhauser R, leni JR, Zukin SR (1986) Characterisation and autoradiographic visualisation of (+)-[3HJSKF 10,047 binding in rat and mouse brain: Further evidence for phencyclidine/“sigma opiate” receptor commonalty. J Pharmacol Exper Ther 237: 681–688
Su TP (1982) Evidence for sigma opioid receptor: Binding of [3H1-SKF 10047 to etorphine-inaccessible sites in guinea pig brain. J Pharmacol Exper Ther 223: 284–290
Tam SW, Cook L (1984) a-opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]-SKF 10,047 and [3H]haloperidol binding in guinea pig membranes. Proc. Natl Acad. Sci. USA 81: 5618–5621
Taylor DP, Dekleva J (1987) Potential antipsychotic BMY 14802 selectively binds to sigma sites. Drug Dev Res 11: 65–70
Vaupel DB (1983) Naltrexone fails to antagonize the a effects of PCP and SKF 10.047 in the dog. Eur J Pharmacol 92: 269–274
Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC (1990) Sigma receptors: Biology and function. Pharmacol Reviews 42: 355–402
Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JFW (1986) 1,3-Di(2[5–3H]tolyl)guanidine: A selective ligand that labels a-type receptors. Proc Natl Acad Sci 83: 8784–8788
Zukin SR, Tempel A, Gardner EL, Zukin RS (1986) Interaction for psychotomimetic opiates and antipsychotic drugs. Proc Natl Acad Sci 83:8784–8788. of [3H](-)-SKF 10,047 with brain a receptors: Characterization and autoradiographic visualisation. J. Neurochem. 46: 1032–1041
Kreiskott H, Vater W (1959) Verhaltensstudien am Goldhamster unter dem Einfluß zentral-wirksamer Substanzen. Naunyn-Schmiedeberg’s Arch exp Path Pharm 236: 100–105
Lorenz K (1943) Die angeborenen Formen möglicher Erfahrung. Zeitschr Tierpsychol 5: 235–409
Lorenz K (1965) Evolution and modification of behavior. University of Chicago Press, Chicago
Lorenz K (1966) Evolution and modification of behavior. Methuen & Co Ltd, London
Ther L, Vogel G, Werner Ph (1959) Zur pharmakologischen Differenzierung und Bewertung von Neuroleptica. Arzneim Forsch/Drug Res 9: 351–354
Lorenz K (1943) Die angeborenen Formen möglicher Erfahrung. Zeitschr Tierpsychol 5: 235–409
Lorenz K (1966) Evolution and modification of behavior. Methuen & Co Ltd, London
Vogel G, Ther L (1960) Das Verhalten der Baumwollratte zur Beurteilung der neuroleptischen Breite zentral-depressiver Stoffe. Arzneim Forsch/Drug Res 10: 806–808
Courvoisier S, Fournel J, Ducrot R, Kolsky M, Koeschet P (1953) Propriétés pharmacodynamiques du chlorhydrate de chloro-3-(diméthylamino-3’-propyl)-10-phenothiazine (4.560 R.P.) Arch Int Pharmacodyn 92: 305–361
Giaja J (1938) Sur l’analyse de la fonction de calorification de l’homéotherme par la dépression barométrique. C R Soc Biol 127: 1355–1359
Giaja J (1940) Léthargie obtenue che le Rat par la dépression barométrique. C R Acad Sci 210: 80–84
Giaja J (1953) Sur la physiologie de l’organisme refroidi. Press Medicale 61: 128–129
Giaja J, Markovic-Giaja L (1954) L’hyperthermie produite par la chlorpromazine et la résistance a l’asphyxie. Bull Soc Chim Biol 36: 1503–1506
Ther L, Lindner E, Vogel G (1963) Zur pharmakologischen Wirkung der optischen Isomeren des Methadons. Dtsch Apoth Ztg 103: 514–520
Ther L, Vogel G, Werner P (1959) Zur pharmakologischen Differenzierung und Bewertung der Neuroleptica. Arzneim Forsch/Drug Res 9: 351–354
Vogel G (1959) Über die Wirkung von Dolantin und Polamidon im Vergleich zu anderen stark wirksamen Analgetica an der unterkühlten Ratte nach Giaja. Naunyn-Schmiedeberg’s Arch exp Path Pharmak 236: 214–215
Costall B, Naylor RJ (1973) Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effects? Psychopharmacol (Berl.) 32: 161–170
Costall B, Naylor RJ (1974) On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacol (Berl.) 34: 233–241
Duvoisin R (1976) Parkinsonism: Animal analogues of the human disorder. In: Yahr M (ed) The Basal Ganglia. Raven Press, New York, pp 293–303
Honma T, Fukushima H (1976) Correlation between catalepsy and dopamine decrease in the rat striatum induced by neuroleptics. Neuropharmacol 15: 601–607
Locke KW, Dunn RW, Hubbard JW, Vanselous CL, Cornfeldt M, Fielding S, Strupczewski JT (1990) HP 818:A centrally analgesic with neuroleptic properties. Drug Dev Res 19: 239–256
Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel “atypical” anti-psychotic agent. J Pharmacol Exp Ther 262: 545–551
Szewczak MR, Cornfeldt, ML, Dunn RW, Wilker JC, Geyer HM, Glamkowski EJ, Chiang Y, Fielding S (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent. 1. In vivo profile. Drug Dev Res 11: 157–168
Cook L, Catania AC (1964) Effects of drugs on avoidance and escape behavior. Fed Proc 23: 818–835
Cook L, Weidley E. (1957) Behavioral effects of some psycho- pharmacological agents. Ann NY Acad Sci 66: 740–752
Dunn RW, Carlezon WA, Corbett R., (1991) Preclinical anxiolytic versus antipsychotic profiles of the 5-H1’3-antagonists Ondansedron, Zacopride, 3a-tropanyl-1 H-indole-3carboxylic ester, and laH, 3a, 5aH-tropan-3-y1–3,5-dichlorobenzoate
Locke KW, Dunn RW, Hubbard JW, Vanselous CL, Cornfeldt M, Fielding S, Strupczewski JT, (1990) HP 818:A centrally acting analgesic with neuroleptic properties. Drug Dev Res 19: 239–256
Szewczak MR, Cornfeldt, ML, Dunn RW, Wilker JC, Geyer HM, Glamkowski EJ, Chiang Y, Fielding S (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent. 1. In vivo profile. Drug Dev Res 11: 157–168
Tedeschi RE, Tedeschi DH, Mucha A, Cook L, Mattis PA, Fellows EJ. (1959) Effects of various centrally acting drugs on fighting behavior of mice. J Pharmacol Exp Ther 125: 28–34
Brodie DA, Moreno OM, Malis JE, Boren JJ (1960) Rewarding properties of intracranial stimulation. Science 131: 920–930
Broekkamp CLE, Van Rossum JM (1975) The effect of micro-injections of morphine and haloperidol into the neostriatum and the nucleus accumbens on self-stimulation behavior. Arch Int Pharmacodyn 217: 110–117
Corbett D, Laferriere A, Milner P (1982) Plasticity of the medial prefrontal cortex: Facititated acquisition of intracranial self-stimulation by pretraining stimulation. Physiol Behav 28: 531–543
Cornfeldt M, Fisher B, Fielding S (1982) Rat internal capsule lesion: a new test for detecting antidepressants. Fed Proc 41: 1066
Dunn RW, Carlezon WA, Corbett R (1991) Preclinical anxiolytic versus antipsychotic profiles of the 5-HT3 antagonists ondansetron, zacopride, 3a-tropanyl-1H-indole-3-carboxylic acid ester, and laH, 3a, 5aH-tropan-3-y1–3,5-dichlorobenzoate. Drug Dev Res 23: 289–300
Fielding S, Lal H (1978) Behavioral actions of neuroleptics. In: Iversen LL, Iversen SD, Snyder SH (eds.) Neuroleptics and Schizophrenia, Vol 10, pp 91–128, Plenum Press, New York
Gallistel CR, Freyd G (1987) Quantitative determination of the effects of catecholaminergic agonists and antagonists on the rewarding efficacy of brain stimulation. Pharmacol Biochem Behav 26: 731–741
Goldstein JM, Malick JB (1983) An automated descending rate-intensity self-stimulation paradigm: usefulness for distinguishing antidepressants from neuroleptics. Drug Dev Res 3: 29–35
Koob GF, Fray Pi, Iversen SD (1978) Self-stimulation at the lateral hypothalamus and locus caeruleus after specific unilateral lesions of the dopamine system. Brain Res 146: 123–140
Mekarski JE (1989) Main effects of current and pimozide on prepared and learned self-stimulation behaviors are on performance not reward. Pharmacol Biochem Behav 31: 845–853
Mora F, Vives F, Alba F (1980) Evidence for an involvement of acetylcholine in self-stimulation of the prefrontal cortex in the rat. Experientia 36: 1180–1181
Olds J (1961) Differential effects of drives and drugs on self-stimulation at different brain sites. In:Sheer DE (ed.) Electrical Stimulation of the Brain. University of Texas Press, Austin TX, pp 350–366
Olds J, Milner P (1954) Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47: 419–427
Olds ME (1972) Alterations by centrally acting drugs of the suppression of self-stimulation behavior in the rat by tetrabenazine, physostigmine, chlorpromazine and pentobarbital. Psychopharmacology 25: 299–314
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. 2nd Edition; Academic Press, New York
Roberts DCS, Zito KA (1987) Interpretation of lesion effects on stimulant self-administration. In: Bozarth MA (ed) Methods for Assessing the Reinforcing Properties of Abused Drugs. Springer Verlag New York, Berlin, Heidelberg, pp 87–103
Szewczak MR, Cornfeldt, ML, Dunn RW, Wilker JC, Geyer HM, Glamkowski EJ, Chiang Y, Fielding S (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent. 1. In vivo profile. Drug Dev Res 11: 157–168
Derlet RW, Albertson TE, Rice P (1990) Protection against d-amphetamine toxicity. Am J Emerg Med 8: 105–108
Locke KW, Dunn RW, Hubbard JW, Vanselous CL, Cornfeldt M, Fielding S, Strupczewski JT (1990) HP 818: A centrally acting analgesic with neuroleptic properties. Drug Dev Res 19: 239–256
Ljungberg T, Ungerstedt U (1985) A rapid and simple behavioral screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol Biochem Behav 23: 479–485
Locke KW, Dunn RW, Hubbard JW, Vanselous CL, Cornfeldt M, Fielding S, Strupczewski JT (1990) HP 818: A centrally acting analgesic with neuroleptic properties. Drug Dev Res 19: 239–259
Machiyama Y (1992) Chronic methylamphetamine intoxication model of schizophrenia in animals. Schizophren Bull 18: 107–113
Bischoff S, Christen P, Vassout A. (1988) Blockade of hippocampal dopamine ( DA) receptors: A tool for antipsychotics with low extrapyramidal side effects. Prog Neuropsychopharmacol Biol Psychiat 12: 455–467
Brown F, Campell W, Clark MSG, Graves DS, Hadley MS, Hatcher J, Mitchell P, Needham P, Riley G, Semple J (1988) The selective dopamine antagonist properties of BRL 34779: a novel substituted benzamide. Psychopharmacology 94: 350–358
Cabib S, Puglisi-Allegra St (1988) A classical genetic analysis of two apomorphine-induced behaviors in the mouse. Pharmacol Bioch Behav 30: 143–147
Corral C, Lissavetzky J, Valdeolmillos A, Bravo L, Darias V, Sanchez Mateo C (1992) Neuroleptic activity of 10-(4methyl-1-piperazinyl)-thieno(3,2-b)(1,5)benzothiazepine derivatives. Arzneim Forsch/Drug Res. 42: 896–900
Costall B, Naylor RJ, Nohria V (1978) Climbing behavior induced by apomorphine in mice: A potent model for the detection of neuroleptic activity. Eur J Pharmacol 50: 39–50
Duterte-Boucher D, Costentin J 1989 ) Appearance of a stereotyped apomorphine-induced climbing in unresponsive DBA2 mice after chronic manipulation of brain dopamine transmission. Psychopharmacology 98: 56–60
Horvath K, Andrasi P, Berzsenyi P, Patfalusy M, Patthy M, Szab G, Sebestyén L, Bagdy E, Körösi J, Botka P, Hamaori T, Lang T (1989) A new psychoactive 5H-2,3-benzodiazepine with an unique spectrum of activity. Arzneim Forsch/Drug Res 39: 894–899
Moore NA, Axton MS (1988) Production of climbing behaviour in mice requires both DI and D2 receptor activation. Psychopharmacology 94: 263–266
Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 262: 545–551
Protais P, Costentin J, Schwartz JC (1976) Climbing behavior induced by apomorphine in mice: A simple test for the study of dopamine receptors in the striatum. Psychopharmacology 50: 1–6
Szewczak MR, Cornfeldt, ML, Dunn RW, Wilker JC, Geyer HM, Glamkowski EJ, Chiang Y, Fielding S (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent. 1. In vivo profile. Drug Dev Res 11: 157–168
Vasse M, Chagraoui A, Protais P (1988) Climbing and stereotyped behaviors in mice require the stimulation of D-1 dopamine receptors. Eur J Pharmacol 148: 221–229
Akbas O, Verimer T, Onur R, Kayaalp SO (1984) The effects of yohimbine and neuroleptics on apomorphine-induced pecking behavior in the pigeon. Neuropharmacol 23: 1261–1264
Andén NE; Rubenson A, Fuze K, Hoekfelt T (1967) Evidence for dopamine receptor stimulation by apomorphine. J Pharm Pharmac 19: 627–629
Christensen A, Fjalland B, Moller Nielsen I (1976) On the supersensitivity of dopamine receptors, induced by neuroleptics. Psychopharmacology 48: 1–6
Clow A, Theodorou A, Jenner P, Marsden CD (1980) A comparison of striatal and mesolimbic dopamine function in the rat during a 6-month trifluoperazine administration. Psycho-pharmacology 69: 227–233
Costall B, Naylor RJ (1973) On the mode of action of apomorphine. Eur J Pharmacol 21: 350–361
Dall’Olio R, Gandolfi 0. (1993) The NMDA positive modulator D-cycloserine potentiates the neuroleptic activity of D, and D2 dopamine receptor blockers in the rat. Psychopharmacology 110: 165–168
Ernst AM (1967) Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologie (Berl.) 10: 316–323
Gower AJ, Berendsen HHG, Princen MM, Broekkamp CLE (1984) The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity. Eur J Pharmacol 103: 81–89
Janssen PAJ, Niemegeers CJC, Jageneau AHM (1960) Apomorphine-antagonism in rats. Arzneim Forsch. 10: 1003–1005
Jolicoeur FB, Gagne MA, Rivist R, Drumheller A, St Pierre S (1991) Neurotensin selectively antagonizes apomorphine-induced stereotypic climbing. Pharmacol Biochem Behav 38: 463–465
Klawans HL, Rubovits R (1972) An experimental model of tardive dyskinesia. J Neural Transmiss 33: 235–246
Kostowski W, Krzascik P (1989) Research for evaluating the role of dopaminergic mechanisms in the action of valproate. Biogen Amin 6: 169–176
Ljungberg T, Ungerstedt U (1978) Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action. Psychopharmacology 56: 239–247
Locke KW, Dunn RW, Hubbard JW, Vanselous CL, Cornfeldt M, Fielding F, Strupczewski JT (1990) HP 818: A centrally acting analgesic with neuroleptic properties. Drug Dev Res 19: 239–256
StMhle L, Ungerstedt U (1983) Assessment of dopamine autoreceptor properties of apomorphine, (+)-3-PPP and (—)-3-PPP by recording of yawning behaviour in rats. Eur J Pharmacol 98: 307–310
Szewczak MR, Cornfeldt, ML, Dunn RW, Wilker JC, Geyer HM, Glamkowski EJ, Chiang Y, Fielding S (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent. 1. In vivo profile. Drug Dev Res 11: 157–168
Tarsy D, Baldessarini RJ (1974) Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacol 13: 927–940
Fielding S, Marky M, Lal H (1975) Elicitation of mouse jumping by combined treatment with amphetamine and L-dopa: Blockade by known neuroleptics. Pharmacologist 17: 210
Fielding S, Lal H (1978) Behavioral actions of neuroleptics. In: Iversen LL, Iversen SD, Snyder SH (eds.) Neuroleptics and Schizophrenia Vol 10, pp 91–128, Plenum Press, New York
Lal H, Colpaert F, Laduron P (1975) Narcotic withdrawal-like mouse jumping produced by amphetamine and L-dopa. Eur J Pharmacol 30: 113–116
Lal H, Marky M, Fielding S (1976) Effect of neuroleptic drugs on mouse jumping induced by L-dopa in amphetamine treated mice. Neuropharmacol 15: 669–671
Carlson M, Carlson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221–226
Verma A, Kulkarni SK (1992) Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacol 107: 431–436
Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH39166: A dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247: 1093–1102
Janssen PA, Niemegeers CJE, Shellekens HL. (1965) Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Arzneim.- Forsch. 15: 1196–1206
Janssen PAJ, Niemegeers CJE, (1959) Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenylpiperidino)-butyrophenone. Part II — Inhibition of apomorphine vomiting in dogs. Arzneim.-Forsch. 9: 765–767
Rotrosen J, Wallach MB, Angrist B, Gershon S., (1972) Antagonism of apomorphine-induced stereotypy and emesis in dogs by thioridiazine, haloperidol and pimozide. Psychopharmacol (Berl.) 26: 185–195
Bernardini GL, Gu X, Viscard E, German DC (1991) Amphetamine-induced and spontaneous release of dopamine from A9 and A10 cell dendrites: an in vitro electrophysiological study in the mouse. J Neural Transm 84: 183–193
Bowery B, Rothwell LA, Seabrock GR (1994) Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br. J Pharmacol 112: 873–880
Bunney BS, Grace AA (1978) Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 23: 1715–1728
Cedarbaum JM, Aghajanian GK (1977) Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur J Pharmacol 44: 375–385
Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effect of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1607–1619
Marwaha J, Aghajanian GK (1982) Relative potencies of alpha-1 and alpha-2 antagonists in the locus coeruleus, dorsal raphe and dorsal lateral geniculate nuclei: an electrophysiological study. J Pharmacol Exp Ther 222: 287–293
Mooney RD, Bennett-Clarke C, Chiaia NL, Sahibzada N, Rhoades RW (1990) Organization and actions of the noradrenergic input to the hamster’s superior colliculus. J Comp Neurol 292: 214–230
Nybäck I1V, Walters JR, Aghajanian GK, Roth RH (1975) Tricyclic antidepressants: effects on the firing rate of brain noradrenergic neurons. Eur J Pharmacol 32: 302–312
Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic Coordinates. 2nd ed, Academic Press, Sydney, Australia
Schmidt CJ, Black CK, Taylor VL, Fadayel GM, Humphreys TM, Nieduzak TR, Sorensen SM (1992) The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotoninergicdopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethylamphetamine. Eur J Pharmacol 220: 151–159
Scuvée-Moreau JJ, Dreese AE (1979) Effect of various antidepressant drugs on the spontaneous firing rate of locus coenileus and dorsal raphe neurons of the rat. Eur J Pharmacol 57: 219–225
Todorova A, Dimpfel W (1994) Multiunit activity from the A9 and A10 areas in rats following chronic treatment with different neuroleptic drugs. Eur Neuropsychopharmacol 4: 491–501
White FJ, Wang RY (1983) Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci 32: 983–993
White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054–1057
Chen G (1964) Antidepressives, analeptics and appetite suppressants. In: Laurence DR, Bacharach AL (eds.) Evaluation of Drug Activities: Pharmacometrics. pp 239–260. Academic Press, London and New York
Johnson RW, Reisine T, Spotnitz S, Weich N, Ursillo R, Yamamura HI (1980) Effects of desipramine and yohimbine on oc2- and ß-adrenoreceptor sensitivity. Eur J Pharmacol 67: 123–127
Kuhn R (1958) The treatment of depressive states with G22355 (imipramine hydrochloride) Am J Psychiatry 115: 459–464
Vetulani J, Stawarz RJ, Dingell JV, Sulser F (1976) A possible common mechanism of action of antidepressant treatments: Reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn-Schmiedebergs Arch. Pharmacol. 293: 109–114
Coyle JT, Snyder SH (1969) Catecholamine uptake by synaptosomes in homogenates of rat brain: Stereospecificity in different areas. J Pharmacol Exper Ther 170: 221–231
Hertting G, Axelrod J (1961) Fate of tritiated noradrenaline at the sympathetic nerve endings. Nature 192: 172–173
Iversen LL (1975) Uptake mechanisms for neurotransmitter amines. Biochem Pharmacol 23: 1927–1935
Lippmann W, Pugsley TA (1977) Effects of 3,4-dihydro-1H1,4-oxazino[4,3-a]indoles, potential antidepressants, on biogenic amine uptake mechanisms and related activities. Arch Int Pharmacodyn 227: 324–342
Morin D, Zini R, Urien S, Tillement JP (1989) Pharmacological profile of Binedaline, a new antidepressant drug. J Pharmacol Exp Ther 249: 288–296
Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter. Nature 350: 350–354
Schloss P, Mayser W, Betz H (1992) Neurotransmitter transporters. A novel family of integral plasma membrane proteins. FEBS Lett 307: 76–80
Snyder SH, Coyle JT (1969) Regional differences in H’norepinephrine and H3-dopamine uptake into rat brain homogenates. J Pharmacol Exper Ther 165: 78–86
Tehani-Butt SM (1992) [3H]Nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 260:427–436
Altar CA, Marshall JF (1987) Neostriatal dopamine uptake and reversal of age-related movement disorders with dopamine-uptake inhibitors. Ann NY Acad Sci 515: 343–353
Carroll FI, Gao Y, Abraham P, Lewin AH, Lew R, Patel A, Boja JW, Kuhar MJ (1992) Probes for the cocaine receptor. Potentially irreversible ligands for the dopamine transporter. J Med Chem 35: 1814–1817
Cline EJ, Scheffel U, Boja JW, Carroll FI, Katz JL, Kuhar MJ (1992) Behavioral effects of novel cocaine analogs: a comparison with in vivo receptor binding potency. J Pharmacol Exp Ther 260: 1174–1179
Cooper BR; Hester TJ, Maxwell RA (1980) Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): Evidence of selective blockade of dopamine uptake in vivo. J Pharmacol Exper Ther 215: 127–134
Elsworth JD, Taylor JR, Berger P, Roth RH (1993) Cocaine-sensitive and -insensitive dopamine uptake in prefrontal cortex, nucleus accumbens and striatum. Neurochem Int 23: 61–69
Giros B, El Mestikawi S, Bertrand L, Caron MG (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 295: 149–153
Giros B, El Mestikawi S, Godinot N, Zheng K, Han H, YangFeng T, Caron MG (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42: 383–390
Heikkila RE, Orlansky H, Cohen G (1975) Studies on the distinction between uptake inhibition and release of [3H]dopamine in rat brain slices. Biochem Pharmacol 24: 847–852
Horn AS, Coyle JT, Snyder SH (1970) Catecholamine uptake by synaptosomes from rat brain: Structure-activity relationships of drugs with different effects on dopamine and norepinephrine neurons. Mol. Pharmacol. 7: 66–80
Hunt P, Raynaud J-P, Leven M, Schacht U (1979) Dopamine uptake inhibitors and releasing agents differentiated by the use of synaptosomes and field-stimulated brain slices in vitro. Biochem. Pharmacol. 28: 2011–2016
Kilty JE, Lorang D, Amara SG (1991) Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254: 578–579
Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, Al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL, Milius RA, Wang S, Smith EO, Roth RH, Charney DS, Hoffer PB, Innis RB (1993) SPECT imaging of dopamine and serotonin transporters with [123I]ß-CIT: Pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295–309
Madras BK, Spealman RD, Fahey MA, Neumeyer JL, Saha JK, Milius RA (1989) Cocaine receptors labeled by [3H]213carbomethoxy-30-(4-fluorophenyl)tropane. Mol Pharmacol 36: 518–524
Michel MC, Rother A, Hiemke Ch, Ghraf R (1987) Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. Biochem Pharmacol 36: 3175–3180
Reith MEA, de Costa B, Rice KC, Jacobson AE (1992) Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol 227: 417–425
Richfield AK (1991) Quantitative autoradiography of the dopamine uptake complex in rats brain using [3H]GBR 12935:binding characteristics. Brain Res 540: 1–13
Rothman RB, Grieg N, Kim A, de Costa BR, Rice KC, Carroll FI, Pert A (1992) Cocaine and GBR 12909 produce equivalent motoric responses at different occupancy of the dopamine transporter. Pharmacol Biochem Behav 43: 1135–1142
Saijoh K, Fujiwara H, Tanaka C (1985) Influence of hypoxia on release and uptake of neurotransmitters in guinea pig striatal slices: dopamine and acetylcholine. Japan J Pharmacol 39: 529–539
Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P, Kuhar M, Uhl G (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254: 576–578
Snyder SH, Coyle JT (1969) Regional differences in H3norepinephrine and H3-dopamine uptake into rat brain homogenates. J. Pharmacol Exper Ther 165: 78–86
Tuomisto L, Tuomisto J (1974) Dopamine uptake in striatal and hypothalamic synaptosomes: conformational selectivity of the inhibition. Eur J Pharmacol 25: 351–361
Usdin RB, Mezey E, Chen C, Brownstein MJ, Hoffman BJ (1991) Cloning of the cocaine-sensitive bovine dopamine transporter. Proc Natl Acad Sci USA 88: 11168–11171
Ashberg M, Thoren P, Traskman L, Bertillson L, Ringberger V (1975) “Serotonin depression” - A biochemical subgroup within the affective disorders. Science 191:478–480
Biegon A, Mathis C (1993) Evaluation of [3H]paroxetine as an in vivo ligand for serotonin uptake sites: a quantitative autoradiographic study in the rat brain. Synapse 13: 1–9
Blakely RD, Berson HE, Fremeau RT, Caron MG, Peek MM, Prince HK, Bradley CC (1991) Cloning and expression of a functional serotonin transporter from rat brain. Nature 354: 66–70
de Montigy C (1980) Enhancement of 5HT neurotransmission by antidepressant treatment. J Physiol (Paris) 77: 455–461
Fuller RW (1990) Drugs affecting serotonin neurones. Progr Drug Res 35: 85–108
Fuller RW (1993) Biogenic amine transporters Neurotransmissions 9 /2: 1–4
Fuller RW, Wong DT (1990) Serotonin uptake and serotonin uptake inhibition. Ann NY Acad Sci 600: 68–80
Gershon MD, Miller Jonakait G (1979) Uptake and release of 5-hydroxytryptamine by enteric 5-hydroxytryptaminergic neurons: Effects of fluoxetine (Lilly 110140) and chlorimipramine. Br J Pharmacol 66: 7–9
Grimsley SR, Jahn MW (1992) Paroxetine, sertaline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 11: 930–957
Hallstrom COS, Rees WL, Pare CMB, Trenchard A, Turner P (1976) Platelet uptake of 5-hydroxytryptamine and dopamine in depression. Postgrad Med J 52 (Suppl 3): 40–44
Hoffman BJ Mezey E, Brownstein MJ (1991) Cloning of a serotonin transporter affected by antidepressants. Science 254: 579–580
Horn AS (1973) Structure-activity relations for the inhibition of 5-HT uptake into rat hypothalamic homogenates by serotonin and tryptamine analogues, J Neurochem 21: 883–888
Horn AS, Trace RCAM (1974) Structure-activity relations for the inhibition of 5-hydroxytryptamine uptake by tricyclic antidepressants into synaptosomes from serotoninergic neurons in rat brain homogenates. Br J Pharmacol 51: 399–403
Koe BK, Weissman A, Welch WM, Browne RG (1983) Sertaline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-l-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 226: 686–700
Langer SZ, Moret C, Raisman R, Dubocovich ML, Briley M (1980) High-affinity [3H]imipramine binding in rat hypothalamus: association with uptake of serotonin but not of epinephrine. Science 210: 1133–1135
Luo H, Richardson JS (1993) A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants. Internat Clin Psychopharmacol 8: 3–12
Marcusson JO, Norinder U, Högberg T, Ross SB (1992) Inhibition of [3H]paroxetine binding by various serotonin uptake inhibitors: Eur J Pharmacol 215: 191–198
Mennini T, Mocaer E, Garattini S (1987) Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunynschmiedeberg’s Arch Pharmacol 336: 478–482
Ögren SO, Ross SB, Holm AC, Renyi AL (1981) The pharmacology of zimelidine: a 5-HT selective reuptake inhibitor. Acta Psychiatr Scand 290: 127–151
Ross SB (1980) Neuronal transport of 5-hydroxytryptamine. Pharmacol 21: 123–131
Scatton B, Claustre Y, Graham D, Dennis T, Serrano A, Ar-billa S, Pimoule C, Schoemaker H, Bigg D, Langer SZ (1988) SL 81.0385: a novel selective and potent serotonin uptake inhibitor. Drug Dev Res 12: 29–40
Shank RP, Vaught JL, Pelley A, Setler PE, McComsey DF, Maryanoff BE (1988) McN-5652: a highly potent inhibitor of serotonin uptake. J Pharmacol Exp Ther 247: 1032–1038
Shaskan EG, Snyder SH (1970) Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. J Pharmacol Exp Ther 175: 404–418
Wong DT, Bymaster FP, Reid LR, Mayle DA, Krushiski JH, Robertson DW (1993) Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacol 8: 337–344
Fuller RW, Snoddy HD, Perry KW, Bymaster FP, Wong DT (1978) Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin — Comparison of fluoxetine and chlorimipramine. Biochem. Pharmacol. 27: 193–198
Harvey JA, McMaster SE, Yunger LM (1975) p-Chloramphetamine: Selective neurotoxic action in brain. Science 187: 841–843
Meek JL, Fuxe K, Carlsson A (1971) Blockade of pchloromethamphetamine induced 5-hydroxytryptamine depletion by chlorimipramine, chlorpheniramine and meperidine. Biochem. Pharmacol. 20: 707–709
Sekerke HJ, Smith HE, Bushing JA, Sanders-Busch E (1975) Correlation between brain levels and biochemical effects of the optical isomers of p-chloroamphetamine. J Pharmacol Exper Ther 193: 835–844
Squires R (1972) Antagonism of p-chloramphetamine (PCA) induced depletion of 5-HT from rat brain by some thymoleptics and other psychotropic drugs. Acta Pharmacol Toxicol 31: 35
Banerjee SP, Kung SL, Riggi SJ, Chanda SK (1977) Development of 0-adrenergic receptor subsensitivity by antidepressants. Nature 268: 455–456
Bergstrom DA, Kellar KJ (1979) Adrenergic and serotoninergic receptor binding in rat brain after chronic desmethylimipramine treatment. J Pharmacol Exper Ther 209: 256–261
Blackshear MA, Sanders-Bush E (1982) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exper Ther 221: 303–308
Bylund DB, Snyder SH (1976) Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 12: 568–580
Charney DS, Menkes DB, Heninger GR (1981) Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry 38: 1160–1180
Clements-Jewery S (1978) The development of cortical 13adrenoreceptor subsensitivity in the rat by chronic treatment with trazodone, doxepin and mianserine. Neuropharmacol 17: 779–781
Enna SJ, Mann E, Kedall D, Stancel GM (1981) Effect of chronic antidepressant administration on brain neurotransmitter receptor binding. In: Enna SJ, Malick JB, Richelson E, Antidepressants: Neurochemical, Behav ioral, and Clinical Perspectives. pp 91–105, Raven Press New York
Lee T, Tang SW (1984) Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res 12: 277–285
Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3H]Ketanserin (R 41 468) a selective 3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21: 301–214
Maggi A, U’Prichard DC, Enna SJ (1980) Differential effects of antidepressant treatment on brain monoaminergic receptors. Eur J Pharmacol 61: 91–98
Matsubara R, Matsubara S, Koyama T, Muraki A, Yamashita I (1993) Effect of chronic treatment with milnacipran (TN-912), a novel antidepressant, on (3-adrenergic-receptoradenylate cyclase system and serotonin2 receptor in the rat cerebral cortex. Jpn J Neuropsychopharmacol 15: 119–126
Meyerson LR, Ong HH, Martin LL, Ellis DB (1980) Effect of antidepressant agents on I3-adrenergic receptor and neurotransmitter regulatory systems. Pharmacol Biochem Behav 12: 943–948
Peroutka SJ, Snyder SH (1980) Regulation of serotonin2 (5HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exper Ther 215: 582–587
Reynolds CP, Garrett NJ, Rupniak N, Jenner P, Marsden CD (1983) Chronic clozapine treatment of rats down-regulates 5-HT2 receptors. Eur J Pharmacol 89: 325–326
Savage DD, Frazer A, Mendels J (1979) Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on 3H-serotonin receptor binding in rat brain. Eur J Pharmacol 58: 87–88
Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660–672
Schmidt CJ, Black CK, Taylor VL, Fadayel GM, Humphreys TM, Nieduzak TR, Sorensen SM (1992) The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergicdopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 220: 151–159
Scott JA, Crews FT (1983) Rapid decrease in rat brain beta adrenergic receptor binding during combined antidepressant alpha-2 antagonist treatment. J Pharmacol Exp Ther 224: 640–646
Segawa T, Mizuta T, Nomura Y (1979) Modifications of central 5-hydroxytryptamine binding sites in synaptic membranes from rat brain after long-term administration of tricyclic antidepressants. Eur J Pharmacol 58: 75–83
Sellinger-Barnette MM, Mendels J, Frazer A (1980) The effect of psychoactive drugs on beta-adrenergic receptor binding in rat brain. Neuropharmacol 19: 447–454
Vetulani J, Stawarz RJ, Dingell JV, Sulser F (1976) A possible common mechanism of action of antidepressant treatments: Reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn-Schmiedeberg’s Arch Pharmacol 293: 109–114
Wilmot CA, Szczepanik AM (1989) Effects of acute and chronic treatment with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 487: 288–298
Banerjee SP, Kung SL, Riggi SJ, Chanda SK (1977) Development of 13-adrenergic receptor subsensitivity by antidepressants. Nature 268: 455–456
Clements-Jewery S (1978) The development of cortical 3adrenoreceptor subsensitivity in the rat by chronic treatment with trazodone, doxepin and mianserine. Neuropharmacol 17: 779–781
Heal D, Cheetham SH, Martin K, Browning J, Luscombe G, Buckett R (1992) Comparative pharmacology of dothiepin, its metabolites, and other antidepressant drugs. Drug Dev Res 27: 121–135
Lefkowitz RJ, Stadel JM, Caron MG (1983) Adenylate cyclase-coupled beta-adrenergic receptors. Struture and mechanisms of activation and desensitization. Ann Rev Biochem 52: 159–186
Maggi A, U’Prichard DC, Enna SJ (1980) Differential effects of antidepressant treatment on brain monoaminergic receptors. Eur J Pharmacol 61: 91–98
Meyerson LR, Ong HH, Martin LL, Ellis DB (1980) Effect of antidepressant agents on 13-adrenergic receptor and neurotransmitter regulatory systems. Pharmacol Biochem Behav 12: 943–948
Salomon Y (1979) Adenylate cyclase assay. In: Brooker G, Greengard P, Robinson GA (eds): Advances in Cyclic Nucleotide Research. Raven Press, New York, Vol 10, pp 35–55
Sulser F (1978) Functional aspects of the norepinephrine receptor coupled adenylate cyclase system in the limbic forebrain and its modification by drugs which precipitate or alleviate depression: molecular approaches to an understanding of affective disorders. Pharmacopsychiat 11: 43–52
Vetulani J, Stawarz RJ, Dingell JV, Sulser F (1976) A possible common mechanism of action of antidepressant treatments: Reduction in the sensitivity of the noradrenergic cyclic AMP generating system in the rat limbic forebrain. Naunyn-Schmiedebergs Arch Pharmacol 293: 109–114
Wolfe BB, Harden TK, Sporn JR, Molinoff PB (1978) Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther 207: 446–457
Johnson RW, Reisine T, Spotnitz S, Weich N, Ursillo R, Yamamura HI (1980) Effects of desipramine and yohimbine on a2- and ß-adrenoreceptor sensitivity. Eur J Pharmacol 67: 123–127
Scott JA, Crews FT (1983) Rapid decrease in rat brain betaadrenergic receptor binding during combined antidepressant-alpha-2 antagonist treatment. J Pharmacol Exp Ther 224: 640–646
Starke K, Borowski E, Endo T (1975) Preferential blockade of presynaptic a-adrenoceptors by yohimbine. Eur J Pharmacol 34: 385–388
Hollister LE (1964) Complications from psychotherapeutic drugs–1964. Clin Pharmacol Ther 5: 322–333
Marks MJ, Romm E, Collins AC (1987) Genetic influences on tolerance development with chronic oxotremorine infusion. Pharmacol Biochem Behav 27: 723–732
Meyerhöffer A (1972) Absolute configuration of 3-quinuclidinyl benzilate and the behavioral effect in the dog of the optical isomers. J. Med. Chem. 15: 994–995
Smith CP, Huger FP (1983) Effects of zinc on [3H]-QNB displacement by cholinergic agonists and antagonists. Biochem Pharmacol 32: 377–380
Snyder SH, Yamamura HI (1977) Antidepressants and the muscarinic acetylcholine receptor. Arch. Gen. Psychiatry 34: 236–239
Snyder SH; Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch. Gen. Psychiatry 31: 58–61
Wamsley JK, Gehlert DL, Roeske WR, Yamamura HI (1984) Muscarinic antagonist binding site as evidenced by autoradiography after direct labeling with [311-QNB and [3H1-pirenzepine. Life Sci 34: 1395–1402
Yamamura HI, Snyder SH (1974) Muscarinic cholinergic binding in rat brain (quinuclidinyl benzilate/receptors). Proc. Nat. Acad. Sci. USA 71: 1725–1729
Callingham BA (1989) Biochemical aspects of the pharmacology of moclobemide. The implications of animal studies. Br J Psychiatry 155 (Suppl 6): 53–60
Cesura AM, Pletscher A (1992) The new generation of mono- amine oxydase inhibitors. Progr Drug Res 38: 171–297
Colzi A, d’Agostini F, Cesura AM, Da Prada M (1992) Brain microdialysis in rats: a technique to reveal competition between endogenous dopamine and moclobemide, a RIMA antidepressant. Psychopharmacology 106: S17 — S20
Haefeli W, Burkard WP, Cesura AM, Kettler R, Lorez HP, Martin JR, Richards JG, Scherschlicht R, Da Prada M (1992) Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacol 106: 56 — S14
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297
Kettler R, Da Prada M, Burkard WP (1990) Comparison of monoamine oxydase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl 82: 101–102
Knoll J (1980) Monoamine oxidase inhibitors: Chemistry and pharmacology. In: Sandler M (ed.) Knoll J. pp 151–173. University Park Press
Ozaki M, Weissbach H, Ozaki A, Witkop B, Udenfriend S (1960) Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro. J Med Pharmac Chem 2: 591–607
Rowler CJ, Ross SB (1984) Selective inhibitors of monoamine oxydase A and B: biochemical, pharmacological, and clinical parameters. Med Res Rev 4: 323–358
Waldmeier PC (1993) Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, Brofaromine. Progr Neuro-Psychopharmacol Biol Psychiat 17: 183–198
Waldmeier PC, Stöcklin K (1990) Binding of [3H]brofaromine to monoamine oxydase A in vivo: displacement by clogyline and moclobemide. Eur J Pharmacol 180: 297–304
White HL, Scates PW (1992) Mechanism of monoamine oxydase inhibition by BW 137U87. Drug Dev Res 25: 185–193
Wurtman RI, Axelrod J (1963) A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol 12: 1439–1441
Czermak J (1873) Beobachtungen und Versuche über “hypnotische” Zustände bei Thieren. Pflüger’s Arch ges Physiol 7: 107–121
Danilewski B (1881) Über die Hemmungen der Reflex-und Willkürbewegungen. Beiträge zur Lehre vom thierischen Hypnotismus. Pflüger’s Arch ges Physiol 24: 489–525
Heubel E (1877) fiber die Abhängigkeit des wachen Gehirnzustandes von äusseren Erregungen. Ein Beitrag zur Physiologie des Schlafes und zur Würdigung des Kircher’schen Experimentum mirabile. Pflüger’s Arch ges Physiol 14: 158–210
Kircher A (1646) Experimentum mirabile. De imaginatione gallinae. In: “Ars magna lucis et umbrae” Romae, Lib.11, pars I, 154
Schwenter D (1636) Deliciae physico-mathematicae oder Mathematische und Philosophische Erquickstunden. Nürnberg
Verworn M (1898) Beitraege zur Physiologie des Centralnervensystems. Erster Theil. Die sogenannte Hypnose der Thiere. G Fischer Jena, pp-92
Vogel G, Ther L (1963) Zur Wirkung der optischen Isomeren von Aethyltryptamin-acetat auf die Lagekatalepsie des Huhnes und auf die Motilitaet der Maus. Arzneim Forsch/ Drug Res 13: 779–783
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: A new potential antidepressant. Drug Dev Res 25: 267–282
Borsini F, Meli A. (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psycho-pharmacology 94: 147 160
Buckett WR, Fletcher J, Hoperoft RH, Thomas PC (1982) Automated apparatus for behavioural testing of typical and atypical antidepressants in mice. Br J Pharmacol 75: 170 P
Giardina WJ, Ebert DM (1989) Positive effects of captopril in the behavioral despair swim test. Biol Psychiatry 25: 697–702
Kauppila T, Tanila H, Carlson S, Taira T (1991) Effects of atipamezole, a novel z -adreno-receptor antagonist, in openfield, plus-maze, two compartment exploratory, and forced swimming tests in the rat. Eur. J. Pharmacol. 205: 177–182
Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioural despair in rats: a new model sensitive to antidepressive treatments. Eur J Pharmacol 47: 379–391
Porsolt RD, Bertin A, Jalfre M (1977) Behavioural despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn 229: 327–336
Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: A new animal model sensitive to antidepressant treatments. Nature 266: 730–732
Porsolt RD, Martin P, Lenègre, Fromage S, Drieu K.: (1990) Effects of an extract of Ginkgo biloba (EBG 761) on “learned helplessness” and other models of stress in rodents. Pharmacol Biochem Behav 36: 963–971
Wallach MB, Hedley LR (1979) The effects of antihistamines in a modified behavioral despair test. Communic Psychopharmacol 3: 35–39
Steru L, Chermat R, Thierry B, Simon P (1985) Tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology 85: 367–370
Trullas R, Jackson B, Skolnick P (1989) Genetic differences in a tail suspension test for evaluating antidepressant activity. Psychopharmacology 99: 287–288
van der Heyden J, Molewijk E, Olivier B (1987) Strain differences in response to drugs in the tail suspension test for antidepressant activity. Psychopharmacology 92: 127–130
Curzon G, Kennett GA, Sarna GS, Whitton PS (1992) The effects of tianeptine and other antidepressants on a rat model of depression. Br J Psychiatry 160 (Suppl 15): 51–55
Giral P, Martin P, Soubrie P, Simon P (1988) Reversal of helpless behavior in rats by putative 5-HT,A agonists. Biol Psychiat 23: 237–242
Maier SF, Seligman MEP (1976) Learned helplessness: Theory and evidence. J Exp Psychol 105: 3–46
Overmier JB, Seligman MEP (1967) Effects of inescapable shock upon subsequent escape and avoidance learning. J comp Physiol Psychol 63: 28–33
Porsolt RD, Martin P, Lenègre A, Fromage S, Drieu K (1990) Effects of an extract of Ginkgo biloba (EGB 761) on “learned helplessness” and other models of stress in rodents. Pharmacol Biochem Behav 36: 963–971
Sherman AD, Allers GL, Petty F, Henn FA (1979) A neuropharmacologically-relevant animal model of depression. Neuropharmacology 18: 891–893
Simiand J, Keane PE, Guitard J, Langlois X, Gonalons N, Martin P, Bianchetti A, LeFur G, Soubrie P (1992) Antidepressive profile in rodents of SR 5811A, a new selective agonist for atypical ß-adrenoreceptors. Eur J Pharmacol 219: 193–201
Vaccheri A, Dall’Olio R, Gaggi R, Gandolfi O, Montanaro N (1984) Antidepressant versus neuroleptic activities of sulpiride isomers on four animal models of depression. Psychopharmacology 83: 28–33
Horovitz ZP, Ragozzino PW, Leaf RC. (1965) Selective block of rat mouse-killing by anti-depressants. Life Sci 4: 1909–1912
Karli P, Vergnes M, Didiergeorges F (1969) Rat-mouse inter-specific aggressive behaviour and its manipulation by brain ablation and by brain stimulation. In: Garattini S, Sigg EB (eds.) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 47–55
Kreiskott H (1969) Some comments on the killing response behaviour of the rat. In: Garattini S, Sigg EB (eds) Aggressive Behaviour. Excerpta Medica Foundation, Amsterdam, pp 56–58
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: A new potential antidepressant. Drug Dev Res 25: 267–282
De Feo G, Lisciani R, Pavan L, Samarelli M, Valeri P (1983) Possible dopaminergic involvement in biting compulsion induced by large doses of clonidine. Pharmacol Res Commun 15: 613–619
Klawans HL, Rubovits R (1972) An experimental model of tardive dyskinesia. J Neural Transmiss 33: 235–246
Molander L, Randrup A (1974) Investigation of the mechanism by which L-DOPA induces gnawing in mice. Acta Pharmacol Toxicol 34: 312–324
Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C (1991) Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196: 257–266
Pedersen V, Christensen AV (1972) Antagonism of methylphenidate-induced stereotyped gnawing in mice. Acta Pharmacol Toxicol 31: 488–496
Randall PK (1985) Quantification of dopaminergic supersensitization using apomorphine-induced behavior in the mouse. Life Sci 37: 1419–1423
Ther L, Schramm H. (1962) Apomorphin-Synergismus ( Zwangs-nagen bei Mäusen) als Test zur Differenzierung psycho-[roper Substanzen. Arch Int Pharmacodyn 138: 302–310
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: A new potential antidepressant. Drug Dev Res 25: 267–282
Cox B, Lee TF (1981) 5-Hydroxytryptamine-induced hypothermia in rats as an in vivo model for the quantitative study of 5-hydroxytryptamine receptors. J Pharmacol Meth 5: 43–51
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: A new potential antidepressant. Drug Dev Res 25: 267–282
Benesovâ O, Ndhunek K (1971) Correlation between the experimental data from animal studies and therapeutic effects of antidepressant drugs. Psychopharmacologia (Berl.) 20: 337–347
Doble A, Girdlestone D, Piot O, Allam D, Betschart J, Boireau A, Dupuy A, Guérémy C, Ménager J, Zundel JL, Blanchard JC (1992) Pharmacological characterisation of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist. Br J Pharmacol 15: 27–36
Gylys JA, Muccia PMR, Taylor MK (1963) Pharmacological and toxicological properties of 2-methyl-3-piperidinopyrazine, a new antidepressant. Ann NY Acad Sci 107: 899–913
Jamieson DD, Duffield PH, Cheng D, Duffield AM (1989) Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum) Arch Int Pharmacodyn 301: 66–80
Nakagawa T, Ukai K, Kubo S (1993) Antidepressive effects of the stereoisomer cis-dosulepin hydrochloride. Arzneim Forsch/Drug Res 43: 11–15
Rubin B; Malone MH, Waugh MH, Burke JC (1957) Bioassay of Rauwolfia roots and alkaloids. J Pharmacol Exp Ther 120: 125–136
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: A new potential antidepressant. Drug Dev Res 25: 267–282
Askew BM (1963) A simple screening procedure for imi- pramine-like antidepressant drugs. Life Sci 10: 725–730
Bill DJ, Hughes IE, Stephens RJ (1989) The effects of acute and chronic desimipramine on the thermogenic and hypoactivity responses to a2-agonists in reserpinized and normal mice. Br J Pharmacol 96: 144–152
Bourin M (1990) Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests? Fundam Clin Pharmacol 4: 49–64
Koe BK, Lebel LA, Nielsen JA, Russo LL, Saccomano NA, Vinick FJ, Williams IA (1990) Effects of novel catechol ether imidazolidinones on calcium-dependent phosphodiesterase activity, (’H)Rolipram binding, and reserpineinduced hypothermia in mice. Drug Dev Res 21: 135–142
Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991) Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant Venlafaxine. Drug Dev Res 23: 191–199
Pawlowski L, Nowak G (1987) Biochemical and pharmacological tests for the prediction of ability of monoamine uptake blockers to inhibit the uptake of noradrenaline in vivo: the effects of desimipramine, maprotiline, femoxitine and citalopram. J Pharm Pharmacol 39: 1003–1009
Ahtee L, Saarnivaara L. (1971) The effect of drugs upon the uptake of 5-hydroxytryptamine and metaraminol by human platelets, J. Pharm. Pharmacol 23: 495–501
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: A new potential antidepressant. Drug Dev Res 25: 267–282
Chen G (1964) Antidepressives, analeptics and appetite suppressants. In: Laurence DR, Bacharach AL (eds) Evaluation of Drug Activities: Pharmacometrics. Academic Press, London and New York, pp 239–260
Corne SJ, Pickering RW, Warner BT (1963) A method for assessing the effects of drugs on the central actions of 5hydroxytryptamine. Br J Pharmacol 20: 106–120
Martin P, Frances H, Simon P (1985) Dissociation of head twitches and tremors during the study of interactions with 5-hydroxytryptophan in mice. J Pharmacol Meth 13: 193–200
Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 262: 545–551
Shank RP, Gardocki JF, Schneider CR, Vaught JL, Setler PE, Maryanoff BE, McComsey DF (1987) Preclinical evaluation of McN-5707 as a potential antidepressant. J Pharmacol Exp Ther 242: 74–84
Shank RP; Vaught JL, Pelley KA, Setler PE, McComsey DF, Maryanoff BE (1988) McN-5652: A highly potent inhibitor of serotonin uptake. J Pharmacol Exp Ther 247: 1032–1038
Ahtee L, Saarnivaara L. (1971) The effect of drugs upon the uptake of 5-hydroxytryptamine and metaraminol by human platelets, J. Pharm. Pharmacol 23: 495–501
Colpaert FC, Janssen PA (1983) The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: Antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology 22: 993–1000
Hallberg H, Carlson L, Elg R (1985) Objective quantification of tremor in conscious unrestrained rats, exemplified with 5-hydroxytryptamine-mediated tremor. J Pharmacol Meth 13: 261–266
Matthews WD, Smith CD (1980) Pharmacological profile of a model for central serotonin receptor activation Life Sci 26: 1397–1403
Shank RP, Gardocki JF, Schneider CR, Vaught JL, Setler PE, Maryanoff BE, McComsey DF (1987) Preclinical evaluation of McN-5707 as a potential antidepressant. J Pharmacol Exp Ther 242: 74–84
Alpermann HG, Schacht U, Usinger P, Hock FJ (1992) Pharmacological effects of Hoe 249: A new potential antidepressant. Drug Dev Res 25: 267–282
Bourin M, Malinge M, Colombel MC, Larousse C (1988) Influence of alpha stimulants and beta blockers on yohimbine toxicity. Prog Neuro-Psychopharmacol Biol Psychiat 12: 569–574
Goldberg MR, Robertson D (1983) Yohimbine: A pharmacological probe for study the a2-adrenoreceptor. Pharmacol Rev 35: 143–180
Quinton RM (1963) The increase in the toxicity of yohimbine induced by imipramine and other drugs in mice. Br J Pharmacol 21: 51–66
Knoll J (1980) Monoamine oxidase inhibitors: Chemistry and pharmacology. In: Sandler M (ed.) Knoll J. pp 151–173. University Park Press
Ozaki M, Weissbach H, Ozaki A, Witkop B, Udenfriend S (1960) Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro. J. Med. Pharmac. Chem. 2: 591–607
Duvoisin RC (1976) Parkinsonism: Animal analogues of the human disorder. in: Yahr MD (ed) The Basal Ganglia. Raven Press, New York, pp 293–303
Hornykiewicz 0 (1975) Parkinsonism induced by dopaminergic antagonists. In: Caine DB, Chase TN, Barbeau A (eds) Advances in Neurology. Raven Press, New York, pp 155–164
Marsden CD, Duvoisin RC, Jenner P, Parkes JD, Pycock C, Tarsy D (1975) Relationship between animal models and clinical parkinsonism. In: Caine DB, Chase TN, Barbeau A (eds) Advances in Neurology. Raven Press, New York, pp 165–175
Miller R, Hiley R (1975) Antimuscarinic actions of neuroleptic drugs. In: Caine DB, Chase TN, Barbeau A (eds) Advances in Neurology. Raven Press, New York, pp 141–154
Vernier VG (1964) Anti-Parkinsonian agents. In: Laurence DR, Bacharach AL (eds) Evaluation of Drug Activities: Pharmacometrics. Academic Press, London, New York, pp 301–311
Agarwal JC, Chandishwar N, Sharma M, Gupta GP, Bhargava KP, Shanker K (1983) Some new piperazino derivatives as antiparkinson and anticonvulsant agents. Arch Pharm (Weinheim) 316: 690–694
Bebbington A, Brimblecombe RW, Shakeshaft D (1966) The central and peripheral activity of acetylenic amines related to oxotremorine. Br J Pharmacol 26: 56–67
Cho AK, Haslett WL, Jenden DJ (1962) The peripheral actions of oxotremorine, a metabolite of tremorine. J Pharmacol Exp Ther 138: 249–257
Clement JG, Dyck WR (1989) Device for quantitating tremor activity in mice: Antitremor activity of atropine versus so-man-and oxotremorine-induced tremors. J Pharmacol Meth 22: 25–36
Coward DM, Doggett NS, Sayers AC (1977) The pharmacology of N-carbamoyl-2-(2,6-dichlorophenyl)acetamidine hydrochloride (LON-954) a new tremorogenic agent. Arzneim Forsch/Drug Res 27: 2326–2332
Duvoisin RC (1976) Parkinsonism: Animal analogues of the human disorder. in: Yahr MD (ed) The Basal Ganglia. Raven Press, New York, pp 293–303
Everett GM (1964) Animal and clinical techniques for evaluating anti-Parkinson agents. In Nodin JH, Siegler PE (eds) Animal and clinical pharmacologic techniques in drug evaluation. Year Book Medical Publ., Inc. Chicago, pp 359–368
Johnson JD, Meisenheimer TL, Isom GE (1986) A new method for quantification of tremors in mice. J Pharmacol Meth 16: 329–337
Matthews RT, Chiou CY (1979) A rat model for resting tremor. J Pharmacol Meth 2: 193–201
Ringdahl B, Jenden DJ (1983) Pharmacological properties of oxotremorine and its analogs. Life Sci 32: 2401–2413
Turner RA (1965) Anticonvulsants, Academic Press, New York & London, pp 164–172
Vernier VG (1964) Anti-Parkinsonian agents. In: Laurence DR, Bacharach AL (eds) Evaluation of Drug Activities: Pharmacometrics. Academic Press, London and New York, pp 301–311
Bemardini GL, Speciale SG, German DC (1990) Increased midbrain dopaminergic activity following 2’CH3-MPTPinduced dopaminergic cell loss: an in vitro electrophysiological study. Brain Res 527: 123–129
Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: Selective destruction of dopaminergic neurones in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l,2,3,6tetrahydropyridine. Proc Natl Acad Sci, USA, 80: 4546–4550
Chiba K, Trevor A, Castagnoli N (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574–578
Fuxe K, Janson AM, Rosén L. Finnman UB, Tanganelli S, Morari M, Goldstein M, Agnati LF (1992) Evidence for a protective action of the vigilance promoting drug Modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp Brain Res 88: 117–130
Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against dopaminergic neurotoxicity of 1-methyl4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxydase inhibitors. Nature 311: 467–469
Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M (1992) A-77363:a potent and selective D, receptor antagonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229: 203–209
Kindt MV, Youngster SK, Sonsalla PK, Duvoisin RC, Heikkila RE (1988) Role for monoamine oxydase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2’Me-MTPT. Eur J Pharmacol 146: 313–318
Nomoto M, Jenner P, Marsden CD (1985) The dopamine D2 agonist LY 141865, but not the D, agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine ( MPTP) in the common marmoset. Neurosci Lett 57: 37–41
Nomoto M, Jenner P, Marsden CD (1988) The D, agonist SKF 38393 inhibits the anti-parkinsonian activity of the D2 agonist LY 141555 in the MPTP-treated marmoset. Neurosci Lett 93: 275–280
Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R, Lataste X (1989) Antiparkinsonian activity of CY 208–243, a partial D1 dopamine receptor agonist, in MTPT-treated marmosets and patients with Parkinson’s disease. Movement Disord 4: 261–265
Abbott B, Starr BS, Starr MS (1991) CY 208–243 behaves as a typical D-I agonist in the reserpine-treated mouse. Pharmacol Biochem Behav 38: 259–263
Agarwal JC, Chandishwar N, Sharma M, Gupta GP, Bhargava KP, Shanker K (1983) Some new piperazino derivatives as antiparkinson and anticonvulsant agents. Arch Pharm (Weinheim) 316: 690–694
Amt J (1985) Behavioral stimulation is induced by separate dopamine Dl and D2 receptor sites in reserpine pretreated but not in normal rats. Eur J Pharmacol 113: 79–88
Duvoisin RC (1976) Parkinsonism: Animal analogues of the human disorder. in: Yahr MD (ed) The Basal Ganglia. Raven Press, New York, pp 293–303
Agarwal JC, Chandishwar N, Sharma M, Gupta GP, Bhargava KP, Shanker K (1983) Some new piperâzino derivatives as antiparkinson and anticonvulsant agents. Arch Pharm (Weinheim) 316: 690–694
Agid Y, Javoy F, Glowinski J, Bouvet D, Sotelo C (1973) Injection of 6-hydroxydopamine into the substantia nigra of the rat. II. Diffusion and specificity. Brain Res 58: 291–301
Carey RJ (1989) Stimulant drugs as conditioned and unconditioned stimuli in a classical conditioning paradigm. Drug Devel Res 16: 305–315
Carpenter MB, McMasters RE (1964) Lesions of the substantia nigra in the rhesus monkey. Efferent fiber degeneration and behavioral observations. Am J Anat 114: 293–319
Clineschmidt BV, Martin GE, Bunting PR (1982) Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 135–145
Costall B, Kelly ME, Naylor RJ (1983) The production of asymmetry and circling behavior following unilateral, intrastriatal administration of neuroleptic agents: a comparison of abilities to antagonise striatal function. Eur J Pharmacol 96: 79–86
De Jonge MC, Funcke ABH (1962) Sinistrotorsion in guinea pigs as a method of screening central anticholinergic activity. Arch Int Pharmacodyn 137: 375–382
Engber TM, Susel Z, Juncos JL, Chase TN (1989) Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 168: 291–298
Etemadzadeh E, Koskinen L, Kaakola S (1989) Computerized rotometer apparatus for recording circling behavior. Meth and Find Exp Clin Pharmacol 11: 399–407
Fuxe K, Agnati LF, Corrodi H, Everitt BJ, Hökfelt T, Löfström A, Ungerstedt U (1975) Action of dopamine receptor agonists in forebrain and hypothalamus: rotational behavior, ovulation, and dopamine turnover. In: Caine DB, Chase TN, Barbeau A (eds) Advances in Neurology. Raven Press, New York, pp 223–242.
Herrera-Marschitz M, Terenius L, Grehn L, Ungerstedt U (1989) Rotational behaviour produced by intranigral injections of bovine and human ß-casomorphins in rats. Psycho-pharmacology 99: 357–361
Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M (1992) A-77363: a potent and selective D, receptor antagonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229: 203–209
König JFR, Klippel RA (1963) The rat brain — A stereotaxic atlas. Williams and Wilkins Co., Baltimore, Md
Mandel RJ, Wilcox RE, Randall PK (1992) Behavioral quantification of striatal dopaminergic supersensitivity after bilateral 6-hydroxydopamine lesions in the mouse. Pharmacol Biochem Behav 41: 343–347
Morelli M (1990) Blockade of NMDA transmission potentiates dopaminergic D-1 while reduces D-2 responses in the 6OHDA model of Parkinson. Pharmacol Res 22, Suppl 2: 343
Schwarz RD, Stein JW; Bernard P (1978) Rotometer for recording rotation in chemically or electrically stimulated rats. Physiol Behav 20: 351–354
Ungerstedt U (1971) Postsynaptic hypersensitivity after 6hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand, Suppl 367: 69–93
Vernier VG, Unna KR (1963) The central nervous system effects of drugs in monkeys with surgically-induced tremor: Atropine and other antitremor agents. Arch Int Pharmacodyn 141: 30–53
Yasuda Y, Kikuchi T, Suzuki S, Tsutsui M, Yamada K, Hiyama T (1988) 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist. Life Sci 42: 1941–1954
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Vogel, H.G., Vogel, W.H. (1997). Psychotropic and neurotropic activity. In: Vogel, H.G., Vogel, W.H. (eds) Drug Discovery and Evaluation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-03333-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-662-03333-3_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-03335-7
Online ISBN: 978-3-662-03333-3
eBook Packages: Springer Book Archive